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 Abstract  
Understanding the neurobiological underpinnings of major depressive disorder (MDD) is 
of utmost importance. Recently, it was shown in post-mortem tissue of MDD patients that 
the number of glia cells is reduced, accompanied by atrophy of neuronal cells and a 
decreased volume of the prefrontal cortex (PFC). Following the observation that 
morphological deficits are present in both cell-types, it is likely that a misregulation in the 
communication between glia and neuronal cells might be one of the key factors underlying 
the development of MDD. Furthermore, the coverage of blood vessels by astrocytic 
endfeet has been shown to be reduced in MDD, implicating a misregulation also at the 
level of the glia-vasculature interface. A well-established approach to understand these 
deficits is the investigation of the molecular responses of neuronal cells to antidepressants 
(AD) in a cell-type specific manner. ADs have been shown to influence astrocytes as well 
as neurons and have been implicated in the regulation of gene expression via modulation of 
epigenetic modifications, like posttranslational histonemodifications (PTM).  
To understand these molecular changes, I first investigated the expression pattern of 
several PTMs (H3K4me3, H3K27me3 and H3K27ac) both, on global and cell-type 
specific levels before and after treatment with fluoxetine (FLX), one of the most 
commonly used ADs, in high anxiety-related behavior (HAB) rats, serving as a well-
established model for comorbid depressive-like behavior. I focused on the PFC, hence this 
brain area is known to be highly involved in depression in humans and animal models, 
although not much is known about epigenetic modifications in this area. For examining 
deeper cell-type specific changes and responses to ADs, I used both in vitro and in vivo 
models. In the present study I demonstrated that under baseline conditions, HAB rats 
resumed not only the human loss of glia cells in the PFC, but they also showed a putatively 
upregulated gene expression indicated by a 2-3 fold increase of H3K4me3, an activating 
PTM. I further showed that increased activation of H3K4me3 was specific of astrocytes 
and was targeted by FLX treatment. I additionally demonstrated that H3K27me3, a 
repressive mark which is supposed to be a counteracting partner of H3K4me3, is 
downregulated in HAB animals. Moreover, it decreased even further after FLX treatment, 
whereas H3K27ac, a permissive mark, was also decreased in HAB animals, which 
suggested that it might be a target of FLX, but after long term treatment. Together these 
data indicate a unique code of epigenetic modification in HAB rats under baseline 
conditions that presumably can be altered by AD treatment. In course of this study, I was 
further able to identify, for the first 
time, an aberrantly high gene expression of ephrinA1, regulated by a high accumulation of 
H3K4me3 at its promoter, in HAB astrocytes as well as in the PFC of HAB rats, thus 
suggesting that this might represent a novel target of AD therapy in MDD. In view of the 
crucial role that the ephrin/Eph system plays at the glia-neuron interface to modulate 
synaptic transmission, its misregulation may very well lead to the development of 
depressive symptoms.  
In addition, I identified GDF15, a neurotrophic factor, as a target of AD treatment in vitro 
and in vivo. My findings indicated that the ADs desipramine and FLX might induce 
increased expression of GDF15, leading to altered astrocytic morphology both in cell 
culture and around blood vessels of the PFC. An in-depth analysis revealed that FLX was 
specifically able to increase the sprouting of new processes as well as the elongation of 
preexisting ones, after a prolonged treatment in normal cells (derived from non-selectively 
bred animals, NAB), thereby also rescuing the morphology of the diseased HAB 
astrocytes, which showed a lack of processes with respect to NAB cells. These data 
corresponded to the in vivo findings in HAB rats, which show a reduced coverage of blood 
vessels with astrocytic processes. This deficit could be reversed by AD treatment. 
Moreover, I investigated the effects of exogenous GDF15 on astrocytic processes. 
Application of GDF15 was able to restore in HAB astrocytes both the number and length 
of processes in a dose- and time-dependent manner. Taken together, these data suggested 
that GDF15 might be involved in recovering a proper glia-vasculature interface that is 
needed for the proper exchanges of substances at the blood-brain-barrier. 
 
Zusammenfassung 
Es ist äußert wichtig die neurobiologischen Grundlagen einer Depression zu verstehen. 
Erst kürzlich konnte in postmortalem Gewebe gezeigt werden, dass depressive Patienten 
eine geringere Anzahl an Gliazellen, neuronale Atrophie sowie ein vermindertes Volumen 
des präfrontalen Kortex aufweisen. Da morphologische Veränderungen in diesen beiden 
Zelltypen auftreten ist es sehr wahrscheinlich, dass eine fehlerhafte Kommunikation 
zwischen Glia- und neuronalen Zellen eine Schlüsselrolle in der Entstehung einer 
Depression spielen könnte. Des Weiteren konnte gezeigt werden, dass die Blutgefäße in 
depressiven Patienten zu einem geringeren Ausmaße mit den Fortsätzen von Astrozyten 
bedeckt sind, was eine Deregulierung in diesem System bedeuten könnte. Ein gängiger 
Ansatz diese Defizite zu untersuchen, besteht darin die Reaktion dieser Systeme nach 
Behandlung mit Antidepressiva auf molekularer sowie zellspezifischer Ebene zu 
untersuchen. Antidepressiva können Astrozyten und Neurone beeinflussen und wurden 
bereits mit der Regulation von Genexpression mittels epigenetischer Modifikationen, wie 
beispielsweise posttranslationaler Histonmodifikationen (PTM) in Zusammenhang 
gebracht. Um diese molekularen Veränderungen zu verstehen, habe ich die 
Expressionsmuster verschiedener PTMs (H3K4me3, H3K27me3 und H3K27ac), vor und 
nach Behandlung mit Fluoxetin (FLX), auf globaler sowie zell-spezifischer Ebene 
untersucht. Als Tiermodell für diese Analyse habe ich high anxiety-related behavior 
(HAB) Ratten genutzt, die ein bereits gut etabliertes Tiermodel für Depression darstellen. 
Ich konzentrierte mich auf den präfrontalen Kortex, da diese Gehirnregion in der 
Pathophysiologie dieser Erkrankung sehr stark involviert ist, obwohl in diesem Areal 
bisher nur wenig über epigenetische Veränderungen bekannt ist. Um eine bessere 
Vergleichbarkeit zu erzielen, nutzte ich sowohl in vitro als auch in vivo Modelle. Mit der 
vorliegenden Studie konnte ich zeigen, dass HAB Ratten den humanen Phänotyp, welcher 
eine verringerten Anzahl an Glia Zellen aufweist, widerspiegeln, sowie dass diese Tiere 
eine vermeintlich gesteigerte Geneexpression haben, welche durch ein 2-3 fach höheres 
H3K4me3 Vorkommen angedeutet wird. Des Weiteren, konnte ich zeigen, dass die 
gesteigerte H3K4me3-Aktivität spezifisch in Astrozyten vorkommt und durch FLX 
Behandlung beeinflusst werden kann. Außerdem konnte ich zeigen, dass H3K27me3, eine 
repressive PTM, welche zudem vermutlich ein Gegenspieler von H3K4me3 ist, in HAB 
Ratten unter basalen Bedingungen herunterreguliert ist und durch eine längere FLX 
Behandlung sogar noch weiter reduziert wird. H3K27ac, eine aktivierende PTM, hingegen 
ist in HAB Ratten ebenfalls herunterreguliert und scheint durch eine längere FLX
 Behandlung beeinflussbar zu sein. Zusammenfassend weisen meine Daten darauf hin, dass 
in HAB Ratten eine einzigartige Kombination dieser PTMs existiert, welche sehr 
wahrscheinlich durch Antidepressiva verändert werden kann. Im Zuge dieser Studie konnte 
ich ephrinA1, als ein Gen identifizieren, welches in HAB Astrozyten sowie im 
präfrontalem Kortex von HAB Ratten aufgrund eines gesteigertem H3K4me3 
Vorkommens in dessen Promoter abnorm stark exprimiert wird. Diese Daten weisen darauf 
hin, dass ephrinA1 ein neues therapeutisches Ziel für die Behandlung einer Depression 
sein könnte. Eine Fehlregulation des Eph/ephrin Systems, welches maßgeblich an der 
synaptischen Übertragung zwischen Glia und neuronalen Zellen beteiligt ist, könnte zu den 
morphologischen Defiziten dieser Schnittstellen beitragen und letztendlich zu depressiven 
Symptomen führen. 
Zudem konnte ich GDF15, einen neurotrophen Faktor, identifizieren, welcher durch 
Antidepressiva beeinflussbar ist. Meine Ergebnisse deuten darauf hin, dass die Expression 
von GDF15 in Astrozyten durch die Gabe von Antidepressiva gesteigert werden kann, was 
zu einer morphologischen Veränderung dieser Zellen führt. Eine detaillierte Analyse hat 
gezeigt, dass FLX das Entstehen neuer, sowie die Verlängerung bereits bestehender 
Astrozyten-Fortsätze in „gesunden“ Zellen begünstigt. In HAB Zellen scheint FLX die 
aberrante Morphologie der Astrozyten so zu verändern, dass sie dem „gesunden“ Phänotyp 
gleichen. Diese Daten korrespondieren zu den in vivo Experimenten, in denen gezeigt 
wurde, dass eine verringerter Abdeckung der Blutgefäße mit Astrozyten-Fortsätzen in 
HAB Ratten durch FLX Behandlung verbessert werden kann. Weiterführend habe ich 
zudem die Effekte von exogen verabreichtem GDF15 untersucht. Die Behandlung von 
Astrozyten mit exogenem GDF15 führt dazu, dass neue Fortsätze entstehen und 
bestehende verlängert werden. Dieser Effekt scheint von der Dosis und der 
Behandlungsdauer abhängig zu sein. Aufgrund dieser Daten lässt sich spekulieren, dass 
GDF15 vermutlich daran beteiligt ist die funktionelle Schnittstelle zwischen Gliazellen und 
den Blutgefäßen wiederherzustellen, um damit einen angemessen Austausch von 
Substanzen zwischen dem Blutstrom und dem Hirnparenchym zu gewährleisten. 
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 Introduction  1.
1.1. Major depressive disorder (MDD)  
According to a recently published new data set by the world health organization (WHO 
[7]), unipolar disorder, also known as major depressive disorder (MDD), has become the 
leading cause of disability worldwide. Globally, over 350 million people of all ages are 
estimated to be affected by depression. MDD is a polygenic and multifactorial disease with 
a high lifetime prevalence, hence it is considered that one out of three people may suffer 
from depressive episodes during the life [8-10]. This disease is characterized by core 
symptoms of depressed mood and anhedonia, often accompanied by changes in body 
weight, loss of energy or pleasure, disturbances in sleep and cognitive functions [11, 12]. 
Especially the lack of specific biomarkers which might help to properly define the state of 
depression makes it very complicated to get a precise diagnosis. Moreover, the high 
comorbidity with other psychiatric illnesses, especially anxiety-related disorders, 
complicate a proper diagnosis even further [13]. Patients suffering from MDD also exhibit 
a markedly reduced lifespan, not necessarily due to concomitant suicide, but rather due to a 
well-documented increased risk of other life-threatening diseases, such as diabetes or 
cardiovascular disease [14]. Unfortunately, to date the most reliable criterion to diagnose/ 
categorize the state and severity of depression is based on questionnaires for the patients 
(DSM-Ⅴ, 2013), making a definite diagnosis dependent on subjective perceptions rather 
than on concrete pathophysiological evidences. Therefore, it is of utmost importance to 
understand the etiology and pathophysiology of MDD, its underlying molecular and 
additionally cell-type specific mechanisms to distinguish early on time people who might 
be prone to develop depression and to eventually being able to formulate a clearer 
diagnosis using specifically identified biomarkers. To approach these questions it is highly 
important to open new ways to identify novel targets and develop better and faster-acting 
therapeutics. Unfortunately, some of the major drawbacks in antidepressant (AD) therapy 
are still the high rate of non-responders (about 50-70%) and the delayed onset of 
amelioration of symptoms (4-12 weeks [15]).  
 
1.2. Neuronal circuits involved in depression  
Several limbic and cortical brain regions have been shown to play crucial roles in 
depression (see Fig.1, adapted from [2, 3]). These highly interconnected circuits involve 
brain structures that are important for interpreting and responding to stress and reward as 
well as cognitive functions [3, 16]. In the simplified scheme, one can see dopaminergic 
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neurons (blue arrows) projecting from the ventral tegmental area (VTA) to the nucleus 
accumbens (NAc) and hippocampus (HIPPO), among other areas. The NAc receives 
glutamatergic inputs (red arrows) from the prefrontal cortex (PFC), the HIPPO and 
amygdala (AMY) [2, 3, 16]. These interaction between the PFC and NAc are primarily 
part of the reward system and are implied in MDD [17]. Degeneration or lesions in these 
areas were found to increase the risk of patients to develop depressive episodes [18], while 
deep brain stimulation in the NAc and Cg25 (subcallosal cingulate gyrus) of treatment 
resistant patients successfully reduced depressive symptoms [19, 20]. With regard to these 
connections, it has been postulated that the PFC can exert regulatory effects on the NAc. 
Reciprocal connections between the PFC, especially the medial (m)PFC and AMY, via the 
uncinate fasciculus (black arrow, a long-range white matter association fiber-tract in the 
human brain, connecting the orbitofrontal cortex to the anterior temporal lobes through a 
direct, bidirectional monosynaptic pathway [21]) have been shown to exist in rats and non-
human primates [22]. A reduction in the PFC-AMY connectivity has been suggested to 
play a role in MDD and it normalizes after drug treatment [23]. Another important area is 
the dorsal raphe nucleus (DR), which is the main site of serotonin (5-HT) synthesis in the 
brain. It receives glutamatergic inputs from the PFC [24], among which most of the 
projections terminate onto local GABAergic (γ-Aminobutyric acid) interneurons that 
inhibit 5-HT neurons, impacting neuronal excitability. Antidepressant treatment with, for 
example, selective-serotonin-reuptake inhibitors (SSRIs) might interact with these 
connections. Dysfunctional HIPPO-PFC interactions are known to play a central role in 
MDD, which is not surprising, considering the central role of the HIPPO in regulation of 
the hypothalamic-pituitary-adrenal (HPA) axis [25]. The HIPPO is also highly 
interconnected via glutamatergic projections to the NAc and AMY, which both play 
important roles in the formation of emotional memory [26]. So far, most studies focused on 
the HIPPO and NAc, but the PFC represents an emerging target in the pathophysiology of 
depression, whose implications still need to be explored thoroughly.  
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1.3. Theories on the etiopathogenesis of depression  
Since the discovery of the first ADs [27], many hypotheses have been developed to explain 
the pathophysiology of depression and the action of ADs. With the emerging of new 
research fields and advances in the understanding of this multifaceted disorder, the theories 
were refined and new perspectives were added. Nevertheless, to date, none of them is able 
to fully explain the development of MDD and how ADs work. Therefore, I will introduce 
the main hypotheses that developed over the past 60 years, specifically focusing on the 
most promising ones.  
1.3.1. Monoamine hypothesis  
The ´monoamine hypothesis´ of depression was the first one to be postulated [28], stating 
that depression is caused by a decrease in monoaminergic signaling in the brain. This 
assumption is based on clinical findings of the late 1950s. Back then, two structurally 
unrelated compounds originally developed for non-psychiatric diseases, namely ipronazid 
(for tuberculosis) and imipramine (IMI, for schizophrenia) were found to “enhance the 
mood” in patients treated with these drugs [29]. Both drugs were later proven to affect the 
monoaminergic system by enhancing the availability of 5-HT and noradrenalin (NA) 
transmission. Since then, several antidepressants have been developed, but most of them 
are still designed to intervene with the monoaminergic system, either by inhibiting 
neuronal re-uptake of 5-HT or NA (e.g. fluoxetine (FLX), a SSRI; reboxetine, a selective 
noradrenalin reuptake inhibitors (NRI); venlafaxine, a serotonin and noradrenalin reuptake 
Fig. 1: Neuronal circuitries involved in depression (adapted from [2, 3])  
Abbreviations: PFC = prefrontal cortex, AMY = amygdala, HIPP = hippocampus, NAc= Nucleus 
accumbens, PVN = paraventricular nucleus of hypothalamus, VTA = ventral tegmental area, HYP = 
Hypothalamus, DR= dorsal raphe nucleus, LC = locus coereleus. Blue arrows = dopaminergic neurons 
projecting from VTA, red arrows = glutamatergic projections to NAc, black arrows = grey matter 
connections, green arrows = GABAergic connections  
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inhibitor (SNRI)) or by inhibiting their degradation (e.g. phenelzine, a monoamine oxidase 
A inhibitors (MAOI)) [11]. Although these compounds have been proven to be potent 
antidepressants, the simplified view that a sole monoamine deficiency is causing 
depression has been disproven. First of all, such substances increase the availably of 
monoamines on an acute basis, whereas behavioral amelioration requires several weeks. 
Moreover, a depletion of monoamines in animal models is not sufficient to elicit 
depressive symptoms [30]. Furthermore, illegal drugs like cocaine and amphetamines, 
which enhance the availability of serotonin, dopamine or norepinephrine do not seem to 
possess antidepressant effects. These data suggest that a dysregulation of the monoamine 
system is far from being the only factor which contributes to MDD.  
1.3.2. Neurotrophic hypothesis  
To target the question why antidepressants require several weeks of treatment before an 
amelioration of symptoms takes place, it was thought that an enhancement of monoamines 
in the synaptic cleft might lead to subsequent changes in neuroplasticity. As far as these 
changes are dependent on transcriptional and translational adaptations they might probably 
require a longer time scale, thereby explaining the delayed onset of ADs´ action. Together 
with data from post-mortem tissue and imaging studies, which showed structural 
alterations in several brain areas (e.g. PFC and HIPPO [31, 32]), this hypothesis proposes 
that depression might result from a decreased neurotrophic support, which in turn leads to 
neuronal atrophy (i.e. decreased dendritic arborization and synaptic contacts), a decreased 
hippocampal neurogenesis and glia cell loss, and that antidepressants are capable to block 
and/or reverse these deficits [33-35]. Among other neurotrophic factors (e.g. vascular 
endothelial growth factor, VEGF; insulin-like growth factor -2, IGF-2; fibroblast growth 
factor-1, FGF-1; glia-cell derived neurotrophic factor, GDNF), the most prominent and 
best-studied is brain-derived neurotrophic factor (BDNF) [34, 36-40]. Decreased levels of 
BDNF were found in post-mortem brain tissue as well as in the serum of depressed 
patients [34, 41]. Decreased levels of BDNF in specific brain areas are found in several 
animal models of stress-induced depression, thereby substantiating the human results [26, 
34, 38]. Infusions of BDNF in relevant brain areas are sufficient to elicit AD-like effects, 
but these effects seem to be dependent on the respective brain area. While BDNF displays 
antidepressant properties in the HIPPO [42], it exerts pro-depressive effects in the NAc 
[43]. Additionally, depletion of BDNF is not sufficient to cause depressive symptoms in 
male knockout mice [44]. Pinning down the cause of depression to a single neurotrophic 
factor, like BDNF, might as well be too simplistic. However this theory raises awareness to 
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incorporate the fact that neurotrophic factors are involved in neuroplastic responses to 
stress and antidepressant treatment. Numerous studies have shown that stress and 
antidepressants evoke opposite effects on neurogenesis and neuronal complexity. This 
might be a possible explanation for the delayed onset of symptomatic improvement. 
Neurogenesis occurs in specific brain areas of the adult brain, the subventricular zone 
(SVZ) that gives rise to neurons of the olfactory bulb and the subgranular zone (SGZ) that 
generates granular cells of the dentate gyrus [45]. Different types of acute and chronic 
stress, both psychological and physiological, decrease neurogenesis [46], while several 
classes of antidepressants, including SSRIs (e.g. FLX) and SNRIs induce it [45, 47]. 
Nonetheless, inhibiting neurogenesis, via irradiation [47] or genetic manipulations is not 
sufficient to induce depressive-like behavior in rodents. Although this theory sheds light on 
some important mechanisms that need to be considered, it can neither explain why 
antidepressant efficacy varies greatly among patients (high rate of non-responder) nor does 
it consider differences in pathways between stress-induced depression and genetically 
determined (“endogenous”) depression.  
1.3.3. Glia cell hypothesis  
Pioneering work by Rajkowska and colleagues extended the complex topic of depression 
even further [12, 31, 48]. Their work revealed tremendous glia cell impairment, with 
regard to both number and size, in post-mortem tissue of MDD patients [31, 49-51], 
thereby attracting notice to astrocytic abnormalities as a cause and/or consequence of 
depression. Additionally, several studies observed neuronal atrophy, displayed by smaller 
cell body sizes and reduced branching [31, 32, 50, 52], rather than complete loss of 
neurons. These results were substantiated by a study examining the serum of MDD patients 
for the amount of enolase 2 (a neuron-specific protein). The authors could not detect any 
difference in its expression, whereas the levels of S100β, an astrocyte specific marker, 
were elevated [53]. Furthermore, injecting a neuron-specific toxin (ibotenic acid) into the 
PFC of rodents did not cause any behavioral changes, while ablation of astrocytes (via L-
alpha-aminoadipic acid (L-AAA)) was sufficient to induce a depressive-like behavior [54]. 
These data led to the suggestion that MDD might not primarily be caused by neuronal 
deficiencies but in first instance by alterations in astrocytes. In fact, astrocytes have been 
shown to play a pivotal role in synaptic transmission by physically stabilizing synapses and 
also by actively participating in the exchange of signaling molecules, such as diverse 
neurotrophic factors and glutamate, between the pre- and post-synaptic terminals. On the 
one hand, astrocytes enwrapping synapses can clear the synaptic cleft from excess of those 
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signaling molecules, on the other hand, they supply neurons with diverse neurotransmitters 
and nutrients, such as glucose [55-57]. In particular, astrocytes play an important role in 
regulating the release and reuptake of glutamate, which in high concentrations is 
detrimental for neuronal survival. Dysfunctional astrocytes may contribute to the 
development of MDD, as their buffering capacities on the glutamate system seem to be 
compromised, thereby leading to a consequential (not causal) loss of neurons [11, 58]. This 
hypothesis further suggests that antidepressants may act on the remaining astrocytes by 
increasing their number and reinstate a proper glia-neuron proportion via enhancing their 
proliferation through the release of glia-derived trophic factors [59]. Such neurotrophic 
factors released from astrocytes (e.g. BDNF and GDNF) can signal back to neurons, which 
in turn are capable to control presynaptic activity through regulation of factors responsible 
for neuronal survival and maturation [11]. Indeed, those neurotrophic factors play an 
important role in the neurogenic response to antidepressants. They have been shown to be 
beneficial in restoring the physiological state of neuronal branching that is reduced under 
pathological conditions [60, 61]. Antidepressants can also directly act on astrocytes. 
Several classes of antidepressants activate specifically the ERK/MAPK (extracellular 
signal–regulated kinases/mitogen-activated protein kinase) pathway, whose downstream 
effectors are, among others, GDNF and BDNF [57, 62, 63].  
Further supporting the role of glia cells in response to antidepressants is the involvement of 
the blood brain barrier (BBB) in the uptake of clinically efficient dosages of drugs.  
The BBB is most tightly regulated by astrocytic endfeet, which surround and interact with 
blood vessels, thus controlling the passage of exogenous substances in and out of the brain. 
Very recently it has been shown that in MDD patients, blood vessels of the prefrontal 
cortex (PFC) lack the coverage with Aqp-4 (aquaporin-4)-positive endfeet of astrocytes 
[12]. A finding that was reproduced by our group in an animal model of depressive-like 
behavior (see below 1.11) [51]. Furthermore, we could show that Aqp-4 is necessary to 
mediate antidepressant effects on restoring a basal amount of astrocytic processes in 
astrocytes derived from the PFC of an animal model for depression. Considering these 
facts about astrocytes as cause and/or consequence of MDD and their responses to 
antidepressant treatment, it makes them a highly interesting target to study in order to 
elucidate molecular underpinnings of depression.  
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1.3.4. Epigenetic hypothesis  
Over the past decade several epigenetic mechanisms have been identified as important 
effectors of psychiatric diseases [3, 16, 64, 65]. It is known that depression can, at least 
partially, be inherited (heritability around 40% in familial cases [66]), nevertheless so far 
only very few genetic variants could be robustly correlated with depression. Additionally, 
the high discordance rate in monozygotic twins cannot be explained by pure genetic 
underpinnings. Therefore, the combination of genes with environment came into the 
spotlight of research. Indeed, epigenetic mechanisms are ideal candidates to study mental 
diseases that are caused by interaction of genetic factors (predisposition) and 
environmental exposure. Several lines of evidence have linked alterations in PTMs, DNA 
methylation and non-coding RNAs to psychiatric diseases. It is proposed that misbalances 
in such a delicate system of epigenetic modifications can severely impact brain functions. 
Various animal models of stress-induced depression and early life experiences 
demonstrated aberrant histonemodification, leading to changes in gene expression. The 
glucocorticoid receptor (GR) is one of these candidates, whose expression is altered in 
offspring derived from low maternal care mothers [67], regulated by DNA methylation. 
This effect could be reversed by application of histone-deacetylase inhibitors (HDACi), 
suggesting a crosstalk between epigenetic mechanisms. HDACi can also exert 
antidepressant-like effects dependent on the brain area. Besides acetylation, several other 
PTMs occur to play a role in MDD, foremost methylation of different histones (see below). 
For example elevate levels of a specific activating PTM (histone 3-lysine 4-trimethylation, 
H3K4me3), were found at the synapsin promoter in the PFC of depressed patients [68], 
whereas histone 3-lysine 27-trimethylation (H3K27me3, repressive) levels are increased at 
certain BDNF promoters in the PFC and both can be reversed by AD treatment. Research 
has only begun to understand how epigenetic modifications influence the outcome of MDD 
and how to target inter-individuals differences. Understanding the interplay of a potential 
predisposition interacting with environmental circumstances on the development of 
psychiatric diseases needs more detailed analysis to identify how epigenetic regulation 
impacts specific genes or gene networks related to depression. Keeping these hypotheses in 
mind, it seems valid to take a closer look at the different levels and at their functions under 
physiological and pathological conditions.  
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1.4. Astrocytes  
In the 1850s the term “Nervenkitt” (i.e. “brain glue”) was first introduced by the 
pathologist Rudolf Virchow. He defined neuroglia cells as small round-shaped cells that 
fill up the extracellular space as parts of the connective tissue. Although the term neuroglia 
still persists, to date especially the definition of astrocytes has changed drastically [69]. 
With the rise of more elaborate techniques than a simple Nissl staining, it is now well 
accepted that astrocytes are a highly heterogeneous cell population with numerous 
functions in the brain [70].  
Glia cells are considered to be the most abundant cell-type in the mammalian CNS (central 
nervous system) [71]. A comprehensive study by Pelvig and colleagues [72] quantified the 
number of neurons and glia cells in the neocortex of adult humans. Their results show that 
the total number of glia cells ranges between 27.9 billion (females) and 38.9 billion 
(males), while the total number of neurons only ranks between 21.4 billion (females) to 
26.3 billion (males), providing a 1.3-1.5 glia/neuron ratio. With about an average of 75%, 
oligodendrocytes account for the majority of glia cells, followed by astrocytes (20%) and 
microglia cell (5%). 
 
1.5. Lineage of astrocytes  
Gliogenesis is the generation of astrocytes and oligodendrocytes, which starts in the late 
embryonic development and continues during the neonatal and postnatal period. The 
cerebral cortex is one of best documented brain regions for gliogenesis. Astrocytes derive 
from three different sources. As depicted in Fig. 2, they derive from (1) radial glia cells in 
the embryonic ventricular zone (VZ), (2) progenitors in the postnatal SVZ and (3) probably 
another lineage determined by glia-restricted precursors. 
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Fig. 2: Diagram summarizing different lineages of neuron glia development [69] 
 
Radial glia cells originate from the early transformation of neuroepithelial cells in the VZ. 
They have the potential to generate both neurons and astrocytes [73]. After a period of 
neuronal migration along radial fibers, these cells retract their processes and transform into 
star-shaped astrocytes during the perinatal period [74]. They can further develop into 
specialized astrocytes, e.g. Bergmann glia in the cerebellum.  
In the early neonatal period radial progenitor cells can generate intermediate progenitors 
before transforming into astrocytes of the SVZ. These intermediate progenitors migrate 
into the cortex and differentiate into mature astrocytes or oligodendrocytes [69].  
Recent studies suggest the existence of multipotent, bi-potential progenitor [75] cells and 
possibly glia-restricted progenitors in the neonatal SVZ [76], though these multipotent 
progenitors need to be further investigated.  
1.5.1. Characterization  
Astrocytes, originally named after their star-shaped appearance, are defined as process-
bearing cells that lack axons and dendrites and are distributed throughout the CNS [69]. 
But the different astrocytic lineages already indicate that these cells are highly 
heterogeneous and that it is not easy to distinguish all sub-populations by a single criterion. 
For this reason, I will elucidate the most important criteria how astrocytes can be 
characterized.  
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a. Morphology  
 
Fig. 3: schematic illustration of protoplasmic and fibrous astrocytes [77] 
 
In general astrocytes can be distinguished by their particular location and morphology. 
Protoplasmic astrocytes (Fig. 3) are found in the grey matter and mainly derive from 
embryonic radial glia cell (to a lesser extent also from intermediate progenitors). These 
astrocytes are characterized by their numerous, highly branched processes (~50µm length) 
that envelop synapses. They can also contact blood vessels via their so-called ´perivascular 
endfeet´. 
Fibrous astrocytes (Fig. 3), on the other hand, are mostly found in the white matter. They 
are predominantly derived from SVZ progenitors. Their characteristic morphology 
encompasses long (up to 300µm), thin and widely unbranched processes, with endfeet 
enveloping the nodes of Ranvier [78]. With their processes, astrocytes are capable to 
infiltrate neuronal networks including synaptic terminals, dendrites and dendritic spines, 
though the degree of synaptic ensheathment varies greatly among brain areas. In the 
HIPPO only 57% of synapses have astrocytic processes opposing them, and among those 
only half surround the synaptic interface [79]. Such an arrangement might allow a certain 
degree of neurotransmitter spillover between synapses. Whereas in the cerebellum the 
degree of ensheathment can be as high as 94% in climbing fibers, which are sending 
excitatory inputs to Purkinje cells [69]. Recent studies have elucidated the organization 
within mature astrocytes, suggesting that they may consist of hundreds of independent 
compartments, each capable to interact autonomously with the ensheathed synapse. This 
high degree of compartmentalization allows them to communicate with synapses in a one-
to-one manner which may be necessary hence a single astrocytes can contact over 100,000 
synapses at once [80]. This work also led to a reevaluation of astrocytic morphology away 
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from the star-shaped appearance to a more spongiform one, with dense ramifications of 
fine processes extending 2-10 µm from the main branches.  
b. Antigenic properties 
Another commonly used approach to identify astrocytes is via their expression of diverse 
markers. The major component of their cytoskeletal intermediate filaments is the glial 
fibrillary acidic protein (GFAP), which is strongly expressed in mature and reactive 
astrocytes [81]. To date, eight different isoforms of GFAP have been identified to 
distinguish specific subpopulations of astrocytes during development, aging and disease. 
But GFAP is not exclusively expressed in astrocytes. Cells derived from radial glia 
progenitor cells, like ependymal cells, which do not belong to the astrocytic family, also 
express GFAP [82]. Consequently, it seems necessary to include other markers in the 
characterization of astrocytes. S100β is another commonly used marker, which belongs to 
the family of calcium binding proteins and is predominantly expressed in astrocytes of the 
grey matter [83]. Other markers which are considered to be exclusively expressed in 
astrocytes are glutamate transporters, such as the glutamate aspartate transporter-1 
(GLAST-1) and the glutamate transporter (GLT-1) (equivalent to human EAAT1 and 
EAAT2) [84], glycogen granules and glutamine synthase (GS), an enzyme that catalyzes 
the conversion of ammonia and glutamate into glutamine [85]. In addition some channels, 
including Kir 4.1, an inwardly rectifying K
+
 channels and Aqp-4 (water channel) and the 
most recently identified aldehyde dehydrogenase family, member 1 (AldhL1), represent 
possible candidates to identify specific astrocytic populations.  
c. Receptors  
Furthermore, astrocytes express virtually all receptors of the major neurotransmitter 
systems, including the glutamatergic, GABAergic, serotonergic, dopaminergic, 
acetylcolinergic and purinergic ones [86]. Astrocytes also express receptors for growth 
factors, chemokines, steroids and receptors involved in the innate immune response [69]. It 
is also important to take into account that astrocytes can modify their receptor expression 
according to the environmental surrounding, e.g. after brain injury astrocytes express EGF 
(ependymal growth factor) receptors, which can trigger resting astrocytes to become 
reactive [87]. This high degree of adaptability is very interesting to study the roles of 
astrocytes in a variety of psychiatric disorders.  
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1.6. Astrocyte activity  
Astrocytes were long considered as non-excitable cells, because their activity cannot be 
measured by electrophysiological recordings. However, astrocytes exhibit regulated 
increases in intracellular calcium concentrations that represents a form of excitability [88]. 
By now, a large body of evidence suggests, that these intracellular oscillations are of 
functional significance in astrocyte-astrocyte and astrocyte-neuron communication. 
Astrocytes respond to synaptic activity with increases in cytosolic Ca
2+
. These Ca
2+ 
elevations occur as intrinsic oscillations resulting from calcium release of internal stores 
triggered by glutamate, which is released during neuronal activity and might reach 
astrocytic receptors through synaptic spillover or ectopic release [89]. Thereby, astrocytes 
can trigger receptor mediated currents of neighboring cells [71]. This mode of excitability 
has been implicated in direct roles on synaptic transmission and in the functions at the 
vasculature [90] as well as in response to antidepressant treatment [91].  
 
1.7. Functions of astrocytes 
In the CNS astrocytes display a great variety of functions, which, next to metabolic 
support, include promoting neuronal maturation and survival, synapse formation, 
regulating angiogenesis and maintenance of a viable microenvironment for neurons.  
1.7.1. Metabolic support  
The most accepted functions of astrocytes include the maintenance and support of neuronal 
development. Astrocytes represent the major source of adhesion molecules and proteins of 
the extracellular matrix (ECM). Cultured astrocytes can act bi-directionally depending on 
the surrounding environment and constitution of the ECM, either promoting or inhibiting 
neurite outgrowth. Growth-promoting factors include laminin, N-cadherin, fibronectin and 
NCAM (neural cell adhesion molecule). Moreover, they also express inhibitory 
proteoglycans and synthesize/secrete proteolytic enzymes, like MMPs (matrix 
metalloproteases) that play important roles in degradation and remodeling of the ECM 
[92]. In vitro studies have well characterized the growth factors released from astrocytes, 
including BDNF, FGF, nerve growth factor (NGF), neurotrophin-3 (NT-3) and GDNF. All 
of them control neuronal maturation, survival and differentiation, some via Ca
2+ 
- 
dependent pathways. 
Due to their close proximity to blood vessels, neuronal axons, perikarya and synapses, 
astrocytes are in a superior position to take up metabolites (e.g. glucose) and provide them 
to different neuronal elements in the brain. Compelling evidence demonstrates that 
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astrocytic glycogen utilization can sustain neuronal activity during hypoglycemia and 
periods of high neuronal activity [93].  
Furthermore, astrocytes can buffer extracellular K
+ 
ions that are released during neuronal 
activity, but can elicit detrimental effects when present in too high concentrations. 
Astrocytes can take up the excessed K
+
, distribute them through the gap junction-coupled 
astrocyte syncytium and extrude the ions at sites with lower K
+
. To exert these regulatory 
mechanisms astrocytes possess channels and co-transporters (for a passive uptake) as well 
as Na
+
/K
+
 - ATPases for active transport. Passive uptake is mainly mediated by K
+
 
channels (Kir) expressed at their endfeet. Blockade of Kir channels (e.g. Kir4.1) results in 
depolarization of astrocytes. This in turn leads to impaired K
+
 buffering, glutamate uptake 
and thereby possibly to behavioral abnormalities [94, 95]. 
1.7.2. The blood-brain barrier  
The BBB is a specialized system that regulates the penetration of molecules in and out of 
the brain parenchyma. The major constituents of the BBB are cerebral capillary endothelial 
cells that form tight junctions and are surrounded by a basal lamina, perivascular pericytes 
and astrocytic endfeet. Together they form close connections with capillaries, thus making 
astrocytes the primary target of any molecule entering the brain [96]. During development, 
astrocytes contribute to the tightening of the BBB and the up-regulation of different 
transporter mechanisms. Several astrocytic signals that regulate various aspects of BBB 
properties have been identified, including transforming growth factor-β (TGF-β), GDNF, 
FGF, interleukin- 6 (IL-6) and Aqp-4 [12, 51]. The release of these molecules opens the 
paracellular pathway by increasing the permeability of tight junction, indicating that 
astrocytes are involved in regulating the BBB by cross-talk with endothelial cells, possibly 
upon Ca
2+ 
and ATP receptor mediated signaling. Interestingly, components of the BBB 
have been implicated to play a role in depression and in response to antidepressants (see 
below).  
1.7.3. GABA and Glutamate  
Astrocytes express a high density of high affinity GABA transporters, which are located 
near the synaptic cleft, most likely controlling GABA spillover from the cleft either alone 
or together with neuronal transporters. Just recently, astrocytes were also indicated as 
GABA-releasing cells. This release is proposed to occur through different pathways: (1) 
vesicular release, (2) reversal of GABA transporters and (3) non-vesicular channel 
mediated release [97]. But the identification of the true mechanism still needs to be 
determined. 
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Astrocytes also express glutamate transporters, including GLAST (in human EAAT1) and 
GLT-1 (in human EAAT-2) suggesting active participation in the uptake, metabolism and 
recycling of glutamate. Glutamate is internalized and subsequently converted within the 
astrocytes to glutamine via the GS [85]. The newly synthesized glutamine is released by 
astrocytes, taken up by neurons and can be converted to glutamate or GABA.  
The regulation of extracellular levels of these transmitters by astrocytes has raised an 
avalanche of new studies investigating its function in health and disease. 
1.7.4. Neurotransmission and synapses  
It is well established that astrocytes sense neuronal activity through activation of ion 
channels, transporters and receptors, resulting in fast depolarization and/or intracellular 
calcium increases [98]. Calcium transients can be induced following the activation of 
different metabotropic receptors. It was shown that astrocytic depolarizations following 
neuronal stimulation is involved in short-term plasticity [90]. These findings indicate that 
astrocytes have the capability to process and integrate information in response to neuronal 
activity.  
In fact, with the postulation of the tripartite synapse [90], it became clearer that astrocytes 
actively participate in the regulation of synapses. Using-time lapse confocal microscopy 
Haber and colleagues demonstrated that astrocytes can rapidly extend or retract fine 
processes to and from postsynaptic dendritic spines [99], suggesting a possible 
involvement in synaptic plasticity [100]. At the synaptic level, astrocytes contribute to the 
regulation of synaptic and extrasynaptic transmission [101]. In particular they control the 
level of activation of presynaptic metabotropic glutamate receptors on glutamatergic 
terminals, thereby regulating the strength of excitatory synapses. Astrocytes seem to be 
directly involved in dendritic spine formation, shown by a study using astrocyte-
conditioned medium, which promotes proliferation of spines [102]. Furthermore, Nishida 
and Okabe could show that astrocytic motility is essential to stabilize individual dendritic 
protrusions and their subsequent maturation into spines [103]. Additionally, they could 
show that manipulations of the ephrin/Eph dependent neuron-astrocytes signaling suggest 
the involvement of this pathway in astrocyte-dependent stabilization of newly dendritic 
protrusion. 
 
1.8. Astrocytes in depression 
Considering the multiple functions of astrocytes under physiological conditions, a fruitful 
research field opened, examining possible functions in various neuropathological diseases.  
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A major branch of these studies is dedicated to the involvement of astrocytes in psychiatric 
disorders like MDD. In the following section I will focus on the findings implicating 
astrocytes as a cause and/or consequence in the development of MDD, based on 
aberrancies from the physiological state.  
1.8.1. Morphometric evidence  
Groundbreaking work in 1999 by Rajkowska and independently also by Öngür revealed 
that the observed volumetric changes in post-mortem tissue of MDD patients are most 
likely not caused by neuronal cell loss, but rather occur due to the loss of glia cells [31, 
104]. 3D cell counting approaches identified that neurons are indeed affected in 
depression, but it is rather a shrinkage or morphological atrophy than a complete loss, as 
observed in neurodegenerative diseases, like Huntington´s disease. A reduction of glia cell 
density in the PFC is accompanied by enlargement of glia cell bodies, making this 
combination a unique patter for MDD, hence typically enlargement of glia cell bodies 
occurs together with increased glia cell density [31, 104]. The significantly reduced 
cortical thickness in MDD is possibly related to decreased metabolic support in response to 
neuronal activity, implying an extremely important function of astrocytes in MDD. These 
studies were the first to implicate glia cells in the histopathology of depression, opening 
new insights into the underlying neurobiological mechanisms. Since then, the knowledge 
about morphological aberrancies in depression greatly enhanced. Using animal models, it 
became possible to investigate underlying mechanism of neuronal atrophy and glia cell 
loss. Chronic stress paradigms or application of glucocorticoids decreased the number and 
length of apical dendrites in hippocampal CA3 pyramidal neurons of tree shrews and 
reduced neurogenesis [105]. Moreover, adult rats subjected to chronic unpredictable stress 
(CUS) exhibit a reduction in glia cells in the prelimbic cortex and selective ablation of glia 
cells, by using astrocyte specific L-AAA, but not neuronal toxins is sufficient to induce 
depression-like behavior [54]. Together these findings indicate that stress paradigms might 
provide a cellular basis for the astrocytic impairments seen in MDD patients [106]. 
In 2011 a post-mortem study investigated further the exact morphological alterations in 
cortical astrocytes, comparing healthy subjects to depressed suicide completers [52].  
Fibrous astrocytes of the Brodmann area 24 in suicide completers were found to be larger 
and to extend longer and more ramified processes than in matched controls, shedding light 
on selective cellular changes occurring in the white matter in depression, independently 
from adjacent protoplasmic astrocytes of the grey matter. These hypertrophic fibrous 
astrocytes might reflect local inflammatory processes on the white matter, suggesting 
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neuroinflammatory processes among additional causes of depression [107]. It has been 
documented that MDD patients have significantly higher levels of circulating pro-
inflammatory cytokines and that these cytokines are implicated in stress-induced 
depressive symptoms [108]. Previous studies demonstrated a significant reduction in the 
number of astrocytes (in HIPPO) after chronic social stress. This loss of glia cells could be 
reversed by chronic FLX treatment [109]. Data suggest that antidepressants might enhance 
gliogenesis. Pronounced gliogenesis has been observed after electroconvulsive therapy in 
the HIPPO and PFC, as well as after FLX treatment in animals [59, 110].  
1.8.2. Antidepressants act on astrocytes  
Knowing about the drawbacks of current antidepressant treatment options, several groups 
independently analyzed transcriptional and translational changes with unbiased approaches 
to reveal common molecular targets of different antidepressants [111, 112]. Interestingly, 
they found pronounced up- or down-regulation of astrocyte associated genes like GFAP, 
Aqp-4 and vimentin, whereas others reported upregulation of connexin 43 (a major 
component of astrocytic gap junctions) in the PFC upon chronic FLX or clozapine 
treatment, whereas non-antidepressants (lithium, haloperidol) showed opposite effects 
[113]. Furthermore, astrocytes release several trophic factors and cytokines which have 
been hypothesized to be misregulated in depression. For example, stress-induced reduction 
of GFAP and GDNF expression in the HIPPO could be reversed by clomipramine (a 
tricyclic antidepressant) in a rodent model of depressive-like behavior [114]. Additionally, 
other trophic factors are affected by antidepressants. In primary cortical astrocytes, 
treatment with the SSRIs FLX and paroxetine caused a pronounced up-regulation of 
BDNF, VEGF and VGF mRNA expression [115], although tricyclic antidepressants (IMI, 
desipramine) did not affect these factors.  
We and other groups have identified the ERK/MAPK pathway as a common target in glial 
cells for most antidepressants [57, 62, 63]. FLX and several other classes of 
antidepressants applied to primary rat astrocytes or C6 glioma cells (a model cell line for 
astrocytes) in vitro targeted the MAPK signaling pathway and induced specific 
downstream effects on BDNF, GDNF and their respective receptors TrkB and GFRα. 
Furthermore, in our lab we could show that reboxetine and norquetiapine (the major 
metabolite of a recently approved antidepressant) activate simultaneously ERK1 and 
ERK2, with a subsequent increased release of GDNF [116]. A recent study demonstrated a 
differential epigenetic status of the GDNF gene that is responsible for susceptibility vs. 
resilience to chronic stress [117]; the authors demonstrated that IMI could reverse these 
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effects, indicating a possible underlying mechanism of an increased GDNF expression 
after antidepressant treatment. These data led to the suggestion that interfering with the 
MAPK pathway specifically in astrocytes may allow a faster response to antidepressants. 
Given the plethora of divergent receptors expressed on astrocyte, many of which have 
already been implicated in depression, it became very interesting to investigate their 
contribution in response to antidepressants. FLX and nortriptyline were shown to block 
Kir4.1, an astrocytic inwardly rectifying K
+
 channel, responsible for potassium buffering in 
astrocytes [94, 118], a highly interesting finding since potassium channels have been 
implicated in the pathophysiology of mood disorders in human and animal models [119]. 
Among the receptors expressed on astrocytes, also glutamate and GABA receptors have 
been implicated in the pathophysiology of mood disorders. Post-mortem microarray 
studies in the locus coereleus and cortical areas of depressed patients revealed significant 
changes in the expression of proteins involved in glutamate homeostasis, some of which 
are highly associated with astrocytes [120]. Central or region-specific injections of 
dihydrokainic acid, an inhibitor of GLT-1, cause anhedonia and cognitive impairments 
similar to depressive symptoms [121]. In a stress paradigm the observed depressive-like 
phenotype, accompanied by impaired glia cell metabolism in the PFC, could be restored by 
riluzole, a glutamate-modulating drug [122], enhancing the glutamate uptake from the 
extracellular space (ECS) by astrocytes. Compelling evidence demonstrated that the 
glutamatergic and GABAergic systems are involved in MDD and in response to 
antidepressants presumably via activation and/or inhibition of astrocytes.  
Astrocytes are excitable by Ca
2+
 oscillations resulting in the release of glutamate into the 
ECS, thereby triggering receptor mediated currents in neurons [90]. Two SSRIs (FLX and 
citalopram) have been shown to elicit calcium signals in the PFC of acute mouse brain 
slices, even if neuronal signal propagation is inhibited. The intracellular calcium signaling 
is involved in the regulation of numerous essential functions, therefore it seem highly 
important to investigate the calcium signaling propagation in astrocytes under pathological 
conditions.  
Astrocytic processes, as part of the tripartite synapse, actively participate in the modulation 
of synaptic transmission, in response to environmental cues [90, 100]. Synaptic plasticity is 
one of the most fundamental functions in the CNS, playing a key role in memory 
processing, specifically short- and long-term memory, and the disruption of underlying 
mechanisms has been implicated in depression. Post-mortem studies found reduced 
numbers of synapses in the PFC of depressed patients [123]. Chronic administration of 
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MAOIs increase the levels of monoamines in the synaptic cleft and can thereby interfere 
with neurotransmission on different levels, including neurogenesis, neurotrophic factor 
expression and synapse formation. Chronic FLX treatment has been shown to ´rejuvenile´ 
the adult brain via the re-opening of the so-called critical period of postnatal development. 
In the ocular dominance paradigm, Maya Vetencourt and colleagues demonstrated that 
FLX is able to induce recovery of visual functions of the deprived eye through reactivation 
of the neuroplastic program [124]. Similar observations were made in the amygdala, where 
it has been shown that FLX can change the fate of neuronal circuits, important for fear 
conditioning. In both studies BDNF was implicated in the effects of FLX [125]. Moreover, 
there is evidence that chronic FLX treatment can increase spine density and block the 
effects of chronic stress [126, 127]. 
Further implications of effects of ADs on astrocytes come from the aforementioned work 
by Rajkowska and colleagues [12, 128], which demonstrated that the coverage of blood 
vessels by astrocytic endfeet is significantly reduced in MDD patients. But this reduction 
was only observed in astrocytic processes immunoreactive for Aqp-4 in the grey matter. 
Just recently our group could substantiate these finding in high anxiety-related behavior 
(HAB) animals, further validating HAB rats as a good model for depression [51]. 
Aqp-4, as mentioned above is the predominant water channel in the adult CNS and is 
primarily expressed on the endfeet of astrocytes [129]. It balances K
+ 
-buffering in 
astrocytes [130] and has been in implicated as a mediator of antidepressant efficacy and as 
protective factor against corticosterone-induced depressive-like behavior, which is 
accompanied by an astrocyte pathology [105, 131]. Furthermore, Aqp-4 plays a role in 
regulating adult neurogenesis [132] and is necessary for FLX induced neurogenesis, thus 
making Aqp-4 in astrocytes a new target for the mechanism of action of antidepressants. 
The decrease in Aqp-4
+ 
-positive
 
astrocytic endfeet might have many consequences. The 
decreased number might reduce the effective surface for exchanges with the blood 
circulation, thereby putatively regulating the uptake of antidepressants from the blood 
stream. Thus, possibly explaining the slow onset of AD efficacy, as far as first the BBB 
needs to recover a proper coverage with astrocytic processes before clinically effective 
dosages of ADs can be transported into the brain parenchyma. Therefore we examined 
further if FLX causes morphological alterations in our animal model.  
 Our data [51], together with the observation in humans [31], support the link between 
cerebrovascular pathology and MDD, providing the first links at the cellular level.  
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Fig. 4: The nucleosome is the major constituent of chromatin 
The nucleosome core consists of 147bp of DNA wrapped around a core octamer consisting of two 
copies of each histone H2A, H2B, H3 and H4. The nucleosomes are linked via a H1-linker histone. 
Taken together, the findings that antidepressants can directly target several astrocytic 
functions as the regulation and availability of neurotransmitters (GABA, glutamate), the 
regulation of metabolic homeostasis and are involved in regulation at the level of the BBB 
and synapses, make them promising target to study mechanisms underlying the effects of 
ADs.  
 
1.9. Epigenetic mechanism  
Originally, the term epigenetics was defined by Conrad Waddington [133] as “the 
interaction of genes with their environment which brings the phenotype into being”, stating 
further “the importance of epigenetic modifications as being a mechanism for an adaptive 
response that can be fixed without waiting for a mutation to occur”.  
More recent definitions describe epigenetic modifications as an “ensemble of alterations in 
gene functions that are heritable through both mitosis and meiosis, but cannot be explained 
by changes in the DNA sequence itself” [134]. On the molecular level, epigenetic 
mechanisms represent biochemical modifications of the DNA and histone proteins which 
are the major constituents of chromatin. Histones (Fig. 4) consist of a basic protein core 
octamer encompassing two copies of each histone (H2A, H2B, H3 and H4), and an N-
terminal histone tail composed of loosely-structured sequences of amino acids. 147bp of 
DNA are wrapped around the core, typically linked to the next nucleosome via an H1-
linker histone.  
Posttranslational modifications occur on virtually all amino acids of the N-terminus, 
controlling the spacing between nucleosomes and degree of condensation, thereby 
determining access of the transcriptional machinery to the DNA, and ultimately 
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determining the degree of gene activity. Generally spoken, chromatin consists of a 
continuum between inactivated, highly condensed heterochromatin, and open, easily 
accessible, euchromatin (Fig. 5). 
 
 
 
These chromatin states determine gene activity in a highly regulated manner by complex 
biochemical processes. In general, there are three major epigenetic mechanisms that can be 
clearly distinguished: 1. DNA methylation, 2. non-coding RNA and 3. posttranslational 
histonemodifications. Only very little is known about non-coding RNAs in psychiatric 
diseases, therefore I will focus mainly on PTMs with a short overview about DNA 
methylation. 
1.9.1. DNA methylation  
DNA methylation occurs throughout the genome, but predominantly at so-called CpG 
islands (i.e. cytosine-guanine dyads [5]), often found at promoter regions. Due to the 
covalent binding of methyl-groups at the C5 carbon in cytosine projecting into the major 
groove of DNA, DNA methylation is thought to be the most stable epigenetic mark [135] 
which can persist throughout the lifetime. In the human genome approximately 3% of all 
cytosines are methylated and this methylation is highly involved in cell differentiation, 
genetic imprinting, suppression of repetitive elements and X-chromosomal inactivation. 
DNA methylation is catalyzed by DNA-methyltransferases (DNMTs) including DNMT1 
DNMT2, DNMT3a, and DNMT3b [136], which play very distinct roles. DNMT1 is also 
known as the ´maintenance methyltransferase´ that perpetuates DNA methylation during 
replication, whereas DNMT3a and 3b catalyze ´de novo´ methylation at the unmehtylated 
heterochromatin,  
condensed  
euchromatin, 
open 
Fig. 5: Highly condensed heterochromatin and easily accessible euchromatin  
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DNA double-strand. Although generally considered to be gene silencing, DNA 
methylation has been shown to exert also gene activating effects, depending on the 
recruitment of other transcription factors. Nearly 80 different transcription factors are 
known to interact with DNMTs [137]. For example, interaction with methyl-CpG-binding 
proteins (MeCP) can further recruit modifying enzymes to compact nucleosomes and 
inhibit gene expression. Moreover, additional studies identified more forms of DNA 
methylation such as 5-hmC (5-hydroxymehtylcytosine), 5-formylcytosine and 5-
carboxylcytosine. These chemical variant of 5-mC are thought to derive through oxidation 
steps catalyzed by TET (ten-eleven-translocation) enzymes, representing a mechanism of 
active demethylation. Together these findings indicate that DNA methylation is rather a 
highly dynamic, especially in the brain, than a permanent modification.  
1.9.2. Posttranslational histonemodification  
More than 100-amino acid residue-specific PTMs are known in vertebrae cells [138, 139]. 
These modifications include mono-, di- and tri- methylation, acetylation, phosphorylation, 
ubiquitination, sumoylation and several recently found additional types, like crotonylation 
and succinylation [138, 139]. The best studied modifications are the ones occurring on 
histone tails, but several new modifications were identified also on the globular domains of 
histones, which are not yet functionally characterized. Here, I will focus on acetylation and 
methylation, with only briefly mentioning phosphorylation and ubiquitination.  
a. Acetylation 
Acetylation occurs mainly on lysine (K) residues and is associated with active gene 
transcription (permissive mark), by neutralizing the positive charge of the ε-amino group. 
This event causes a decrease in the affinity to the DNA (negatively charged) and leads to 
less condensed, more easily accessible chromatin. Histones are acetylated by HAT 
(histone-acetyltransferases) using acetyl coenzyme A as a co-substrate and can be 
deacetylated by HDAC (histone-deacetylases). HDACs are divided into four classes, 
classⅠ (HDAC 1-3, 8) located in the nucleus and mainly involved in epigenetic 
regulation. ClassⅡ (HDAC 4, 7, 9, 10) can be shuttled between the nucleus and cytoplasm 
and function to deacetylate histones and cytoplasmic proteins. ClassⅢ, also known as 
sirtuins are dependent on the NAD
+
 (nicotinamide adenine dinucleotide) and are important 
regulators of metabolisms and transcription through the deacetylation of numerous histones 
and non-histone substrates. ClassⅣ (HDAC 11) is largely unknown.  
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b. Methylation  
Methylation on the other hand is associated with both actively transcribed and silenced 
genes, depending on the residues (lysine (K), arginine (R) and histidine (H)) and valence 
state (mono-, di-, or tri-methylated) [140]. Combinations on different lysine residues play a 
crucial role in gene expression, whereas methylation on arginine residues is poorly 
understood. By now more than 20 methyl-marks have been described [141]. Most studies 
so far focused on six specific sites, namely histone 3-lysine 4 (H3K4), histone 3-lysine 9 
(H3K9), histone 3-lysine 27 (H3K27), histone 3-lysine 36 (H3K36), histone 3-lysine 79 
(H3K79) and histone 4-lysine 29 (H4K29).  
Several examples exist indicating the complexity of lysine methylation. H3K4me1 is 
highly involved in neuronal activity-induced transcription at enhancer sequences, but di- 
and trimethylated forms are mainly found at the 5´-end of genes. H3K4me3 is mostly 
arranged as distinct sharp peaks within 1-2 Kb of the transcription start site, providing a 
docking station for remodeling complexes either inducing transcription or silencing [141]. 
The enzymes involved are histone-methyltransferases (HMT) transferring methyl groups 
from the donor S-adenosyl-methionine (SAM) to the lysine residues and histone-
demethylases (HDM).  
c. Phosphorylation  
Phosphorylation is most commonly associated with active gene transcription, by creating a 
repulsive force between the negative charges of the phosphorylated histones and DNA. 
This repulsion leads to decondensation of chromatin and hence increases the accessibility 
of the transcriptional machinery to the DNA. This modification provides a functional link 
between chromatin remodeling and intracellular signaling pathways, which both depend on 
kinases and phosphatases.   
d. Ubiquitination  
Attachment of the 76 amino acid ubiquitin peptide to residues on the histone tail is 
associated with transcriptional activation and nucleosomal loosening and has been 
identified as prerequisite for subsequent methylation. 
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1.9.3. Histone code hypothesis  
An essential feature of PTMs is their ability to crosstalk. Such modifications can act in 
concert involving multiple feed-forward and feed-back mechanisms on the same 
nucleosome or histone or even on distinct histones [142]. This led to the formulation of the 
“histone code hypothesis” by Jenuwein and Allis [143] stating that the sum of 
modifications at a particular gene defines a specific state of gene activation or silencing. 
  
The crosstalk between different modifications can either enhance chromatin condensation 
or chromatin opening depending on whether gene activity or silencing is required. The 
enzymes described above, which are responsible to establish and remove these 
modifications, operate independently and in synergy to establish the histone code, which 
determines the patter of gene expression in response to external stimuli [5, 143] (Fig. 6). 
Combinations of different epigenetic modifications have been identified in depression on 
the Bdnf promoter in stressed mice. Stress induces an increase in the demethylation of 
H3K27, a repressive modification. Although treatment with ADs is sufficient to reverse the 
behavioral phenotype, the specific H3K27me2 is not targeted by them. Instead, ADs rather 
Fig. 6: Epigenetic marks on histone tails  [5] 
Schematic representation of the N- and C- termini of histones and their residue specific epigenetic 
modifications. Depicted is the crosstalk between different modifications of the H3- N-terminus tail.  
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increase acetylation of other PTMs of the Bdnf promoter, leading to an increased gene 
expression [144]. Therefore, investigation of the interplay between different kinds of 
modifications, acting either in combination or excluding each other, represents a highly 
interesting endeavor to investigate gene specific alterations in depression and might be 
predictive for individual treatment responses to ADs.  
 
1.10. Epigenetic mechanisms in depression  
Epigenetic modifications have been suggested as a potential underlying mechanism in the 
pathophysiology of mood disorders. The first line of evidence that linked 
histonemodifications to antidepressant effects was the observation that HDACi exert AD-
like effects in an adult rodent stress model [144-146]. Administration of HDACi (e.g. 
sodium butyrate) was shown to ameliorate depressive symptoms in socially defeated mice. 
More specifically, the selective HDACi MS275 could reverse the stress induced changes in 
gene expression, in a very similar way as FLX, although both compounds also target very 
unique subsets of genes [147].  
Furthermore, the effects of HDACs were revealed to be brain region specific. In the NAc 
the overexpression of HDAC2 exerts AD-like effects and HDAC5 exerts resilient-like 
effects [148], whereas in the HIPPO HDAC5 seems to have pro-depressive roles. In the 
HIPPO HDAC5 expression is decreased after imipramine treatment in stressed mice and 
overexpression seems to block the AD effects [144]. 
Possible explanations for the opposite effects are that HDAC5 is part of diverse complexes 
depending on the brain regions where it is activated, thereby targeting a subset of genes 
which differentially contribute to vulnerability. Alternatively, HDAC5 may regulate the 
same genes, but these genes elicit different effects in different brain regions. In the cortex 
of inbred mice, high levels of HDAC5 are associated with reduced depressive-like 
behavior [149]. However, further work needs to focus on the precise mechanisms to 
understand how histone acetylation impacts depression and response to ADs.  
Histone methylations and their responsible enzymes are also implicated in psychiatric 
diseases. The first HMT identified in the nervous system was lysine-methyltransferase 2a 
(KMT2a)/Mll1 a member of the mixed lineage leukemia family. In heterozygous mice with 
a loss-of-function mutation in Mll1 distinct abnormalities in hippocampal plasticity and 
related molecular signaling pathways were found to be associated with defects in learning 
and memory [150]. Recently, this HMT was shown to be essential prefrontal synaptic 
plasticity and working memory [151]. Disruption of certain transcription factors such as 
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DLX2 has shown their role as key regulators for the differentiation of forebrain 
GABAergic neurons, possibly contributing to cognitive deficits in Mll1 mutant mice. An 
observation that might be important for the pathophysiology of schizophrenia, as far as 
some patients show deficits in H3K4me3 and gene expression of Gad1, a GABA 
synthesizing enzyme [152]. Additional evidence suggests that epigenetic fine-tuning of 
H3K4-methylation is critical for proper neurodevelopment [141], hence loss-of-function 
mutations in demethylases such as lysine demethylase 5C (KMD5C) have been linked to 
neurodevelopmental disorders such as mental retardation and autism spectrum disorder. 
This demethylase operates in a chromatin remodeling complex together with HDAC1/2 
and the transcriptional repressor REST, thereby poising neuron-restrictive silencer 
elements for H3K4 demethylation and decreasing the expression of target genes, among 
which synaptic proteins and sodium channels [153]. 
KMT6a, a specific H3K27 methyltransferase is associated with the Polycomb Repressive 
Chromatin remodeling complex 2 (PRC2) and is essential for self-renewal of cortical 
progenitor cells and neuron production. Loss of KMT6a function is therefore associated 
with severe thinning of the cerebral cortex and a disproportionate loss of neurons [154]. 
JMJD3, the H3K27-specific demethylase, is important for neurogenesis and neuronal 
lineage commitment [155]. Methylation of this mark is dynamically regulated in the 
mature brain and involved in the neurobiology of psychiatric diseases, as it was shown to 
induce opposite changes in the expression of Bdnf in the HIPPO of mice subjected to either 
enriched environment or chronic stress [144, 156]. Furthermore, alteration in H3K27 
methylation were described at the TRKB gene in the orbitofrontal cortex of suicide 
completers [157].  
Chronic social defeat has been found to decrease several HMTs, such as G9a, GLP and 
SUV39H1 and a co-repressor, Co-REST, which are involved in transcriptional repressive 
complexes in the NAc of susceptible mice, whereas these factors are upregulated in 
resilient animals. Overexpression of G9a (H3K9-specific) leads to antidepressant effects in 
the NAc and its dampening exerts pro-depressive effects. This implicated that stress-
induced loss of repressive methylation might be maladaptive in this context and that ADs 
might act, at least in part, by reinstating these marks at specific loci.  
Very few genes have been identified so far as being implicated in depression and regulated 
by PTMs. One of them is BNDF. For this gene it was shown that electroconvulsive 
stimulation induces H3 and H4 acetylation at the promoter region in the HIPPO, which 
reflects the observed gene expression changes [158]. Follow up studies demonstrated that 
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chronic social defeat decreases total Bdnf mRNA in HIPPO, which was reversed by 
chronic IMI treatment [144], and was correlated with an increase in H3K27me3 
(repressive) at the Bdnf promoter, also persistent after IMI treatment. IMI caused induction 
of acetylation in H3 on Bndf promoter that correlated with reversal of BDNF expression. 
Interestingly, a study examining the effects of postnatal FLX exposure on BDNF 
expression in normal mice did not reveal any differences in H3 acetylation or methylation, 
indicating the necessity of a preexisting stress state for epigenetic changes associated with 
AD treatment [159]. Furthermore, in post-mortem studies, elevated levels of H3K4me3 
were reported for the synapsin gene in the PFC of depressed patients [68].  
Another gene, TrkB.T1, the truncated version of TrkB receptor, also has been found to be 
decreased in the orbitofrontal cortex of suicide completers and this decrease correlated 
with increased H3K27me3 [157]. In the NAc of susceptible vs resilient mice, Uchida and 
colleagues found that GDNF is pro-adaptive to stress. In susceptible mice, GDNF 
expression is decreased in NAc after chronic variable stress and reversed by IMI treatment, 
associated with decreased H3 acetylation, decreased H3K4me3 and increased 
HDAC2/MeCP2 recruitment at the Gdnf promoter. In the resilient animals, GDNF was 
increased in the NAc by chronic stress and this was associated with increased H3 
acetylation and decreased H3K27me3. H3K4me3 was paradoxically decreased after stress 
[117]. A landmark series of experiments was carried out by Meaney and colleagues in 
which they compared the offspring of low grooming (LG) mothers to high grooming (HG) 
mothers. LG offspring show increased anxiety levels and stress reactivity, accompanied by 
decreased GR receptor mRNA in the HIPPO corresponding to decreased H3K9 acetylation 
at the gene promoter compared to HG offspring [67]. They also show lower levels of 
GAD-1 and corresponding decrease in H3K9 binding at the promoter [160]. Although 
much information is available about global epigenetic changes, the evidence on 
misregulated PTMs specifically in astrocytes is very sparse. One epigenome-wide 
association study by Nagy and colleagues identified two candidate genes which are 
affected in the PFC of suicide completers, namely the glutamate receptor, ionotropic 
kainate 2 (GRIK2) and the brain-enriched guanylate kinase-associated protein (BEGAIN) 
[161]. GRIK2 is found in astrocytes and polymorphisms of this gene have been implicated 
in mood disorders [162]. Moreover, mood stabilizers were found to lower GRIK2 levels in 
mouse astrocytes [163]. GRIK2 is hypomethylated in suicide completers, which probably 
influences its splicing. On the other hand BEGAIN is hypermethylated in suicide 
completers. The differentially methylated region of BEGAIN has both gene promoter and 
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enhancer functionalities and in vitro reporter-based assays indicate that DNA methylation 
of this region almost completely abolishes these activities [161]. These data suggest that 
these markers may be specific to depression in the presence of an astrocytic dysfunction.  
However, to date no study is available that directly links PTMs in astrocytes of the PFC to 
MDD. 
 
1.11. Animal model   
To investigate the neurobiological mechanisms of MDD and to understand the underlying 
molecular factors, it is necessary to have proper animal models.  
The difficulty in designing suitable animal models mainly comprises the high complexity 
of mood disorders that need to be mimicked. There are several possibilities on how to 
generate such an animal model, including genetic, environmental or physical as well as 
pharmacological manipulations or a combination of them [164]. A proper animal model 
must fulfill the following criteria to be validated: face validity (i.e. its phenotype is similar 
to the human syndrome), predictive validity (i.e. it has comparable treatment modalities) 
and construct validity (i.e. it shows common pathological substrates). 
In this study, I am using rats derived from a selective breeding approach, either bred for 
high (HAB) or for low (LAB) anxiety- and depression-related behavior [165]. This 
selective breeding approach started in 1990s, by selecting from a cohort of naïve outbred 
Wistar rats, the animals that showed bidirectional performance on the elevated plus-maze 
(EPM, [166]). This test is a well-established, unconditioned test for anxiety that creates a 
conflict between an animal´s exploratory curiosity and avoidance of open brightly-lit 
spaces [167, 168]. To establish the two extreme breeding lines, animals were chosen which 
spent less than 5% (HAB) or more than 40-45% (LAB) time on the open arm [165, 167]. 
Since 2003 these lines are being bred exclusively at the University of Regensburg. Over 
the past decades, exhaustive behavioral, neuroendocrinological and pharmacological 
characterization of these lines was carried out. Due to the fact that in this study I am 
focusing on the depressive-like phenotype of the HAB breeding line, I am summarizing 
briefly the available information.  
1.11.1. Anxiety-related behavior 
In addition to the performance of HAB rats (both genders) on the EPM, these animal were 
also tested in a broad variety of other test for anxiety-related behavior, like the open field, 
modified hole board [169, 170] and the light-dark box, as well as tests for fear 
conditioning, all of which are confirming the highly anxious phenotype. These 
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observations have been shown to be independent from age (overly ultrasonic vocalization 
on post-natal day (PND) 11, behavioral testing between 9 weeks and 19 months of age) 
and gender and have been validated in different European laboratories [171]. 
1.11.2. Depressive-like behavior  
One of the most comprehensive preclinical tests for depressive-like behavior is the forced 
swim test (FST). It is based on observing the coping mechanism of rodents subjected to an 
inescapable situation, i.e. placing the animal in water-filled cylinder. After an initial period 
of active, escape-directed behavior (swimming, struggling) the animals adopt an immobile 
posture, which is indicative of behavioral despair [172-174]. HAB rats display a more 
passive coping style, with a higher immobility (floating) time and less struggling behavior 
[173, 175] in the FST, resembling a depressive-like phenotype. 
1.11.3. Hypothalamic-pituitary-adrenal (HPA) axis and pharmacological 
intervention 
The HPA axis is one of the major stress systems; it is regulated by the release of 
corticotrophin-releasing hormone (CRH) and arginine vasopressin (AVP) from the PVN 
into the pituitary, which stimulates the secretion of adrenocorticotropic hormone (ACTH) 
into the bloodstream. ACTH in turn triggers the release of corticosterone in rodents, which 
facilitates physiological and behavioral adaptations to a stressor. Dysregulation in the HPA 
axis has been linked to several psychopathologies including anxiety and depression [164]. 
HAB rats respond much stronger to a mild, non-social stressor (e.g. open arm exposure), 
by secreting more ACTH and corticosterone, which indicates a hyper-reactive HPA axis 
[176], although under baseline conditions no differences can be measured. HAB also show 
an aberrant response to the dexamethasone-suppression/CRH challenge test [174].  
The DEX/CRH test characterizes neuroendocrine aberrations in depressed patients, who 
typically show signs of non-suppression of ACTH upon DEX exposure and, despite DEX, 
respond to synthetic CRH with an increase in ACTH secretion [177]. This hyper-reactivity 
in HAB animals resembles the clinical situation in patients, whereas persistent 
abnormalities correlate with therapeutic resistance or relapse in patients [178].  
This aberrant DEX/CRH response normalized upon treatment with an acute intravenous 
administration of an AVP V1a receptor antagonist as well as chronic administration of 
paroxetine, a SSRI, by blunting the overexpression of vasopressin in the PVN [165, 173, 
174] In patients, this normalization is indicative of a favorable response to antidepressant 
treatment. Furthermore, the observed depression-like phenotype in HABs is reversible after 
chronic administration (8 weeks) of paroxetine [174]. In comparison to untreated HAB 
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rats, paroxetine-treated animals show a decreased time floating and a higher percentage of 
time engaged in active coping behavior (i.e. struggling) in the FST [165, 174].  
In conclusion, extensive characterization proves HAB rats to be an established and proper 
model to study underlying etiology and mechanism of psychiatric disorders, specifically 
depression.  
 
1.12. Microarray – candidate genes 
Recently, we identified gene expression changes in primary astrocytes and C6 glioma cells, 
a model to study astrocytes, elicited by antidepressant treatment in an unbiased microarray 
screening approach. Several genes were specifically upregulated after treatment with the 
two ADs desipramine and FLX but not with non-ADs (haloperidol, diazepam). Among the 
identified candidate genes, we further investigated the growth differentiation factor 15 
(GDF15) and ephrinA1, a ligand of the EphA2 receptor, which turned out to be 
upregulated in the screening.  
 
 
Fig. 7: Microarray screening and validation via qPCR of candidate genes  
A, Microarray screening on C6 glioma cells revealed that several candidate genes show induced 
expression after 2 h of AD treatment (FLX and desipramine) 
B, Validation in primary rat astrocytes by means of qPCR, showed a significant induction of GDF15 
after treatment with both ADs (n=3, Kruskal-Wallis-test, *p<0.05, **p<0.01, ***p<0.001, data are 
represented as means ± SEM). 
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1.12.1. Growth differentiation factor 15 (GDF15) 
Dysfunctions at the BBB might be indicative for the recently found high degree of 
comorbidity in patients diagnosed with either a primary cerebrovascular pathology or a 
mood disorder [179]. Interestingly, the unbiased microarray screening revealed, GDF15 as 
a factor highly induced by antidepressants in C6 glioma cells and primary astrocytes.  
GDF15 (also known as MIC-1, PTGFB, NAG-1), is a member of the TGF-β superfamily, 
which shows the lowest sequence conservation of all members of this family. GDF15 is 
synthesized as a 62kDa intracellular protein, that is cleaved by a furin-like protease and it 
is secreted as a 25kDa - 35kDa disulfide-linked dimer [180, 181]. Gdf15 mRNA is 
predominantly expressed in prostate, intestinal mucosa, kidney, lung (bronchi and 
bronchioli), exocrine glands, placenta, macrophages and the in the CNS in the choroid 
plexus [182]. Recent studies indicate that GDF15 is secreted in both processed and 
unprocessed forms, at different speeds and via alternate secretory pathway [183], which 
might modulate the amounts of stored and circulating levels. The signaling pathway of 
GDF15 is not fully understood, although there are suggestions that it signals through the 
TGF-β receptors and its downstream signaling pathways, but also that inhibition of the 
PI3K-kinase and ERK block the response to GDF15. Data from the group of Unsicker 
(2003) indicate that GDF15 promotes survival of dopaminergic neurons through a cytokine 
receptor and that phosphorylated Akt and ERK are downstream effectors of GDF15 
mediated signaling on cerebral granule neurons [181]. GDF15 has been greatly implicated 
as a biomarker and predictor for cardiometabolic risk and heart failure [184, 185]. GDF15 
is widely expressed in the central and peripheral nervous system. Its mRNA and protein 
are found in virtually all regions of the rat and mouse CNS, in peripheral nerves and in 
isolated astrocytes. However, the highest levels are found in the choroid plexus, where the 
protein is secreted into the cerebrospinal fluid (CSF) [186]. GDF15 has been shown to be a 
potent neurotropic factor for dopaminergic neurons, as unilateral injections in the medial 
forebrain bundle or the left ventricle significantly reduced the loss of neurons elicited by 6-
hydroxydopamine injections [186]. However, in the unlesioned brain GDF15 expression 
levels are below detection level in glia and neuronal cells [187], indicating that this factor 
might be a specific marker for changes occurring after lesion/inflammation or other 
aberrant changes in the CNS. Knowledge about GDF15 expression and functions in glia 
cells are still very limited. In the CNS GDF15 is synthesized by microglia cells, whereas 
astrocytes in the CNS seem to be devoid of GDF15, which is different from cultured cells, 
where it can be detected [187].Very recently, GDF15 has been implicated as a potential 
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biomarker for bipolar disorder, as it was found to be significantly upregulated in the serum 
of patients suffering from bipolar disorder [188]. Another study found that GDF15 levels 
are 22% higher in the serum of patients suffering from MDD [189], but these findings 
seem to be at least in part dependent on lifestyle factors, such as smoking, alcohol use and 
physical activity. Investigation of the functions and underlying pathways of GDF15, 
especially in the CNS, represents a highly interesting route to be considered in the 
treatment of neurodegenerative and psychiatric diseases. In this study we further elucidate 
implications of GDF15 in the HAB rat model of depression, with a major focus on the 
effects of FLX on its expression in astrocytes.  
1.12.2. Ephrin  
Eph (erythropoietin-producing-heptaocellular carcinoma) receptors (EphR) are the largest 
family of receptor tyrosine kinases (RTK) that transduce extracellular to intracellular 
signals through ligand-induced activation of their kinase domain. EphR mediate contact-
dependent cell-cell communication by interacting with surface-associated ligands – the 
ephrins (Eph receptor-interacting-signals) – located on neighboring cells. [190]. They 
elicit bidirectional signals that affect both- the EphR and ephrins- co-expressed in the same 
cell. Furthermore EphRs can modulate cell behavior independently of ephrin binding and 
kinase activity. This system regulates many developmental processes and adult tissues 
homeostasis and abnormalities in its functionality have been implicated in various diseases. 
 
 
 
 
 
Fig. 8: signaling mechanism in the EphR/Ephrin system [1] 
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a. General features  
EphRs consist of a multidomain extracellular region, including the ephrin ligand-binding 
domain, a single transmembrane segment and a cytoplasmic region that contains the kinase 
domain (Fig. 8). In humans 14 EphRs are described, which can be subdivided into two 
classes (EphA and EphB). Nine EphA-R bind five ephrin-A ligands and five EphB-R bind 
three ephrin-B ligands [1]. Both classes include a conserved Eph-R-binding domain, which 
is connected to the plasma membrane by a linker segment. EphrinAs are attached to the 
cell surface by a GPI anchor, but they can also be released to activate distant receptors. 
EphrinBs contain a transmembrane segment and a short cytoplasmic region. [190]. 
Combinations of these receptors and ligands are present in most cell-types, including the 
brain. 
EphRs bind ephrins on neighboring cells mediating a contact-dependent, bidirectional 
communication that regulate cell shape, movement, survival and proliferation [191]. 
During development this system plays a role in the spatial organization of different cell 
populations, axon guidance, formation of synaptic connections and remodeling of blood 
vessels. In the adult brain, among others it regulates remodeling of synapses, epithelial 
differentiation and integrity [192]. In the EphR/ephrin system three form of signaling are 
described, namely forward, reverse and bidirectional signaling (Fig. 8). Forward signaling 
depends on ephrin binding, which induces EphR clustering, autophosphorylation and 
kinase activity and can lead to endocytosis or proteolytic cleavage, thereby generating 
intracellular fragments with distinctive signaling abilities.  
Reverse signaling is stimulated by EphR binding in the ephrin-expressing cell via 
interaction with signaling partners. EphrinB signaling involves phosphorylation by the 
Sarcoma kinase (SRC) creating binding domains for other signaling proteins, e.g. non-
catalytic region of tyrosine kinase adaptor protein 2 (NCK2), which controls axon pruning, 
synapse formation and dendritic spine morphogenesis in the developing mouse HIPPO 
[193].  
Bidirectional signaling transduction can be further regulated. EphrinAs can be released 
from the cell surface by metalloprotease cleavage and activate EphA receptors in a 
paracrine manner. Interaction between receptor and ligand co-expressed in the same cell 
can attenuate the cell contact-dependent signals induced by trans interaction EphRs can 
also function through non-canonical signaling modalities, including intracellular proteins. 
After binding of the ligand, the EphRs are internalized by endocytosis into either EphR or 
ephrin expressing cell through the formation of vesicles containing plasma membrane 
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fragments derived from both cells in an Ras-related C3 botulinum toxin substrate 1 (RAC-
1) dependent process, termed trans-endocytosis [190]. Besides trans-endocytosis, the 
complexes can activate metalloproteases like ADAM10 which can associate with ephrinA2 
in the same cell surface and cleave it following EphAR binding in trans to enable repulsive 
axon guidance [194]. Ephrin binding and other stimuli can also induce cleavage of EphR 
extracellular domain, followed by further transmembrane proteolytic processing via γ-
secretase to generate cytoplasmic fragments capable of signaling [190]. 
b. Implications in CNS pathologies   
Many receptors and ligands are expressed after injury and negatively affect axon sprouting 
and other repair processes [192]. Several studies established a connection between 
pharmacological inhibition of EphA4-ephrin binding and EphA4 gene inactivation with 
improved functional recovery in rodent spinal cord injuries [195]. In Alzheimer’s disease 
the cytotoxic β amyloid peptides can activate EphA4 forward signaling, which has been 
shown to participate in the synaptotoxicity and can be blocked by EphA4 antagonists 
[196]. Intracellular fragments of EphA4 are decreased in Alzheimer´s disease, but can 
promote dendritic spine formation independently of kinase activity [190]. A soluble form 
of ephrinA1 (ephrinA1-Fc) promotes regeneration of brain dopaminergic neurons in a rat 
model of Parkinson’s disease [197]. The Eph/ephrin system controls blood vessel 
sprouting, assembly, remodeling and stabilization by regulating endothelial cells and 
pericytes. EphA2 regulated vascular permeability, mainly in concert with ephrinA1 
through the interplay with VEGF, indicating that this system represents a promising target 
for therapeutic intervention of vascular pathologies. In glioblastoma, downregulation of 
EphA2 or EphA3 expression either by RNAi or administration of high doses of ephrinA1-
Fc drastically reduces tumorigenicity [198]. In a very recent study, levels of EphB2 and its 
downstream molecules were found to be decreased in the medial PFC in mice that were 
susceptible to chronic social defeat and activation of EphB2 by ephrinB1-Fc produced 
stress-resistant and antidepressant-like behavioral effects in susceptible mice, whereas 
knockdown (k/d) using shRNA (short hairpin RNA) increased susceptibility and induced 
depressive-like behavior. These changes were associated with α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor (AMPAR) trafficking and the expression of 
synaptic protein in the PFC. It also regulated stress-induced spine remodeling in the PFC. 
[199] 
Already in 2003 EphA receptors were shown to be important regulators of spine 
morphology in the HIPPO [200]. However, the role of ephrinAs is less understood. 
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EphrinA5 is linked to spine density and synapse function in the cortex and HIPPO. 
EphrinA5 knockout (k/o) mice have increased numbers of filipodia-like protrusions in the 
cortex during early development [201], but after completion of synaptogenesis these cells 
display significantly fewer dendritic spines. In the HIPPO ephrinA5 regulates synaptic 
development and function by modulating the PI3K/Akt pathway. Presynaptically, 
ephrinA5 promotes BDNF-induced synapse formation, whereas synapse formation is 
significantly reduced in cultured neurons form k/o mice. In contrast, binding of 
postsynaptic EphA receptors to presynaptic ephrinA5 leads to suppression of BDNF-
induced synaptogenesis [202]. As described before, neuron-glia communication is an 
important regulator of synapse development and function [100]. EphR and ephrins are 
especially located at synaptic terminals of hippocampal and cortical neurons and some are 
also localized at the perisynaptic astrocytic processes, allowing them to participate in 
synaptic transmission [203]. Hippocampal astrocytes express high levels of ephrinA3 and 
regulate spine morphogenesis, glutamate transport and long-term potentiation at CA3-CA1 
synapses by interacting with EphA4 on dendrites of CA1 pyramidal neurons [204, 205]. 
K/o animals for either of these factors have abnormally shaped dendritic spines and 
reduced long-term potentiation, as well as impaired contextual fear memory. These deficits 
are most likely due to an upregulation of GLAST and GLT-1 receptors in the k/o animals, 
causing an exaggerated removal of glutamate form the synaptic cleft, which in turn leads to 
reduced LTP. Dysfunction in glutamate metabolism and aberrant dendritic and glia cell 
morphologies have already been implicated in MDD, thus studying these interactions at the 
synaptic level in our animal model might depict a very exciting possibility to shed light on 
the pathophysiology of depression. 
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1.13. Scope of study  
Major depressive disorder has become the leading cause of disability worldwide [7]. 
Although several treatment options exist, the major drawbacks, like late onset of beneficial 
effects and a high rate of non-responders still represent a huge burden for patients. To date 
the molecular underpinnings of MDD are still very poorly understood, making the most 
reliable criterion to diagnose MDD dependent on a subjective perception of symptoms. 
Additionally, suitable animal models mimicking depression are sparse. Therefore, it is 
highly important to identify the underlying molecular mechanisms of depression. In this 
study I specifically focused on posttranslational histonemodifications that might account 
for gene expression changes, which in turn could contribute to the depressive phenotype 
observed in HAB animals.  
Therefore, I first investigated whether under basal conditions HAB animals showed 
different expression patterns of several PTMs in comparison to “healthy” NAB rats and if 
these differences were specific to cortical astrocytes or neurons (ex vivo and in vitro). Both 
cell-types have been implicated in depression, with striking evidence that aberrancies in 
astrocytes, rather than in neurons, might be the cause of depression. Furthermore, I 
investigated if these PTMs were targeted by antidepressant treatment and if the 
misregulation in HAB could be reversed. Moreover, I investigated if the observed 
differences in PTMs could be linked to the expression of specific candidate genes that were 
previously identified to belong to pathways modulated by AD treatment in our lab.  
With regard to our recently published paper, stating astrocytes to be misregulated at the 
level of the blood-brain-barrier, I further investigated if one of the identified candidate 
genes might be involved in the formation of astrocytic processes and whether a putative 
imbalance in its expression could be rescued by antidepressant treatment in vitro and ex 
vivo. On the one hand, I hypothesized that HAB animals display aberrant gene expression 
caused by misregulation of PTMs and that this misregulation could be rescued by AD 
treatment. Moreover, investigation of specific genes might provide a possibility to identify 
new pharmacological targets in the pathophysiology of MDD. On the other hand, I 
investigated how structural aberrancies at the glia-vasculature interface can be targeted by 
antidepressant treatment, focusing on the actions of ADs on astrocytic processes.  
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 Material and MethodsAnimals All animal experiments were approved by the 2.
government of the Oberpfalz (Germany) and carried out in accordance to the European 
communities Council Directive of 24 November 1986 (86/609/EEC).  
For this study, adult male rats (10-12 weeks old, 280-350 gram) selectively bred for high 
anxiety-related behavior (HAB) and weight-matched non-selectively bred Wistar rats 
(NAB), serving as controls, were used. Animals were bred in the in-house animal facility 
at the University of Regensburg (HAB) or purchased from Charles River Laboratories 
(NAB; Charles River, Sulzfeld, Germany; strain code 003). Animals were kept under 
standard housing conditions (room temperature (RT) 22-24°C, humidity 55 %, 12 hours 
(h) light/dark cycle with lights on at 6:00 a.m.). Water and pelleted food were provided ad 
libitum. For preparation of primary cortical astrocytes, HAB and NAB pups on post-natal 
day (PND) 0-4 were used, for cortical neurons NAB embryos on embryonic day 18 (E18) 
were used. 
 
2.2. Drugs 
Fluoxetine hydrochloride (FLX) and escitalopram oxalate (ESC) were purchased from 
Abcam®, Cambridge, UK (#ab12077 and #ab145177, respectively). For experiments in 
brain slices (ex vivo) FLX was diluted on the day of the experiment in phosphate buffered 
saline (PBS) and injected intraperitoneal (i.p.), twice daily, at a concentration of 10 mg/kg, 
on two consecutive days.  
For in vitro experiments both drugs were prepared in water at a stock concentration of 10 
mM and diluted to a final working concentration of 5 µM and 10 µM (for more details, see 
respective experiments). 
 
2.3. Preparation of astrocytes  
Primary cortical astrocytes were isolated on PND 0-4 from cerebral cortices of HAB and 
NAB rat brains. Rat pups were decapitated, the skull was opened using small scissors, and 
meninges were removed carefully. Brains were isolated and cortices dissected in ice-cold 
HBSS (Hanks´ balanced salt solution, Gibco, #14025-092). After fragmentation of the 
cortices into small pieces, the pieces were pooled, transferred to a sterile 15 ml falcon 
containing 5 ml ice-cold HBSS and shortly centrifuged. Supernatants (SN) were removed 
and an appropriate amount of 0.25 % trypsin containing 1 mM EDTA (Sigma, #T4049) 
was added for digestion (20 minutes (min) at 37°C), while gently shaking. Remaining 
brain tissue was homogenized using fire-polished Pasteur-pipettes, with decreasing tips´s 
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diameters, to obtain dissociated cells. Cell homogenates were centrifuged at 90x g for 5 
min, supernatants were aspirated and cells were resuspended in warm astrocyte-growth 
medium DMEM (Dulbecco´s modified eagle medium, Gibco, #41965-062) supplemented 
with 10 % fetal calf serum (FCS, Sigma, #F7524), 1 % antibiotic-antimycotic (100x, 
Sigma, #A5955), 1 % sodium pyruvate (Sigma, #S8636), 1 % HEPES 1M (Gibco, #15630-
056), 1 % MEM non-essential amino acids (Gibco, #11140-035). Cells homogenates were 
plated on poly-D-lysine (PDL, Sigma, Taufkirchen, Germany, #P7886) coated T75 cm
2
 
flasks (Sarstedt, #83.3911.002) [206, 207]. 
2.3.1. Cell culture passaging  
Freshly isolated astrocytes were allowed to grow for approximately 7-10 days in vitro 
(DIV) (37°C, 5 % CO2/ 95 % air) in astrocyte-growth medium that allows the growth of 
astrocytes, but does not favor the growth of other cell-types (e.g. neurons or microglia). To 
remove remaining cell-types (neurons/microglia/oligodendrocytes) flasks were shaken for 
4 h at RT, causing a detachment of these cells which can then be eliminated by washes 
with PBS. This procedure helps to reach a nearly pure astrocytic cell culture. As soon as 
astrocytes reached a confluency of 90-100 % medium was removed, cells were trypsinized, 
resuspended in freezing medium (DMEM supplemented with 20 % FCS and 10 % (v/v) 
dimethylsulfoxide (DMSO, Sigma, #D-2650), aliquoted (approx. 1x10
6 
cells/vial) and 
gradually frozen at -20°C (24 h) followed by -80°C for 24 h until permanent storage in 
liquid nitrogen (-196°C).  
2.3.2. Cultivation  
For cultivation, deep frozen (-196°C, liquid nitrogen) cell aliquots containing 
approximately 1x10
6
 cells were thawed quickly and seeded in a PDL coated T75-flask with 
astrocyte-growth medium. Cells were maintained in growth medium until they reached 
confluency (~14 DIV), with medium change every 3d. Confluent cells were trypsinized and 
seeded into corresponding experimental plates. Primary rat astrocytes were used until 
passage 4 (P4), every trypsinization step was considered as an additional passage. 
 
2.4. Preparation of neurons  
Primary cortical neurons of NAB rats were isolated on E18. In brief, the dam was 
sacrificed using CO2, the peritoneum was opened and the embryos were carefully removed. 
The embryos were decapitated and the skull was opened. The meninges were removed 
carefully, the brains isolated and the cortices dissected. Cortices were centrifuged, debris 
was removed and the pieces were homogenized using fire-polished Pasteur-pipettes. Cells 
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were then seeded in on laminin-coated (Sigma, # L-2020) cover glasses or 24-well plates 
in neuron-specific medium (Neurobasal-A-medium Invitrogen, #10888022, supplemented 
with B27 #17504-044 and Glutamine #25030024). Pure neuronal cultures were allowed to 
grow for 21 DIV. Half of medium per well was changed every 3d. 
 
2.5. Preparation of co-cultures 
For the preparation of co-cultures, primary cortical astrocytes derived from HAB and NAB 
rats were used. Cells were seeded on PDL -coated cover glasses in astrocyte-growth 
medium. Astrocytes were allowed to grow for approximately 3-5 DIV, and then medium 
was changed to neuron-specific medium shortly before freshly isolated neurons were 
plated onto the feeder layer of astrocytes. The resulting co-cultures were allowed to grow 
approximately 14 DIV. Half of the neuron-specific medium was changed every 3d, to 
allow the co-cultures to remain in their established environment.  
2.6. Antidepressant treatment  
After astrocytes reached confluency (90-100 %, approximately 7-14 DIV), medium was 
changed to serum free medium 24 h prior to the treatment with ADs. Cells were treated 
with FLX or ESC for 48 h (once, 10 µM) or 120 h (two times, 5 µM each). According to 
the following scheme: 
 
Neuronal cultures and co-cultures were treated only once at the beginning of the 
experiment with 10 µM FLX or ESC without changing the medium 24 h before. Treatment 
was terminated either after 48 h or 120 h. Eventual variations on AD treatment are 
specified for the single experiments. 
 
2.7. Harvesting  
To terminate the treatment, medium containing ADs was discarded; single cultures were 
washed with ice-cold PBS, scraped off the surface in PBS, transferred to Eppendorf tubes 
and immediately put on ice. Cells were centrifuged for 10 min (12.000 rpm (rounds per 
minute)) using a pre-cooled (4°C) microfuge (Eppendorf AG, Wesseling-Berzdorf, 
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Germany), supernatants were discarded and cell pellets were stored at -80°C until further 
processing.  
 
2.8. Immunofluorescence (IF) analysis  
2.8.1. Drug treatment and perfusion 
For immunofluorescent-immunohistochemical (IF-IHC) analysis, animals were either 
naïve or injected with saline or FLX (i.p., twice daily, 0 or 10 mg/kg FLX for 2d). 12 h 
after the last injection animals were deeply anesthetized using CO2 and perfused 
transcardially with cold PBS, followed by fixation with 4 % paraformaldehyde (PFA, 
Roth, #0335.2) in PBS. 
Brains were removed and post-fixed in 4 % PFA overnight (O.N.) at 4°C. Then, brains 
were washed 3 times with PBS and cryoprotected in 25 % sucrose in PBS or at -80°C until 
they were cut in 40 µm coronal sections on a cryostat (Leica CM1950, Leica 
Microsystems, Nussloch, Germany). Sections were preserved in 25 % ethylene glycol/ 25 
% glycerol in PBS and stored at -20°C until further processed.  
2.8.2. Immunofluorescent-Immunohistochemistry  
Free-floating sections from the PFC were selected and washed thoroughly in PBS (3x 20 
min), followed by permeabilization and blocking in 2 % normal goat serum (NGS, Linaris, 
#S1000), supplemented with 0.1 % Triton-X-100 in PBS, for 1 h at RT.  
After washing, staining was performed by incubating the slices with different combinations 
of primary antibodies, O.N. at 4°C (see Table 1), diluted in the aforementioned solution 
with gentle shaking.  
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Combination Protein Specificity 
Concent
ration 
Company Experiment 
H3K4me3 
global 
rabbit-anti-
H3K4me3 
histone 3 -lysine 
4-trimethylation 
1: 1000 
Millipore. 
#07473 
3.1.1 
3.2.1 
3.2.3 
H3K4me3 in 
neurons 
mouse-anti-
NeuN 
neuron specific 
marker 
1: 500 
Millipore, 
#MAB377 3.1.2 
3.2.2 
3.2.4 rabbit-anti-
H3K4me3 
histone 3 -lysine 
4-trimethylation 
1: 1000 
Millipore. 
#07473 
H3K27me3 
global 
rabbit-anti-
H3K27me3 
histone 3 -lysine 
27-
trimethylation 
1: 1000 
Millipore, 
#07449 
3.4. 
H3K27me3 in 
neurons 
mouse-anti-
NeuN 
neuron specific 
marker 
1: 500 
Millipore, 
#MAB377 
3.4.1 
rabbit-anti-
H3K27me3 
histone 3 -lysine 
27-
trimethylation 
1: 1000 
Millipore, 
#07449 
H3K4me3 in 
astrocytes 
mouse-anti-
GFAP 
glia specific 
marker 
1: 400 
Sigma. 
#G3839 
3.1.2 
3.2.2 
3.2.4 
mouse-anti-
S100β 
glia specific 
marker 
1: 1000 
Sigma, 
#S2532 
rabbit-anti-
H3K4me3 
histone 3 -lysine 
4-trimethylation 
1: 1000 
Millipore. 
#07473 
H3K27me3 in 
astrocytes 
mouse-anti-
GFAP 
glia specific 
marker 
1: 400 
Sigma. 
#G3839 
3.4.1 
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mouse-anti-
S100β 
glia specific 
marker 
1: 1000 
Sigma, 
#S2532 
rabbit-anti-
H3K27me3 
histone 3 -lysine 
27-
trimethylation 
1: 1000 
Millipore, 
#07449 
ephrinA1 
rabbit-anti-
ephrinA1 
ephrinA1 1: 100 
Invitrogen 
#34-3300 
3.6 
EphA4 
mouse-anti- 
EphA4 
EphA4 1: 500 
Invitrogen 
#37-1600 
Table 1: Primary antibody combinations in IF-IHC  
 
On the second day brain slices were washed (3x 10 min in PBS) to get rid of unbound 
primary antibody and incubated for 2 h with the corresponding secondary antibodies. As 
secondary antibodies for neuronal (NeuN) and astrocytic markers (GFAP/S100β) Cy3-
labeled anti-mouse (Sigma, # C2181), at a concentration of 1:250, was used. 
For both histone markers (H3K4me3 and H3K27me3) the biotin-avidin enhancer system 
was applied. First, slices were incubated with biotin-coupled goat anti-rabbit 1: 300 
(Dianova, #111-065-003) followed by the incubation with tertiary fluorescent antibody 
Alexa Fluor 488-labeled avidin anti-biotin 1: 1000 (Invitrogen, # A21370). 
Secondary antibodies for ephrinA1 and EphA4 were goat-anti rabbit-Alexa Fluor 488 
(1:250, Invitrogen, # A-11008) and Cy3-labeled-anti-mouse (1:250), respectively.  
To label nuclei in all IF- experiments DAPI (1: 1000, Sigma, # 32670) was used.  
Secondary and tertiary antibodies were diluted in 2 % NGS in PBS and incubated for 1 h at 
RT, each. At the end of the procedure slices were washed (3x 10 min in PBS) and mounted 
on specimen slides using aqueous mounting medium (Abcam, #ab128982) for confocal 
analysis. 
2.8.3. Immunofluorescent-Immunocytochemistry (IF-ICC)  
For IF-ICC primary cortical rat astrocytes (NAB and HAB) were seeded on glass 
coverslips (Ø 12 mm, Roth, #P231.1), coated with PDL, at a density of 1x10
5
 cells/well. 
Cells were allowed to grow until they reached 80 % confluency. For co-cultures: 24 h 
before neurons were seeded onto the layer of astrocytes, the medium was changed to 
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neuron-specific medium. Then neurons, derived from NAB animals, were seeded on the 
feeder layer of astrocytes. The co-cultures were allowed to grow approximately 14 DIV.  
For functional experiments on ephrinA1/EphA4, the co-cultures were treated according to 
the following scheme:  
 
Ephrin A1-Fc (recombinant human chimera protein, R&D Systems, #6417-A1-050) and 
EphA4-Fc (recombinant human chimera protein, R&D Systems, #6827-A4-050) were used 
at three different concentrations: 1.0 µg/ml 48h, 0.1 µg/ml 48 h and 120 h and 0.01 µg/ml 
120 h.  
ESC and FLX were administered once to the co-cultures at a concentration of 10 µM for 
48 h or 120 h. 
After termination of the treatment, cells were washed with cold PBS and fixed in 4 % PFA 
for 20 min. PFA was removed, cells were washed 3x 10 min in PBS and stored in PBS at 
4°C until further processing.  
For IF-ICC, cells were permeabilized and blocked in 0.1 % Triton-X-100/2 % NGS in PBS 
for 15 min at RT. Subsequently cells were incubated O.N. at 4°C with primary antibodies, 
while gently shaking (Table 2):   
Fig. 9:Layout of Co-Cultures neurons growing on astrocytes derived from either NAB or HAB 
rats. 
NAB-NAB co-cultures were treated with FLX, ESC and recombinant ephrinA1-Fc, at different 
concentrations and time points. HAB-NAB co-cultures were treated with the same way using FLX, 
ESC, but with recombinant EphA4-Fc. 
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Combination Protein Specificity 
Concentratio
n 
Company 
Experim
ent 
Synaptic 
compartments 
 
mouse-anti-
PDS 95 
Postsynaptic 
protein 
1: 300 
NeuroMAB, #75-
028 
3.7 
rabbit-anti-
Synaptophysi
n 
Presynaptic 
protein 
1: 500 Abcam, #ab52636 
chicken-anti-
MAP 2 
Cytoskeletal 
protein 
1: 1000 Acris, #CH22103 
Table 2: primary antibody combination for IF-ICC functional experiments  
 
On the next day cells were washed (3x 10 min in PBS) and incubated for 2 h with the 
corresponding secondary antibodies. For PSD95, Cy3-labelled-anti mouse (1: 500), for 
MAP2 anti-chicken Alexa Fluor488 (1: 1000) and for synaptophysin the avidin-enhancer 
system was used, with biotinylated-anti-rabbit (1:500) and avidin-anti-biotin Alexa Fluor 
647 (1: 1000). For all stainings DAPI (1: 1000) was used to label the nuclei. 
Secondary and tertiary antibodies were diluted in 2 % NGS/PBS and incubated for 2 h at 
RT, each. Finally coverslips were washed (3x 10 min in PBS) and coverslips were 
mounted on specimen slides using aqueous mounting medium for confocal analysis. 
2.8.4. Confocal microscopy 
To analyze IF-IHC and IF-ICC, microphotographs were taken using a Leica SP8 confocal 
microscope (Leica, Wetzlar, Germany) or a Olympus (at the Max Planck Institute of 
Psychiatry, Munich, inverted type IX81, (see below; Olympus Europe holding GmbH, 
Hamburg, Germany). In brief, appropriate lasers for detection of fluorochromes were 
selected and settings were adjusted based on the highest fluorescent signal. The following 
settings were adjusted at the beginning of each experiment and kept constant throughout.  
 objective and digital zoom  
 exact range of wavelengths  
 pinhole  
 gain/offset  
 line average  
 number of pixels per picture (512x512) 
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To ensure an appropriate recoding of entire sections (thickness: brain slices 30-40 µm, 
coverslips with cells 8-9 µm and co-cultures 3-4 µm), Z-stack acquisition was used. The 
focal plane was set, and the beginning and end point were defined, as well as the step size 
(1.23 µm and 1 µm of co-cultures). To avoid bleed-through between the different channels, 
a sequential acquisition mode was used. 
IF-IHC: For each animal 2-3 cortical slices were stained and microphotographs were 
taken. For each slice 8-12 randomly selected, non-overlapping Z-stacks were acquired and 
included for further analysis.  
IF-ICC: 15-20 randomly selected cells (Z-stack) of each treatment condition were taken 
for analysis. 
IF-ICC in co-cultures: only qualitative analysis of single pictures  
 
2.9. Quantitative analysis  
2.9.1. Histone marks  
Fiji allows opening the acquired Z-stacks individually or all at once. 
Acquired images were saved 
by the confocal microscope as 
.lif files, which contained all 
the relevant metadata. A .lif 
file was opened (via 
drag´n´drop, Fig. 10) by the 
Bio-Formats-Importer plugin 
[4] in Fiji (ImageJ 1.50d [6]). 
Fig. 10: Open .lif files in Fiji via drag ´n´drop  
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By choosing to open all series of one .lif file at once, the single stacks are opened 
individually, with the respective default data included by the microscope (Fig.13). Single 
channels were displayed and could be selected by using the slider “C” (red arrow, Fig.13). 
To scroll through the single pictures of the acquired series, the slider “Z” was used (blue 
arrow, Fig.13). 
  
Fig. 13: Bio-Formats Series Options Fig. 13: Slider bars can be used to scroll 
through single channels and picture 
Fig. 11: Import options Bio-Formats Importer Fiji  
To open images, the 
appropriate import 
options in the Bio-
Formats Importer were 
chosen (Fig.11, Stack 
viewing: Hyperstack, 
Display metadata, color 
mode: default, 
Autoscale). 
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For analysis single channels were converted into a composite, displaying all channels in 
the same picture. ImageColor Channel tools Composite (Fig.14) 
 
The final image shows the overlay of all channels and acquired images in one window, still 
giving the possibility to turn on and off the single channels, exemplarily displayed in 
Fig.15. 
 
 
Fig. 14: Conversion of acquired series into a composite 
Fig. 15: Overlay of channels with the possibility to enable single channels 
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Fig. 18: Colocalization analysis of double-
labeled cells  
For the analysis of the single channels, one channel at a time was enabled and all cells, 
labeled with the different fluorescent antibodies, were counted using the Cell Counter 
(Plugins  Cell Counter  Cell Counter, Fig.17) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After initializing the Z-stack for analysis by 
the plugin, I choose different counter types to 
analyse every single channel individually 
(Fig.17).  
First, I counted all nuclei in each single field 
(DAPI staining), which served as a 
normalizer later on. Then, the two other 
channels were analyzed in the same way 
(histone staining, astrocytes or neurons). To 
be able to analyze a possible colocalization 
between the histone marks and astrocytes or 
neurons, both channels were enabled at the 
same time and I counted cells that were labeled with both fluorescent antibodies (Fig.18).  
For statistical analysis, the following parameters were calculated, first for each randomly 
selected field individually: 
global expression histone marks: total number of cells labeled with histone mark/ total 
cell number   
Fig. 17: Cell Counter plugin Fig. 17: Fiji Analysis of single channels using the built-
in plugin Cell Counter 
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Cell-type specific expression: total number of cells colocalizing/total number of specific 
cell-type (astrocytes or neurons) 
Then the mean for each single animal was calculated and the means were used for 
statistical analysis.  
2.9.2. Statistical analysis  
To choose the appropriate statistical test for each data set, the D´Agostino and Pearson 
omnibus normality test was used. Data IF-IHC (histone marks) are depicted as mean of 
single animals (dots and triangles) and mean over all animals (columns) + standard error of 
means (SEM). “n” indicates the number of independent experiments. 
The two-tailed Students t-test was used for the IF-IHC experiments examining H3K4me3, 
when comparison between two groups was suitable. A one-tailed Student´s t test was 
applied for the IF-IHC experiments analyzing H3K27me3, when comparing two groups.  
The one-way ANOVA, followed by Dunnett´s multiple comparison post hoc test, was used 
for the analysis of the western blot experiments, when comparing more than two groups.  
Differences were considered significant, when the level of significance (p-value) was equal 
or less than 5 % (p<0.05, indicated with “*”), very significant, when equal or less than 
1 % (p<0.01, “**”) or extremely significant, when equal or less than 0.1 % (p<0.001, 
“***”). All graphical data were obtained by GraphPad Prism version 5.00 for Windows, 
GraphPad Software, San Diego California USA. 
 
2.10. Western blot experiments  
For western blot experiments HAB and NAB astrocytes were seeded in 6-well plates 
(Corning, #3506) at a concentration of 3x 10
5 
cells/well and maintained (medium change 
every 3d) until they reached confluency. After treatment with ADs (FLX or ESC for 48 h 
(10 µM and 120 h (2x 5 µM)) cells were harvested, as stated above (see 2.7).  
Western blot experiments were performed according to the following protocol. Cell pellets 
were resuspended in 40-80 µl homogenization buffer (1 M Tris at pH 7.5 (Sigma, #1503), 
protease inhibitor cocktail in H2O (Roche Diagnostics, #04693116001) and manually 
homogenized for 30 s, using a pistil. RIPA buffer was added (1: 5 ratio, pH 7.6, containing 
1M sodium dihydrogen phosphate (Roth, # T878.1), 10 mM disodium hydrogen phosphate 
(Roth, #P030.1), 154 mM sodium chloride (VWR, #27810295), 4 mM sodium 
deoxycholate (Sigma, #D6750), 1 % Triton-X-100 (Sigma, #X100), 20 % SDS (sodium 
duodecyl-sulfate, Roth, #4360.1) in H2O). Cell homogenates were lysed O.N. at 4°C, on a 
shaker.  
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On the next day, 5x Laemmli buffer (ratio 1:5, 0.3 M Tris, 5 M Glycerin (Sigma, #2289), 
25 mM EDTA (Roth, # 3053.1), 0.5 M DTT (Sigma, # D0632), 0.5 mM Bromphenolblue 
(Fisher Scientific, # 10187220), 10 % SDS in H2O was added, cell lysates were denatured 
at 99°C for 10 min, quickly spun down and 28 µl lysate were loaded on a SDS-acrylamide 
gel (12 % SDS for histone marks, 10 % SDS for ephrinA1). Additionally, 5 µl of 
PageRuler
TM
 prestained protein ladder (Thermo Scientific, #26616) were loaded to 
ascertain an appropriate separation. Gel run was performed for 1.5 h, 90 V at RT in 
running buffer (25 mM Tris, 190 mM Glycine (Sigma, # G8898), and 0.1 % SDS in aqua 
dest. pH 8.3). After full separation of all the proteins, the gel was transferred to a blotting 
chamber.  
To guarantee the complete protein transfer onto a polyvinylidene fluoride (PVDF) 
membrane (Zefa Laborservice, #79090), proteins were blotted for 2 h, 90 V at 4°C. To 
maintain a stable temperature environment the transfer buffer (20 mM Tris, 140 mM 
Glycine, 20 % Methanol (Merck, #M6009) in aqua dest, pH 8.3) was pre-cooled (4°C) and 
a cooling aggregate was inserted into the blotting chamber. For ephrinA1 the blotting was 
carried out at RT for 2 h at 100 V. After verification of the protein transfer via Ponceau S 
(Applichem, #A29350.500) staining, the membrane was blocked either O.N. in 5 % bovine 
serum albumin (BSA, Roth, #8076.4) at 4°C for histone marks or for 2 h at RT for 
ephrinA1. Afterward, membranes were incubated with primary antibodies for 24 h. All 
ABs were diluted in 5 % BSA in 1x PBS unless stated otherwise. 
The following antibodies were used (Table 3):  
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Protein Concentration Company Experiment 
anti-β-actin 
(42 kDa, mouse) 
1: 2000-4000 
Sigma, 
#A-5441 
Housekeeper in all 
experiments 
anti-H3K4me3 
(15.5 kDa, rabbit) 
1: 1500 
Millipore, 
#07-473 
3.3.1 
anti-H3K27me3 
(15.5 kDa, rabbit) 
1: 1500 
Millipore, 
#07-449 
3.3.2 
anti H3K27ac 
(14 kDa, rabbit) 
1: 1000 
Abcam, 
# ab4729 
3.3.3 
anti-ephrinA1 
(26 kDa, goat) 
1: 500 
Acris, 
# AP22424PU-N 
3.5.2 
3.5.3 
Table 3: primary antibodies for western blot analysis  
 
To enable chemiluminescent analysis, corresponding secondary antibodies coupled with 
horseradish peroxidase (HRP) were used: 
rabbit anti-mouse HRP 1: 5000-10000 (Jackson ImmunoResearch, #315-035-003) 
goat anti-rabbit HRP 1: 2000 (Jackson ImmunoResearch, # 111-035-003) 
rabbit anti-goat HRP 1: 2000-2500 (Jackson ImmunoResearch, #305-035-003) 
Membranes were incubated with the secondary antibodies diluted in 2 %NGS/PBS at RT 
for 2 h, on a rotating shaker.  
Membranes were washed 3x 10 min in PBS and incubated with Pierce
TM
 ECL Western 
blotting substrate (ThermoFisher Scientific, #32106) for 3-5 min. Chemiluminescent 
reaction was visualized with the ImageQuant LAS4000 (GE Healthcare Life Sciences, 
Freiburg, Germany).  
Further analysis was carried out using Fiji (version 1.50d, National Institutes of health, 
USA, http://imagej.nih.gov/ij [6, 208]). 
2.10.1. Protein expression quantification  
Analysis of western blot experiments was carried out using Fiji. In brief, .gel files were 
imported in ImageJ via drag´n´drop, picture contrast was adjusted with the tool 
“Brightness & Contrast” to guarantee a proper analysis. The “gels tool” was used to define 
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the bands of interest and a plot profile was generated by Fiji. The raw data (area and 
percent) were used to calculate the results.  
All lanes were normalized to the corresponding total amount of housekeeper protein (β-
actin) (protein of interest/ actin = normalized results). First the mean of all controls was 
calculated in % (results normalized * 100/ mean of all controls). Then the mean of the 
different treatments (48 h and 120 h) was calculated accordingly. To analyze baseline 
differences in the proteins of interest between NAB and HAB astrocytes, normalized 
results of HAB were expressed as difference with respect to normalized results of NAB 
controls. 
2.11. Short interfering RNAs (siRNA) fot the downregulation of ephrinA1 
2.11.1. Transfection 
HAB and NAB astrocytes were seeded in growth medium on PDL-coated 6-well plates at a 
concentration of 3x10
5
 cell/well for western blot experiments or glass cover slips at 5x10
4
. 
Cells were allowed to grow until reaching 30-50 % confluency.  
I designed siRNAs complementary to the mRNA sequence of ephrin A1 (NCBI Reference 
Sequence: NM_053599.2) using the siDesign Center (Dharmacon Research, Lafayette, Co, 
USA). Four different siRNAs were selected and synthesized: 
 
si1: 5´- GGA GAA GCU GUC UGA GAA A -3´ 
si2: 5´- GGG CAA GGA GUU CAA GGA A -3´ 
si3: 5´- CCG GAG AAG CUG UCU GAG AUU- 3´ 
si4: 5´- GAA GAG ACU CCA AGC AGA UUU -3 
 
A non-targeting scrambled sequence (5´- CCUAAGGUUAAGUCGCCCUUU-3´) served 
as a negative control. All sequences were submitted to a BLAST search in order to verify 
the specific targeting of the siRNAs (si1-4) to ephrinA1, or the lack of targeting of any 
sequence for scrRNA. [209]. 
Transfection of primary rat astrocytes was performed using Lipofectamin
TM 
2000 
(Invitrogen, # 11668-027) according to the manufacturer’s instructions. In brief, 24 h prior 
to transfection the medium was changed to growth medium without antibiotics. The 
appropriate amount of each siRNA was diluted in Opti-MEM Ι Reduced Serum Medium 
(Invitrogen, # 31985-070) to reach a final working concentration of 50 nM or 100 nM. 
Lipofectamin
TM
 2000 was diluted at a ratio of 1: 50 in Opti-MEM Ι Reduced Serum 
Medium and incubated at RT for 5 min. Both dilution were combined and incubated for 20 
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min at RT. Finally the mixture was added onto the cells. Cells were allowed to grow for 
three additional days, before depriving the cells of FCS, 24 h prior to AD treatment. FLX 
was administered for 48 h and 120 h at a working concentration of 10 µM and 2x 5 µM. To 
terminate the treatment, cells were washed with cold PBS and harvested in Eppendorf 
tubes or fixed in 4 % PFA for 20 min at RT. PFA was removed and the fixed cells were 
washed with PBS and stored in PBS at 4°C until further processed with IF-ICC/Western 
blot  
 
2.12. Native chromatin-Immunoprecipitation (ChIP) [151, 210]  
To investigate, if the previously chosen genes of interest (1.12) were regulated by histone 
modifications (H3K4me3), I performed in cooperation with Dr. Mira Jakovcevski (Max 
Planck Institute of Psychiatry, Munich, Germany) a native ChIP on astrocytes derived from 
HAB and NAB rats under baseline conditions. 
2.12.1. Cell culture 
Cells were seeded in growth medium, on PDL-coated 150 mm cell culture dishes (Faust 
Lab Science, Klettau, Germany) at a concentration of 1x10
6
 cells and maintained under 
constant conditions in an incubator with 5 % CO2 at 37°C. Medium was changed every 2-
3d until cells reached 90-100 % confluency (approx. 20 DIV). 24 h before the treatment 
started, astrocyte-growth medium was exchanged to serum free medium. Cells were treated 
for 48 h and 120 h with FLX concentrations according 2.6. Cells were then harvested in 
cold PBS, centrifuged (12.000 rpm, 10 min, 4°C), cell pellets were stored in -80°C and 
sent to Munich on dry-ice, guaranteeing a proper delivery.  
2.12.2. Preparation of native chromatin  
Native ChIP was performed by Dr. Jakovcevski at the Max Planck Institute of Psychiatry, 
as previously published [151, 211]. In brief, samples were directly homogenized in 400 µl 
MNase digestion/nuclei permeabilisation buffer (10 mMTris, pH 7.5, 4 mM MgCl2 and 1 
mM Ca
2+
) and prewarmed to 37°C for 2 min. Afterwards 5 µl of MNase (0.4 U/µl) were 
added and homogenized cells were incubated for 5 min at 37°C for enzymatic sharing of 
chromatin. The reaction was then stopped by adding 40 µl 0.5 M EDTA. 900 µl 
hypotonization buffer (0.2 mM EDTA, supplemented with 0.1 mM Benzamidin, 0.1 mM 
PMSF and 1 mM DTT) were added for 1 h with intermittent vortexing to swell nuclei and 
release chromatin. Cell debris was removed by centrifugation (3000 rpm, at 4°C for 5 
min.). 1000 µl of the supernatants were transferred into a fresh tube and the ChIP was 
carried out by adding ChIP dilution buffer (containing 50 mM EDTA, 200 mM Tris and 
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500 mM NaCl) and anti-H3K4me3 antibody (5 µl, Millipore, #07-473). Samples were 
incubated at 4°C for 16 h. In order to recover the immunoprecipitated chromatin, sample 
were incubated with magnetic Protein G beads for 2 h, beads were washed for 3 min each 
in low salt buffer (150 mM NaCL, 20 mM Tris pH 8.0, 2 mM EDTA, 1 % Triton X-100, 
0.1 % SDS), high salt buffer (500 mM NaCL, 20 mM Tris pH 8.0, 2 mM EDTA, 1 % 
Triton X-100, 0.1 % SDS), followed by lithium chloride buffer (250 mM LiCL, 10 mM 
Tris pH 8.0, 1 mM EDTA, 1 % Deoxycholic acid, 1 % IGEPAL), and finally with TE 
buffer (10 mM Tris pH 8.0, 1 mM EDTA). Bound chromatin was eluted form the beads 
with 0.1 M NaHCO3 and 1 % SDS by vortexing 30 min at 65°C. The eluates, containing 
chromatin, were incubated with 40 mM Tris pH 6.5, 10 mM EDTA and 250 µg/ml 
ProteinaseK for 3- 4 h at 52°C. 
Afterwards, DNA was purified using a QIAqick PCR purification kit (Quiagen, # 28104) 
according to the manufactures instructions. DNA from 200 µl of each input sample was 
extracted in parallel. Input DNA was used to check the efficacy of the enzymatic shearing 
with MNase on a 2 % Agarose gel. For quantification by qPCR, the ChIP DNA was diluted 
1:5 in elution buffer (Quiagen). PCRs (10 µl final volume) were performed using 
QuantiFast SYBR Green PCR Master Mix (Quiagen, # 204054), specific primers (see 
Table 5) at a final concentration of 1:5 µM, and 2 µl of ChIP DNA or input DNA per 
reaction on a LightCycler 2.0 or a LightCycler 96 System (Roche Diagnostics). PCRs were 
run in duplicates. Ct values for the target H3K4me3 enriched sequences of ephrinA1 were 
normalized by the housekeeping gene B2m and by the input Ct value. Expression levels 
are represented relative to NAB control levels set to 1.  
Gene Forward reverse 
B2m (normalizer) CGTCTCTCGGGAAAGGAGTG ACTGTCCGCATACTCGCAAA 
ephrinA1 GGTCCACCATACCTCCCTCT GCCCTTTGTTCTTGCCCTTG 
Table 4: Primer sequences ChIP- qPCR 
 
2.13. GDF15  
Primary astrocytes were derived from HAB and NAB rats (see 2.3). For Western blot 
experiments, cells were seeded in PDL-coated 6-well plates, and for IF-ICC/siRNA 
experiments on glass cover slips and maintained in astrocyte-growth medium (changed 
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every 3d) until reaching 90-100 % confluency (Western blot) or 30-50 % confluency (ICC 
and siRNA). 
2.13.1. Treatment  
For Western blot experiments cells, were treated with FLX at a final concentration of 10 
µm for 48 h and 96 h. Untreated cells served as a control.  
For ICC experiments, cells were treated with exogenous GDF15 (R&D Systems, # 
Q99988) for 48 h and 96 h using the following concentrations:  
 1.0 ng/ml 
 0.1 ng/ml 
 1.0 ng/ml  
Untreated cells served as a negative control and FLX treated cells (10 µM, 48 h and 96 h) 
as treatment control.  
2.13.2. Western blot  
Western blot experiments were carried out as stated above (2.10), with the following 
modifications. Cells were resuspended in 40 µl homogenization buffer and manually 
homogenized using a fire-sealed pipette tip. 10 µl RIPA was added, and cells were allowed 
to lyse O.N. at 4°C. Cells were denatured for 5 min at 99°C. Proteins were separated on a 
10 % SDS-acrylamide gel. Transfer onto PVDF membraned was carried out at 70 V for 1 h 
at RT. Followed by blocking in 5 % BSA for 2 h at RT. Membranes were incubated with 
the following primary antibodies, O.N. 4°C, on a rotating shaker (Table 5): 
 
Protein Concentration Company Experiment 
anti-β-actin 
(42 kDa, mouse) 
1: 4000 
Sigma, 
#A-5441 
Housekeeper 
anti-GDF15 
(35 kDa, goat) 
1: 250 
Abcam, 
#ab39999 
3.10.4 
Table 5: primary antibodies western blot GDF15  
 
Membranes were washed 3x 10 min in PBS + 0.1 % Tween (PBST) and incubated for 2 h 
at RT with secondary antibodies: 
rabbit anti-mouse lgG (H+L) 1: 10000 (Jackson ImmunoResearch, # 315-035-033) 
rabbit anti-goat IgG-HRP 1: 2500 (Santa Cruz, #sc-2020) 
Protein bands were analyzed using Fiji. GDF15 band was normalized to the corresponding 
control (β-actin) (see 2.10.1).  
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2.14. Immunofluorescent analysis - GDF15  
2.14.1. Fluorescent in situ hybridization (FISH) on CD1 mice, HAB and NAB  
First, we generated a fluorescently labelled probe against Gdf15. For this aim, PCR 
oligonucleotides were designed complementary to bases 263–622 of the rat sequence of 
Gdf15 mRNA NM_019216.2 (5'- GGATACTCAGTCCAGAGGTGAGA-3' and 5'-
CTGTCCTGTGCATAAGAACCAC-3'). PCR was performed on cDNA prepared from 
RNA extracted from rat primary astrocytes and cloning and preparation of the probe 
followed as previously described [212]. Sagittal hippocampal slices (350 µM) were 
prepared from CD1 mice that were deeply anesthetized using Isoflorane (Forene, Abbot, 
Wiesbaden, Germany) and quickly decapitated. Both hemispheres were cut on a vibratome 
(Microm HV 650V, Thermo Scientific, Walldorf, Germany). Slices were collected in 
artificial-CSF solution (1 mM magnesium chloride, 2 mM calcium chloride, 125 mM 
sodium chloride, 2.5 mM potassium chloride, 1.24 mM sodium dihydrogenphosphate, 25 
mM D-Glucose, 25mM sodium hydrogencarbonate; D-Glucose, sodium hydrogencaronate, 
sodium chloride from Carl Roth; magnesium chloride, calcium chloride, potassium 
chloride from Merck) constantly bubbled with carbogen (95 % O2/5 % CO2, Linde, 
Munich, Germany). Following a 1 h recovery period, slices were treated for 2 h with 25 
µM FLX. Subsequently slices were washed with 2x SSC (0.3 M sodium chloride, 30 mM 
sodium citrate, pH 7.0), fixed in 4 % PFA O.N. at 4°C and then washed in 2x SSC before 
proceeding to FISH as previously described [212]. 
For combined analysis of GDF15 
+
/GFAP
+ 
processes, brain slices derived from the PFC of 
HAB and NAB rats, were labelled at the end of the FISH with an antibody against GFAP, 
as described before (See 2.8.2 GFAP staining). With the exception that the corresponding 
secondary antibody for GFAP
+
-staining was coupled to Alexa Fluor 488 (green). 
Images were acquired using an Olympus confocal microscope (2.8.4). 
2.14.2. IF-ICC on primary astrocytes  
For IF-ICC, astrocytes (HAB and NAB) grown on PDL-coated glass cover slips were 
treated with exogenous GDF15 according to the following scheme:  
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After terminating the treatment cells were fixed in 4 % PFA for 20 min, washed and 
stained with the following primary antibodies:  
Combination Protein Specificity 
Concentratio
n 
Company Experiment 
astrocytes 
mouse-anti-
S100β 
glia specific 
marker 
1: 1000 
Sigma, 
#S2532 3.10.1 
3.10.2 
3.10.3 
3.10.4 
mouse-anti-
GFAP 
glia specific 
marker 
1: 400 
Sigma. 
#G3839 
GDF15 
mouse-anti- 
GDF15 
GDF15 1: 250 
Abcam, 
#ab39999 
Table 6: Antibody combination GDF15 IF-ICC experiments 
 
Followed by fluorophore-labeled secondary antibodies:  
donkey anti-goat IgG (H+L) AF488 1: 1000 (Invitrogen, # A-11055) 
anti-mouse IgG F(ab’)2 fragment-Cy3 1: 400 (Sigma, # C2181) 
In all IF-ICC DAPI (1:1000) was used to label nuclei. Microphotographs were acquired 
using a confocal microscope Leica SP8 as described 2.8.4. 
 
2.15. RNAi  
siRNAs complementary to the mRNA sequence of GDF15 were designed. 
si1: 5´- ACUCAACCCGGACGAGCUAUU-3´ 
si2: 5´- UGACCCAGCUGUCCGGAUAUU-3´ 
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The same non targeting sequence as in 2.11 served as a negative control. siRNAs were 
subjected to a BLAST search to verify the specific targeting to GDF15 (si1&2).  
Transfection was carried out as described in section 2.11.1 including the following 
alterations: 
GDF15 siRNA oligonucleotides were diluted at a final working concentration of 100 nM 
in 50 µl Opti-MEM I Reduced Serum Medium and cells were treated according to the 
following scheme (Fig.19):  
 
 
 
 
 
 
 
 
 
 
 
 
 
Cells were then incubated for 3d at 37°C (5% O2/95% CO2), cells were deprived of FCS 
and treated with FLX (10 µM) for 48 h, according to (2.6). 
Cells fixed with 4 % PFA underwent IF-ICC staining as described 2.8.3. 
Microphotographs were acquired using a confocal microscope Leica SP8. 
 
2.16. Fluorescent and morphological analysis of GDF15 
To analyze astrocytes around blood vessels, microphotographs were taken using the 
Olympus IX81. As the Olympus software saves pictures and default data as .oib files, the 
files had to be transformed into .tiff files for further analysis in ImageJ, using the Fluoview 
FV1000 program (version 2.1 c, Olympus Fluoview Resource center).  
For the analysis of the fluorescent intensity of Gdf15, the histogram function of Adobe 
Photshop CS3 (Version 10.0, Adobe Systems, San Jose, California, USA) was used. First 
the boundaries of the region of interest (ROI; choroid plexus or blood vessels) were 
marked using the “lasso” tool. The intensity of signal in the red channel, corresponding to 
Gdf15 expression and the number of pixels in the ROI were recorded for each image. For 
Fig. 19: treatment scheme for siRNA directed against GDF15 
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statistical analysis the values obtained were normalized to the pixels of the ROI and 
averaged per animal. 
For the analysis of Gdf15
+ 
 and GFAP
+
 processes, Photoshop was used: in the green 
channel, which depicts GFAP
+
 processes, the processes touching the previously defined 
ROI around blood vessels were counted manually. Additionally, Gdf15
+
 (red channel) 
processes were quantified.  
For the morphological analysis, a plugin of ImageJ, NeuronJ, was used [213, 214]. This 
tool provides the possibility to mark and analyze processes. Images need to be converted 
from the confocal format into 8 bit color pictures to be compatible with the plugin. Here 
NeuronJ was used to count the total number of processes per cell and to measure their 
lengths.  
 
2.17. Statistical analysis  
To choose the appropriate statistical test, the D´Agostino and Pearson omnibus normality 
test was used for each data set. The two-tailed Students t-test was used for the western blot 
experiments examining GDF15, as well as for ChIP experiments and for IF-IHC 
experiments, when comparing two groups. The One-way ANOVA, followed by Dunnett´s 
or Tukey´s multiple comparison post hoc test, was used for the analysis of the IF-ICC 
experiments, when comparing more than two groups as well as for western bot 
experiments. For experiments comparing dependent and independent variables a Two-way 
ANOVA with Dunnett´s or Bonferroni´s multiple comparison post hoc test was used. 
Differences were considered significant, when the level of significance (p-value) was equal 
or less than 5 % (p< 0.05, indicated with “*”), very significant, when equal or less than 1 
% (p< 0.01, “**”) or extremely significant, when equal or less than 0.1 % (p<0.001, 
“***”). All graphical data were obtained by GraphPad Prism version 5.00 for Windows, 
GraphPad Software, San Diego California USA. 
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 Results  3.
3.1. Histone 3 – Lysine 4 – trimethylation (H3K4me3) 
3.1.1. Global expression of H3K4me3  
In order to analyze the differences in the number of cells expressing H3K4me3 between 
HAB and NAB rats, I performed immunofluorescent- immunohistochemical stainings (IF-
IHC) on brain slices derived from the prefrontal cortex (PFC) of both rat strains. As shown 
in Fig. 20a) & b), under baseline conditions, no overall differences could be observed in 
the number of cells expressing H3K4me3 between NAB and HAB rats (NAB: n= 6, 
52.32  ± 3.409 %; HAB: n= 5, 51.21 ± 4.049 %; Student´s t- test, t(9)= 0.2114, p= 0.837, 
n.s.). The total number of cells (DAPI) did not differ between HAB and NAB (see 
Suppl.1a)). 
3.1.2. Cell-type specific expression of H3K4me3  
To investigate whether a specific cell-type might be affected, I performed a colocalization 
analysis of H3K4me3 with astrocytes and neurons. This analysis revealed that in the PFC 
of HAB rats significantly more astrocytes (GFAP/S100β+, Fig. 21 a) colocalized with 
H3K4me3 than in NAB rats; white arrows indicate colocalizing cells; HAB: n= 4, 
64.37 ± 4.194 %; NAB: n= 6, 47.31 ± 4.410 %; Student´s t-test, t(6)= 2.802, p= 0.0311). 
Fig. 20: Global expression of H3K4me3 in 
PFC does not differ between NAB and 
HAB rats, under baseline conditions  
a) Representative microphotographs (Leica 
SP8, Z-stack series, 20-30 µm, step size 
1.23 µm). H3K4me3
+
 cells (green), 
nuclear staining DAPI (blue), scale bar 
10 µm 
b) Quantitative IF-IHC analysis in the PFC 
of NAB (n= 6 animals) and HAB (n= 
5 animals) under baseline conditions, 
revealed no difference. The average 
H3K4-trimethylation [in %] is depicted 
as mean + SEM. Student´s t-test, 
p= 0.837, n.s. 
Results  - 71 - 
Whereas, the colocalization with neurons did not show any differences between the two 
strains (NeuN
+
, Fig. 21 b). In both strains about 75.0 % of all neurons were colocalizing 
with H3K4me3, (Fig. 21 c) (HAB: n= 4, 75.38 ± 8.334 %; NAB: n= 6, 75.01 ± 4.112 %). 
Additionally, I could observe that HAB rats had significantly less astrocytes in the PFC 
than NAB rats (see Suppl. 1b)), but the total number of neurons was equal (see Suppl. 
1c)), as described for post-mortem brain tissue from depressive patients [31]. 
 
Fig. 21: Cell-type specific expression of H3K4me3 in PFC of NAB and HAB, under baseline 
conditions, shows a significantly higher amount of colocalization in HAB astrocytes 
a) + b) Representative microphotographs (Leica SP8, Z-stack series, 20-30 µm, step size 1.23 µm). 
H3K4me3
+
 cells (green), nuclear staining DAPI (blue), GFAP/S100b
+
 (a), red), NeuN
+
 (b), red)); 
scale bar 10 µm 
c) Cell type specific IF-IHC analysis in the PFC of NAB (n= 4/6) and HAB (n= 4), under baseline 
conditions, showed significantly higher colocalization with H3K4me3 in astrocytes in HAB rats. 
H3K4-trimethlyation [in %] is depicted as mean +SEM, Student´s t-test, * p< 0.05 
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3.2. H3K4me3 after fluoxetine treatment  
3.2.1. Global expression of H3K4me3 after FLX injections in NAB  
Subsequently, I investigated whether the differences observed under baseline conditions 
were affected by treatment with FLX. First, NAB rats were injected i.p. with either FLX 
(20 mg/ kg/ d) or saline (SAL). IF-IHC analysis of these animals revealed a significant 
increase in the overall expression of H3K4me3 in the PFC after treatment with FLX for 
2 d (Fig. 22 a) and b), SAL: n= 4, 40.07 ± 3.880 %; FLX: n= 4, 61.41 ± 3.192 %, 
Student´s t-test, t(6)= 3.660, p= 0.0106). Besides that, when comparing basal (not 
injected) NAB to NAB that received a SAL injection, it was possible to rule out that the 
injection itself caused any changes in the overall expression of H3K4me3 (see Suppl. 2) 
3.2.2. Cell-type specific expression of H3K4me3 after FLX injection in NAB  
To investigate which cell-type was targeted by FLX, I performed IF-IHC in the PFC of 
NAB animals, analyzing the colocalization of H3K4me3 with either astrocytes or neurons. 
I could show that in neurons, FLX injections did not change the amount of colocalization 
with H3K4me3 (Fig. 23), SAL neurons: n= 4, 62.48 ± 8.227 %, FLX neurons: n= 4, 
75.59 ± 1.796 %, Student´s t-test, t(6)= 1.556, p= 0.1707). Whereas in astrocytes, after FLX 
Fig. 22: Global expression of H3K4me3 in 
PFC of NAB after injection with FLX vs. 
control (SAL) is significantly increased  
a) Representative microphotographs 
(Leica SP8, Z-stack series, 20-30 µm, 
step size 1.23 µm). H3K4me3
+
 cells 
(green), nuclear staining DAPI (blue), 
scale bar 10 µm 
b) Quantitative IF-IHC analysis in the 
PFC of NAB (n= 4), revealed a 
significant increase in overall 
H3K4me3 after FLX treatment. The 
average H3K4-trimethlyation [in %] is 
depicted as mean +SEM, Student´s t-
test, * p<0.05. 
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treatment, a significant increase in the colocalization with H3K4me3 could be observed 
(Fig. 23); SAL astrocytes: n= 4, 32.28 ± 1.889 %, FLX astrocytes: n= 4, 49.59 ± 2.568 %, 
Student´s t-test, t(6)= 5.422, p= 0.0016). Additionally, neither in astrocytes nor in neurons 
the injection itself changes H3K4me3 levels (see Suppl. 3a)).  
  
Fig. 23: Cell-type specific expression of H3K4me3 in PFC of NAB after injection with FLX shows a 
significantly increased colocalization in astrocytes 
a) + b) Representative microphotographs (Leica SP8, Z-stack, 20-30 µm, step size 1.23 µm). 
H3K4me3
+
 cells (green), nuclear staining DAPI (blue), GFAP/S100b
+
 (red), NeuN
+
 (red); scale 
bar 10 µm 
c) Cell type specific IF-IHC analysis in the PFC of NAB (n= 4), showed significantly higher 
colocalization with H3K4me3 in astrocytes after FLX injection. H3K4-trimethlyation [in %] is 
depicted as mean +SEM, Student´s t-test, ** p< 0.01 
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3.2.3. Global expression of H3K4me3 after FLX injection in HAB  
Furthermore, I investigated if our animal model for depression-related behavior responds 
to pharmacological treatment with FLX. Therefore, HAB rats were injected either with 
FLX (20 mg/ kg/ d) or saline (SAL). IF-IHC analysis of the PFC of these animals revealed 
no significant differences in the global expression of H3K4me3 after treatment with FLX 
for 2d (Fig. 24 a) and b), SAL: n= 3, 60.56 ± 5.480 %; FLX: n= 3, 52.17 ± 1.807 %, 
Student´s t-test, t(4)= 1.454, p= 0.2196). Additionally, in HAB animals it was also possible 
to rule out an effect on H3K4me3 caused by the injection itself (see Suppl. 2).
 
 
 
 
 
 
 
 
 
 
 
Fig. 24: Global expression of H3K4me3 
in PFC of HAB after injection with FLX 
vs. control (SAL) does not show 
differences  
a) Representative microphotographs 
(Leica SP8, Z-stack, 20-30 µm, step 
size 1.23 µm). H3K4me3
+
 cells 
(green), nuclear staining DAPI (blue), 
scale bar 10µm 
b) Quantitative IF-IHC analysis in the 
PFC of HAB (n= 3), showed no 
overall changes of H3K4me3 after 
FLX injection. The average H3K4-
trimethylation [in %] is depicted as 
mean +SEM, Student´s t-test, p= 0.21, 
n.s. 
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3.2.4. Cell-type specific expression of H3K4me3 after FLX injection in HAB  
Cell-type specific analysis of the PFC in HAB animals revealed no differences in the 
colocalization of H3K4me3 with astrocytes after FLX treatment (Fig. 25 a), b) and c), 
SAL astrocytes: n= 3, 70.03 % ± 3.533; FLX: n= 3, 62.53 ± 1.516 %, Student´s t-test, 
t(4)= 1.1951, p= 0.1229. Whereas, in neurons after FLX treatment, a tendency towards a 
decrease could be observed (Fig. 25); SAL neurons: n= 3, 80.21 ± 1.008 %; FLX neurons: 
n= 3, 65.09 ± 5.707 %, Student´s t-test, t(4)= 2.610, p= 0.0594). Also in this case, no cell-
type specific effect of the injection itself could be observed in HAB animals (see Suppl. 
3b)). 
 
Fig. 25: Cell type specific expression of H3K4me3 in PFC of HAB after injection with FLX tends to 
decrease in neurons  
a) +b) Representative microphotographs (Leica SP8, Z-stack, 20-30 µm, step size 1.23 µm). 
H3K4me3
+
 cells (green), nuclear staining DAPI (blue), GFAP/S100b
+
 (red), NeuN
+
 (red,); scale 
bar 10 µm 
c) Cell type specific IF-IHC analysis in the PFC of HAB (n= 3) revealed no differences in the in 
colocalization of H3K4me3 in astrocytes, but a tendency towards a decrease after FLX treatment 
in neurons. H3K4-trimethylation [in %] is depicted as mean +SEM, Student´s t-test, p= 0.0594. 
p=0.0594
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3.3. Posttranslational histone modifications (PTM) – protein expression 
3.3.1. H3K4me3  
In order to analyze if our cell culture model was suitable to reflect the differences observed 
in animals, I used primary cortical astrocytes derived from HAB and NAB rats and treated 
the cells according to the scheme described in (2.6). After treatment of astrocytes with 
FLX or ESC for 48 h (10 µM, one time treatment) or 120 h (5 µM, two times treatment) 
and untreated controls (C), I performed western blot analysis using antibodies specific for 
H3K4me3 and β-actin, serving as the internal normalizer. Using this technique I could 
verify the baseline difference in HAB astrocytes compared to NAB astrocytes, with almost 
2-fold higher expression of H3K4me3 in HAB cells (Fig. 26 and Fig. 27 a; NAB C: n= 10, 
100.00 % ± 13.32; HAB C: n= 6, 198.2 % ± 27.58, Student´s t-test, t(25)= 3.609, 
p= 0.0013). After FLX treatment for 48 h and 120 h, no significant differences in the 
protein expression of H3K4me3 in NAB cells could be detected (Fig. 26 and 27 b; NAB 
48: n= 10,  121.7 ± 19.73 %; NAB 120: n= 6, 150.7 ± 13.82 %; One-way ANOVA, with 
Dunnett´s multiple comparison post hoc test, F (2, 42)= 0.6339, p= 0.5355).  
However, although after 48 h FLX treatment no effect was visible, HAB astrocytes showed 
a significant decrease in H3K4me3 protein expression after 120 h FLX treatment, which 
dropped down to almost the same level observed in NAB C (8c; HAB 48: n= 6, 
188.7 ± 19.73 %, HAB 120: n= 3, 80.32 ± 27.61 %; One-way ANOVA with Dunnett´s 
multiple comparison post hoc test, F (2, 22)= 4.662, p= 0.0205). Comparison between the 
control in the ESC experiments revealed a difference similar to the one observed with FLX 
(Fig. 27, NAB C: n= 4, 100.00 ± 12.86 %; HAB C: n= 6, 344.9 ± 45.97 %, Student´s t-test 
with Welch´s correction, t(9)= 5.131, p= 0.0006). After ESC treatment, no significant 
pharmacological effects were visible, although in both cell-types after 120 h, H3K4me3 
expression seemed to increase (Fig. 27 d-f, NAB 48: n= 4, 157.6 ± 72.18 %, NAB 120: 
n= 5, 232.3 ± 69.45 %; HAB 48: n= 6, 301.5 ±97.66 %, HAB 120: n= 6, 458.1 ± 109.1 %, 
for both a One-way ANOVA with Dunnett´s multiple comparison post hoc test was used. 
NAB: F (2,23)= 1.180, p= 0.3253; HAB: F(2,25)= 0.8162, p= 0.4535). 
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Fig. 26: Representative western blot for H3K4me3 on primary cortical astrocytes 
NAB vs. HAB  
H3K4me3 [15.5 kDa] levels were measured in astrocytes derived from NAB and HAB 
rats under baseline conditions (C) in vitro and after FLX treatment for 48 h and 120 h. 
β-actin [42 kDa], serving as a normalizer 
Results  - 78 - 
 
 
Fig. 27: Western blot analysis on primary cortical astrocytes under baseline conditions showed 2 -
3.5 fold higher expression of H3K4me3 in HAB astrocytes 
H3K4me3 levels were measured in astrocytes derived from NAB and HAB rats under baseline 
conditions (C) in vitro normalized to β-actin before and after treatment with FLX (a-c) and ESC (d-f). 
Relative enrichment [in %] is calculated in respect to NAB C. All data are represented as mean +SEM. 
***p<0.001, **p<0.01, *p<0.05 Student´s t-test (a), with Welch´s correction (d), or one way ANOVA 
with Dunnett´s multiple comparison post hoc test (b, c, e, f) 
FLX  ESC  
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3.3.2. Histone 3-lysine 27-trimethylation 
Along with the activating PTM, I analyzed H3K27me3 (repressive mark) in primary 
astrocytes derived from both HAB and NAB rats. The treatment was carried out in the 
same manner as described before. Astrocytes were treated with FLX or ESC for 48 h and 
120 h. Analysis of H3K27me3 protein expression by means of western blot showed that, 
under baseline conditions, HAB astrocytes expressed 50 % less H3K27me3, as compared 
to NAB astrocytes (Fig. 28 and Fig. 29 a, FLX NAB C: n= 10,  100.0 ± 21.53 %; HAB C: 
n= 5, 45.82 ± 4.933 %, Student´s t-test with Welch´s correction, t(7)= 2.453, p= 0.0439; 
ESC Fig. 29 d NAB C: n= 4,  100.00 ± 4.567 %, HAB C: n= 6, 55.26 ± 7.398 %, 
Student´s t-test, t(9)= 4.885, p= 0.0009). After FLX or ESC treatment in NAB astrocytes no 
significant differences could be observed, neither after 48 h nor after 120 h (Fig. 28 and 
Fig. 29 b, FLX NAB 48: n= 10, 182.6 ± 59.02 %, NAB 120: n= 6, 185.7 ± 62.67 %, One-
way ANOVA with Dunnett´s multiple comparison post hoc test F (2, 24)= 0.7688, 
p= 0.4747; ESC Fig. 29 e, NAB 48: n= 4, 84.78 ± 21.10 %, NAB 120: n= 5, 
113.5 ± 31.54 %, One-way ANOVA with Dunnett´s multiple comparison post hoc test 
F(2, 18)= 0.3658, p= 0.6987 ). However, I should mention that after FLX treatment an 
increase (about 80 %) in NAB astrocytes could be observed, but it did not reach 
significance, probably due to the high heterogeneity of NAB cells. However, in HAB 
astrocytes H3K27me3 expression decreased even further to about 50 % after 120 h FLX 
treatment (Fig. 28 and Fig. 29 c; HAB 120: n= 3,  26.70 ± 3.698 %), whereas after 48 h 
FLX treatment no differences were visible in HAB (Fig. 28 and Fig. 29 c, HAB 48: n= 5, 
49.06 ± 5.388 %, One-way ANOVA with Dunnett´s multiple comparison post hoc test, 
F (2, 27)= 5.906, p= 0.0075). ESC treatment did not show the same effects in HAB, as seen 
after FLX treatment (Fig. 29 f, HAB 48: n= 6, 92.53 ± 17.27 %, HAB 120; n= 6, 
78.43 ± 17.27 %, One-way ANOVA with Dunnett´s multiple comparison post hoc test, 
F (2, 6)= 0.1953, p= 0.8276 
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Fig. 28: Representative western blot of H3K27me3 on primary cortical astrocytes NAB vs. HAB  
H3K27me3 [15.kDa] levels were measured in astrocytes derived from NAB and HAB rats under 
baseline conditions (C) in vitro and after FLX or ESC treatment for 48 h and 120 h. β-actin [42 kDa], 
serving as a normalizer 
 
H3K27me3  
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Fig. 29: Western blot analysis on primary cortical astrocytes under baseline conditions showed that 
HAB astrocytes express less than half of the amount of H3K27me3  
H3K27me3 levels were measured in astrocytes derived from NAB and HAB rats under baseline conditions 
(C) in vitro normalized to β-actin before and after treatment with either FLX (a-c) or ESC (d-f). Relative 
enrichment (in %) is calculated in respect to NAB C. All data are represented as mean +SEM. ***p<0.001, 
**p<0.01,*p<0.05, Student´s t-test (d) with Welch´s correction (a) and one-way ANOVA with Dunnett´s 
multiple comparison post hoc test (b,c,e,f) 
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3.3.3. Histone 3-Lysine 27-acetylation (H3K27ac)  
In addition to the methylation marks, I analyzed the acetylation on H3K27, another 
activating mark, known to interact with the two afore mentioned. Under baseline 
conditions in astrocytes derived from HAB and NAB rats, I observed that in HAB 
H3K27ac was almost 50 % less expressed compared to NAB. (Fig. 30 and Fig. 31 a, FLX 
NAB C: n= 6, 100.00 ± 28.31 %, HAB C: n= 6, 51.84 ± 7.683 %, Student´s t-test with 
Welch´s correction, t(10)= 1.642 p= 0.1317; ESC: Fig. 31 d, NAB C: n= 5, 
100.00 ± 51.11 %; HAB C: n= 6,  53.85 ± 18.42 %, Student´s t-test with Welch´s 
correction, t(8)= 0.9421, p= 0.3737). After treatment with FLX for 48 h and 120 h in both 
cell-types, the analysis revealed a significant decrease of the mark in NAB to almost 60 % 
less, that was already visible after 48 h and persisted along the 120 h treatment (Fig. 31 b; 
NAB 48: n= 6,  46.33 ± 11.76 %; NAB 120: n= 6, 40.19 ± 9.716 %, One-way ANOVA 
with Dunnett´s multiple comparison post hoc test, F (2,31)= 3.459, p= 0.0441). In HAB 
astrocytes, on the other hand, I observed a trend towards an increase after 120 h FLX 
treatment that was not yet present after 48 h. (Fig. 31 c HAB 48: n= 6, 46.58 ± 6.911 %; 
HAB 120: n= 6, 117.8 ± 38.36 %; One-way ANOVA with Dunnett´s multiple comparison 
post hoc test, F (2,29)= 2.851, p= 0.0741). An almost identical treatment effect could be 
observed after ESC treatment (Fig. 31 e, NAB 48: n= 5, 53.85 ± 18.42 %, NAB 120: n= 5, 
69.55 ± 19.96 %, One-way ANOVA with Dunnett´s multiple comparison post hoc test, 
F (2,22)= 0.4281, p= 0.6570). In HAB astrocytes treated with ESC an increase of H3K27ac 
after 120 h was visible, but did not reach statistical significance (Fig. 31 f, HAB 48: n= 5, 
49.47 ± 5.736 %, HAB 120: n= 5, 123.4 ± 42.10 %, One-way ANOVA with Dunnett´s 
multiple comparison post hoc test F (2,20)= 3.079, p= 0.0683). 
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Fig. 30: Representative western blot on primary cortical astrocytes NAB vs. HAB  
H3K27ac levels were measured in astrocytes derived from NAB and HAB rats under baseline 
conditions (C) in vitro and after FLX or ESC treatment for 48 h (10 µM, one time treatment) and 120 
h (5 µM, two times treatment) 
H3K27ac  
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FLX  ESC  
Fig. 31: Western blot analysis of primary cortical astrocytes NAB and HAB after FLX treatment 
H3K27ac levels were measured in astrocytes derived from NAB and HAB under baseline conditions (C) 
and after treatment with FLX (a-c) or ESC (d-f) (10 µM total concentration) for 48 h and 120 h in vitro, 
normalized to β-actin. In NAB astrocytes FLX decreased expression of H3K27ac of about 60 % after 48h 
and 120h (b). In HAB astrocytes the effect of FLX seems to be opposite. FLX increased the expression 
after 120 h to almost the same level seen in NAB C (c). ESC showed similar effects (e, f). Relative 
enrichment in % is calculated in respect to NAB C. All data are represented as mean +SEM. *p<0.05, 
Student’s t-test with Welch´s correction (a, d), One-way ANOVA with Dunnett´s multiple comparison 
post hoc test (b, c, e, f) 
Results  - 85 - 
3.4. Global expression of H3K27me3 under baseline conditions  
Because I could show that in the cell culture model the counteracting mark H3K27me3 
was affected under baseline conditions and seemed to be a pharmacological target of FLX, 
I subsequently analyzed the expression in the PFC of HAB and NAB rats by IF-IHC. As 
shown in Fig. 32 a) and b), I identified that the overall number of cells expressing 
H3K27me3 in the PFC of HAB rats was significantly lower than in NAB rats under 
baseline conditions (NAB: n= 6, 36.05 ± 7.534 %; HAB: n= 6, 20.94 ± 2.297 %, one-tailed 
Student´s t-test, t(10)= 1.918, p= 0.0420). Interestingly, I could also show that expression of 
H3K27me3 in the PFC of HAB animals was lower than the expression of H3K4me3 (see 
Suppl. 4). These data reflect the observation made by western blot analysis. 
 
3.4.1. Cell-type specific expression of H3K27me3  
Taking the results obtained by western blot analysis into consideration, I analyzed the cell-
type specific expression of H3K27me3 in astrocytes of the PFC. In HAB rats I observed a 
trend towards a decrease in astrocytes colocalizing with H3K27me3 under baseline 
conditions (Fig. 33, a) and b) NAB: n= 6, 38.53 ± 5.724 %; HAB: n= 6, 27.60 ± 3.475 %; 
one-tailed Student´s t-test t(10)= 1.633, p= 0.0668).  
Fig. 32: Global expression of H3K27me3 
in the PFC of HAB is lower than in 
NAB, under baseline conditions  
a) Representative microphotographs 
(Leica SP8, Z-stack series, 20-30 µm, 
step size 1.23 µm). H3K4me3
+
 cells 
(green), nuclear staining DAPI (blue), 
scale bar 10 µm 
b) Quantitative IF-IHC analysis in the 
PFC of NAB (n= 6) and HAB (n= 6) 
under baseline conditions, showed 
that HAB have significantly less 
H3K27me3 than NAB. The average 
H3K27-trimethlyation [in %] is 
depicted as mean + SEM, Student´s t-
test, * p< 0.05.  
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3.5. Candidate genes 
In order to establish a more specific H3K4me3-dependent target, that might be 
dysregulated in HAB animals, we performed a chromatin-immunoprecipitation and 
analyzed several candidate genes known to be differentially expressed after AD treatment 
and which might be affected in HAB astrocytes, among which EphA2 and GDF15 
(see 1.12). EphA2 belongs to the EphRs, which generally display highly promiscuous 
binding affinities to their ligands. But from cancer studies, it is known that EphA2 
preferentially interacts with the ligand ephrinA1 [215]. Especially some studies point out 
that there is an interaction with soluble ephrinA1, which is able to interact with EphA2, 
causing phosphorylation of the receptor [216, 217]. Therefore, we further investigated 
whether ephrinA1 might be a target in our animal model, involved in the upregulation of 
EphA2 after AD treatment.  
  
Fig. 33: Astrocyte specific expression of 
H3K27me3 in PFC of NAB and HAB under 
baseline conditions, shows a tendency 
towards decreased colocalization  
a) Representative microphotographs (Leica 
SP8, Z-stack series, 20-30 µm, step size 
1.23 µm). H3K4me3
+
 cells (green), nuclear 
staining DAPI (blue), scale bar 10 µm 
b) Astrocyte specific IF-IHC analysis in the 
PFC of NAB (n= 6) and HAB (n= 6) under 
baseline conditions, showed that HAB tend 
to colocalize less with H3K27me3 than 
NAB. The average H3K27-trimethlyation 
[in %] is depicted as mean +SEM, one-
tailed Student´s t-test, * p< 0.05.  
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3.5.1. Chromatin-immunoprecipitation  
In cooperation with Dr. Mira Jakovcevski, I examined the expression of ephrinA1 in 
cortical astrocytes derived from HAB and NAB rats. We used a ChIP assay, with an 
antibody directed against H3K4me3. Subsequent qPCR, identified that Efna1 promoter-
containing DNA fragments were significantly higher in immunoprecipitates prepared from 
HAB astrocytes, under basal conditions (Fig. 34, NAB: n= 7, 1.016 ± 0.1374 %; HAB: 
n= 7, 1.598 ± 0.1188 %, Student´s t-test, t(12)= 0.0076). 
3.5.2. EphrinA1 protein expression  
After having established that the expression of the ligand of one of our candidate genes 
from the microarray, namely ephrinA1, was regulated by H3K4me3 at the promoter level, I 
analyzed the protein expression in our cell culture model. EphrinA1 appears in two 
isoforms, a 26 kDa and a 15 kDa, which have been characterized before [218]. NAB and 
HAB cells were treated as described before with FLX for 48 h (10 µM, once) and 120 h 
(5 µM, twice). The analysis revealed that under basal conditions HAB astrocytes express 
almost 4-times more ephrinA1 (26 kDa) than NAB astrocytes (See Fig. 35 Fig. 36a, 
26 kDa, NAB C: n= 3,  100.00 ± 54.55 %, HAB C: n= 3, 365.1 ± 99.10 %, Student´s t-test 
with Welch´s correction, t(6)= 2.344, p= 0.0576). Interestingly, in NAB cells, after FLX 
(48 h and 120 h) treatment, ephrinA1 increased gradually although without reaching 
significance (Fig. 36b; NAB 48: n= 3,  138.2 ± 57.81 % , NAB 120: n= 3, 
216.4 ± 82.08 %, One-way ANOVA with Dunnett´s multiple comparison post hoc test, 
F (3,17) = 0.7574, p= 0.5333). In HAB astrocytes FLX decreased the protein expression of 
ephrinA1 (26 kDa) (See Fig. 36c: HAB 48: n= 3, 273.6 ± 134.5 %, HAB 120: n= 3, 
193.2 ± 97.71 %, One-way ANOVA with Dunnett’s multiple comparison post hoc test, 
F (2,10)= 0.4687, p= 0.6389). The 15 kDa form of ephrinA1 was significantly higher 
expressed in HAB than in NAB astrocytes under basal conditions, showing an immense 
Fig. 34: EphrinA1 is regulated by 
H3K4me3 in HAB rat under basal 
conditions 
mRNA expression of Efna1 in 
cortical astrocytes of HAB and NAB 
rats, under basal conditions, were 
analyzed using a ChIP assay with 
antibodies against H3K4me3 and 
B2M.  
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4.5 fold increase in comparison to NAB (Fig. 36 d, NAB C: n= 4, 100.00 ± 38.59 %, HAB 
C: n= 3, 456.0 ± 118.6 %, Student´s t-test, t(8)= 3.376, p= 0.0097). In NAB astrocytes FLX 
did not change the expression of ephrinA1 (15 kDa) significantly (Fig. 36 e, NAB 48: 
n= 4, 120.7 ± 38.95 %, NAB 120: n= 4, 131.1 ± 61.66 %, One-way ANOVA with 
Dunnett´s multiple comparison post hoc test, F (2,15)= 0.1170, p= 0.8960). HAB astrocytes 
showed a biological effect upon FLX treatment, displayed by a reduction of ephrinA1 
(15 kDa) after 120 h, although the level did not show a significant difference (Fig. 36 f, 
HAB 48: n= 4, 563.0 ± 136.4 %, HAB 120: n= 4, 232.0 ± 41.71 %, One-way ANOVA 
with Dunnett´s multiple comparison post hoc test, F (2,14)= 2.518, p= 0.1164). Although the 
data did not reveal a significant effect after FLX treatment, it should be mentioned there, 
that this is probably only due to the high variances among experiments and a possible 
pharmacological effect should not be ruled out. Further experiments to increase the number 
of independent experiment (n) should be carried out. 
 
 
 
 
 
 
Fig. 35: Western blot analysis on primary cortical astrocytes under baseline conditions showed a 
3-fold higher expression of ephrinA1 (26 kDa and 15 kDa) in HAB astrocytes 
EphrinA1 level were measured in astrocytes derived from NAB and HAB rats under baseline 
conditions (C) in vitro normalized to β-actin and after FLX treatment. Relative enrichment in % is 
calculated in respect to NAB C.  
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Fig. 36: Western blot analysis of primary cortical astrocytes NAB and HAB after FLX treatment 
EphrinA1 levels were measured in astrocytes derived from NAB and HAB under baseline conditions 
(C) and after treatment with FLX (10 µM total concentration) for 48 h and 120 h in vitro, normalized to 
β-actin. Revealing a pronounce difference in both forms of EphrinA1 with increases of 3.5 and over 4-
fold in HAB compared to NAB cells. NAB astrocytes seem to respond FLX by gradually increasing 
eprhinA1 (26 and 15 kDa, b, c) expression. In HAB astrocytes 120 h FLX treatment decreased ephrinA1 
protein expression (26 kDa and 15 kDa, c, d). Relative enrichment in % is calculated in respect to NAB 
C. All data are represented as mean +SEM. *p<0.05, Student´s t-test with Welchs correction (a, d) One-
way ANOVA with Dunnett´s multiple comparison post hoc test (b, c, e, f) 
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3.5.3. EphrinA1 knockdown via siRNA 
Hence there was evidence that HAB astrocytes showed an over exaggerated ephrinA1 
expression under baseline conditions, I designed siRNA against ephrinA1 mRNA (see 
2.11), and transfected HAB cells for 3d. Afterwards, I analyzed the expression of ephrinA1 
(15 kDa) by means of western blotting. Preliminary data showed that siRNA 1 50 nM, si3 
100 nM and si4 50 and 100 nM can knockdown ephrinA1 to less than 50 % expression in 
HAB astrocytes (Fig. 37 a and b). The scr sequence showed a slight downregulation of 
ephrinA1 in HAB astrocytes, but it did not reach the NAB C level.  
 
 
3.6. IF-IHC on ephrinA1 and EphA4 in PFC of untreated NAB and HAB 
animals 
In parallel, I was interested to see, if the changes found in vitro represented the situation ex 
vivo. Therefore, I performed IF-IHC in the PFC of HAB and NAB animals together with 
Diana Haba-Schneider, during her internship under my supervision. Subsequent confocal 
analysis showed that the baseline differences observed in cell culture reflected the situation 
in the animals. IF-IHC revealed a significant higher expression of ephrinA1 in the PFC in 
Fig. 37: Western blot analysis of 
primary cortical astrocytes HAB, 
after siRNA mediated knockdown 
of ephrinA1 
a) Representative western blot 
of siRNA mediated 
knockdown  
b) Western blot analysis 
(preliminary data) EphrinA1 
levels were measured in 
astrocytes derived from 
NAB and HAB under 
baseline conditions (C) and 
after transfection with 
different siRNAs in vitro, 
normalized to β-actin. 
siRNA 2,3 and 4 seem to 
effectively decreasing 
ephrinA1 expression in 
HAB.  
a) 
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HAB compared to NAB animals (See Fig. 38, NAB: n= 4, 100.00 ± 9.125 %, HAB: n= 4, 
147.7 ± 7.807 %, Student´s t-test, t(27)= 3.992, p= 0.0005). Moreover, from the morphology 
of the cells which expressed ephrinA1, I could hypothesize that it was mostly expressed in 
astrocytes. Additionally, I analyzed the expression of EphA4, a receptor that is able to bind 
ephrinA1, in the PFC of these animals. The analysis revealed no differences in the 
expression of EphA4 in the PFC (See Fig. 38, NAB: n= 4, 100.00 ± 4.696 %; HAB: n= 4, 
104.2 ± 5.978 %, Student´s t-test, t(27)= 0.5292, p= 0.610). 
Fig. 38: Overall expression of ephrinA1 and its receptor EphA4 in HAB and NAB rats, under 
baseline conditions  
a) Representative microphotographs (Leica SP8, Z-stack series, 20-30 µm, step size 1.23 µm). 
H3K4me3+ cells (green), nuclear staining DAPI (blue), scale bar 10 µm 
b) Quantitative IF-IHC analysis in the PFC of NAB (n= 4 animals) and HAB (n= 4 animals) 
under baseline conditions, reveals not difference in EphA4, but ephrinA1 is significantly higher 
expressed (1.5-fold) compared to NAB. The average EphrinA1 and EphA4 expression [in %] is depicted 
as mean +SEM. Student´s t-test, *** p< 0.001; n.s. p> 0.05. 
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3.7. EphrinA1 and EphA4 
Considering the previous findings showing that ephrinA1 was 1) dysregulated in HAB 
astrocytes (in vitro and ex vivo) and 2) downregulated by FLX treatment, I wanted to 
examine the functional consequences of an excess of ephrinA1 in HAB astrocytes. 
Considering that ephrinA1 is highly involved in the formation of synaptic compartments, I 
established a co-culture model to examine HAB astrocytes together with NAB neurons and 
NAB astrocytes with NAB neurons. The goal was to see whether I could block an eventual 
effect of ephrinA1 overexpression in HAB cells on NAB neuronal synapses using its 
soluble ligand, the EphA4 receptor, and whether I could eventually induce an effect using 
the soluble ephrinA1 ligand to treat NAB neurons [196, 197]. After approximately 14 DIV, 
co-cultures were treated according to the following scheme for either 48 h or 120 h. 
 
I performed IF-ICC with antibodies directed against MAP2 (a neuron-specific cytoskeletal 
protein that labels dendrites, in gray), PSD95 (a postsynaptic protein, in green) and 
synaptophysin (a presynaptic protein, in red) under basal conditions and after treatment 
with either ephrinA1-Fc or EphA4-Fc. So far, only a qualitative analysis of differences at 
the synaptic level was done. According to Fig. 40, co-cultures grown on HAB astrocytes 
showed a reduced expression of both synaptic markers (PSD95 and synaptophysin) as well 
as they showed less mature synapses (indicated by yellow color). FLX treatment 
apparently induced a decrease in the expression of the synaptic markers in both co-cultures 
(HAB-NAB, and NAB-NAB), suggesting that FLX may cause synaptic reorganization. I 
Fig. 39: Layout of Co-Cultures neurons growing on astrocytes derived from either NAB or HAB 
rats. 
NAB-NAB co-cultures were treated with FLX, ESC and recombinant ephrinA1-Fc, at different 
concentrations and time points. HAB-NAB co-cultures were treated with the same way suing FLX, ESC, 
but with recombinant EphA4-Fc. 
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applied different concentrations of ephrinA1-Fc to the NAB-NAB co-cultures in order to 
investigate whether the excess of ephrinA1 can cause a phenotype in NAB similar to HAB. 
Vice versa, I applied EphA4-Fc to block excess of ephrinA1 in HAB-NAB co-cultures to 
investigate possible rescue effects. These first qualitative data indeed showed a rescue 
effect in HAB-NAB co-cultures after treatment for 48 h with EphA4 (0.1 ng/ml), whereas 
on the other hand 0.1 ng/ml ephrinA1 applied for 48 h to NAB-NAB co-cultures 
apparently reduced the expression of synaptic proteins. The higher concentrations of 
1.0 ng/ml EphA4 or ephrinA1 did not show any significant differences. This might be due 
to a too high concentration of the respective compounds. Treatment for 120 h was not 
possible in this paradigm.  
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Fig. 40: Co-Cultures of astrocytes and neurons under baseline conditions and after treatment with 
FLX (10 µM), ephrinA1 or EphA4 (1.0 and 0.1 ng/ml) for 48 h  
Qualitative analysis of  pre- (synaptophysin, red ) and post- (PSD 95, green) as well as MAP2 (gray) 
marker on Co-cultures of HAB astrocytes – NAB neurons (HAB-NAB) and NAB astrocytes – NAB 
neurons (NAB-NAB), showed less expression of synaptic markers in HAB-NAB co-cultures and seems to 
be rescued with EphA4 treatment. Baseline conditions (1 and 2), FLX treatment (3 and 4) and after 
ephrinA1-Fc (1.0 ng/ml, 5 or 0.1 ng/ml, 6) or EphA4-Fc (1.0 ng/ml, 7, or 0.1 ng/ml, 8) 
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3.8. GDF 15 
(Malik et al., in preparation) 
As mentioned before another of our candidate genes, which came up to be regulated by 
ADs (FLX and desipramine )in an unbiased microarray screening, might be of potential 
interest in our animal model for depressive-like behavior. 
3.8.1. Microarray  
In previous experiments, our lab could show that several candidate genes are activated by 
AD treatment (FLX and DMI, 25µM both) after 2 h treatment.  
We used C6 glioma cells, which serve as a model for astrocytes, and primary rat astrocytes 
in order to validate the findings. By means of qPCR we could validate that among these 
candidate genes Gdf15 was especially activated upon AD treatment (
 
Fig. 7, n= 3, Kruskal-Wallis-test, * p< 0.05, ** p< 0.01, *** p< 0.001). 
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3.8.2. In situ hybridization -validation of GDF15 probe 
In order to analyze the physiological role of increased GDF15 after treatment with FLX, I 
generated a fluorescent probe to perform in situ hybridization (ISH) analysis in brain slices 
derived from naïve CD1 mice, treated with FLX for 2 h. As previously published by 
Strelau et al. [219], I observed expression of GDF15 in the choroid plexus, thereby 
confirming the specificity and reliability of the ISH probe to detect Gdf15 mRNA. 
Furthermore, I could show that FLX treatment decreased Gdf15 mRNA in the same region 
significantly, pointing out that Gdf15 mRNA expression is a pharmacological target of 
FLX. Although these results seemed to be counterintuitive, the microarray screening 
showed that FLX upregulated Gdf15 mRNA expression (Fig. 41 a) and b), C: n= 4, 
1.418 ±  0.06, FLX: n= 5, 1.118 ± 0.06), in the choroid plexus different mechanism may 
mediate an AD effect than in the astrocytes derived from the PFC. Moreover, one needs to 
take into account that the choroid plexus mainly consists of ependymal cells, not 
astrocytes, which might react differently to AD treatment. In addition to the known region, 
we observed Gdf15 expression around blood vessels in the PFC (Fig. 41), indicating that 
this factor might play a role at the glia-vasculature interface.  
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a) Fig. 41: Validation of the 
ISH probe targeting 
GDF15 in the choroid 
plexus and in blood vessel 
of the PFC 
a) Representative 
microphotographs of the 
choroid plexus before 
and after treatment with 
FLX and around blood 
vessel in the PFC  
b) Quantitative analysis of 
GDF15 mRNA in the 
choroid plexus showed a 
significant 
downregulation after 
treatment with FLX and 
can be detected around 
blood vessels in the PFC 
 
Choroid plexus  
C FLX blood vessel 
b) 
3.9. GDF15 in blood vessels  
In light of the findings that in the PFC of MDD patients and in our animal model, blood 
vessels show decreased coverage with astrocytic endfeet, [12, 209], we analyzed the 
effects of FLX treatment on Gdf15 around blood vessels in the PFC of HAB and NAB 
animals (ex vivo). Therefore, I performed ISH-IF-IHC on brain slices derived from NAB 
and HAB animals treated with FLX for 2 d and respective controls. I could show that FLX 
increased Gdf15 mRNA expression specifically around blood vessels in the PFC (Fig. 42, 
NAB C: n= 4, 0.0029 ± 0.0006; NAB + FLX: n= 5, 0.007 ± 0.001, Mann-Whitney test, 
p= 0.0317).  
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I also observed the formation of Gdf15-positive processes between the blood vessels and 
parenchymal cells (white arrows Fig. 42 a
IV
). The extension of processes might be a 
reaction of astrocytes upon FLX treatment and could represent a mechanism relevant for 
recovering of a functional glia-vasculature interface in MDD. 
 
3.9.1. GDF 15 expression around blood vessel in HAB 
In a recently published paper from our lab ([209]), we could show that short term treatment 
with FLX (48 h) is sufficient to increase the reduced coverage of blood vessels by GFAP
+
 
processes in the PFC of HAB animals. However, this short treatment time was only 
sufficient to rescue the structural deficiency seen in HAB animals, but not the coverage of 
blood vessels by Aqp-4
+
 processes, suggesting an involvement of different pathways, 
which affect structural and functional changes in astrocytic processes. Therefore, I 
investigated here whether GDF15 might be involved in the modulation of structural 
deficiencies. First we investigated the expression of GDF15 around blood vessels in the 
PFC of NAB and HAB animals both under basal conditions and after FLX treatment (2d). 
Fig. 42: FLX increases GDF15 mRNA expression around blood vessel in the PFC of NAB rats  
A) Representative microphotographs show blood vessels (in blue DAPI staining a
I
, a
II
) and labelling 
with a probe targeting GDF15 mRNA (in red, a
III
, a
IV
) in the PFC of control and FLX treated 
NAB rats. Scale bar 50µM. Arrows pointing at processed between blood vessels and 
parenchymal cells. 
B) Quantitative analysis on the fluorescence- intensity of GDF15 expression (in pixel, GDF15
+
) 
normalized to the total volume of each blood vessel (total pixels) revealed a significant 
upregulation after FLX treatment. NAB C: n=4, NAB + FLX: n= 5, Mann-Whitney-test, 
*p<0.05. Data are represented as mean ± SEM,  
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Global Gdf15 expression did not reveal any differences between HAB and NAB or after 
treatment in HAB animals (Fig. 43 B), NAB C: n= 3, 0.0048 ± 0.0004, HAB C: n= 3, 
0.0053 ± 0.0008, HAB + FLX: n= 3, 0.0056 ± 0.0006, One-way ANOVA with Tukey´s 
multiple comparison post hoc test, F (2,6)= 0.38, p= 0.699). Thus, leading to the suggestion 
that GDF15 in endothelial cells might not be affected in depression-like behavior. 
However, quantification of GFAP
+
 processes around blood vessels confirmed the reduced 
number of blood vessel-associated astrocytic processes, in the PFC of HAB, as previously 
shown. Treatment with FLX for 2d (i.p.) could rescue this deficiency (Fig. 43 C), NAB C: 
n= 3, 2.053 ± 0.259, HAB C: n= 3, 0.945 ± 0.241, HAB + FLX: n= 3, 2.378, ± 0.252. One-
way ANOVA with Tukey´s multiple comparison post hoc test, F (1,2)= 8.98, p= 0.0157).  
I subsequently analyzed whether increased Gdf15 expression might occur at more specific 
site, like astrocytic processes. Therefore changes in the relative number of Gdf15-enriched 
astrocytic processes were quantified. The results revealed no difference between NAB and 
HAB animals, but a tendency towards an increased amount of Gdf15-enriched processes 
after FLX treatment (Fig. 43 D) NAB C: n= 3, 0.049 ± 0.011, HAB C: n= 3, 0.048 ± 0.018, 
HAB + FLX 0.092 ± 0.0067, Kruskal-Wallis test p= 0.0500). These data suggest that a 
basal difference between NAB and HAB might be masked by the underlying lack of 
processes around blood vessels in HAB animals. Thus I conducted a more in-depth 
analysis, preventing this masking effect. I quantified the density of Gdf15
+
/GFAP
+
 -
enriched astrocytic processes. This analysis showed that in HAB animals, not only the 
density of Gdf15
+
/GFAP
+
 processes was reduced, but also that FLX was able to increase 
this number with respect to both NAB and HAB strains (Fig. 43 E) NAB C: n= 3, 
0.094 ± 0.019, HAB C: n= 3, 0.039 ± 0.013, HAB + FLX: n= 3, 0.201 ± 0.008, One-way 
ANOVA with Tukey´s multiple comparison post hoc test, F (2,6)= 32.92, p= 0.0006). 
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3.9.2. GDF 15 protein expression 
The obtained results led to the suggestion that FLX might affect the expression and 
localization of GDF15 around blood vessels at astrocytic processes. To further analyze the 
functional role of GDF15, we used our cell culture model.  
Fig. 43: Coverage of blood vessels by GDF15
 +
 processes in the PFC of NAB and HAB animals 
under basal conditions and after FLX treatment 
A) Representative microphotographs of GDF15
+
/GFAP
+
 processes around blood vessels under 
basal conditions in HAB C and NAB C and after treatment with FLX (2d) 
B) Quantification of GDF15
+
 processed revealed no differences between the groups, neither under 
basal conditions nor after FLX treatment in HAB animals 
C) Analysis of GFAP
+
 processes confirmed the loss of astrocytic processes in HAB animals 
compared to NAB, under basal conditions. FLX treatment was able to restore the number of 
GFAP
+
 processed in HAB animals. One-way ANOVA, F (1,2)= 8.98, *p<0.05 
D) Analysis of GDF15
+
 - enriched astrocytic processes  (GFAP
+
) showed a tendency towards an 
increase in HAB animals after FLX treatment  
E) In depth analysis of GDF15
+
/GFAP
+
 density was significantly less in HAB animals under basal 
conditions and was significantly increased after FLX treatment  
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I then performed a preliminary western blot analysis on astrocytes treated with FLX for 
48 h and 96 h. FLX treatment did not affect GDF15 protein expression, significantly, 
neither after 48 h nor 96 h (Fig. 44, NAB C: n= 3, 100.00 ± 34.18 %, NAB 48: n= 3, 96.34 
± 42.85 %, NAB 96: n= 3, 126.7 ± 18.59 %; HAB C: n= 3, 52.62 ± 9.468 %, HAB 48: 
n= 3, 67.07 ± 13.64 %, HAB 96: n= 1, 216.6, One-way ANOVA with Dunnett´s multiple 
comparison post hoc test, F (4,24)= 0.8102, p= 0.5310). Suggesting that under basal 
conditions endogenously expressed GDF15 does not significantly differ between HAB and 
NAB animals. Nevertheless, FLX treatment might cause an increase of GDF15 in HAB 
astrocytes, but this observation still needs to be clarified.  
 
3.10. In depth analysis of astrocytic process  
In our recently published paper [51], we observed that FLX is able to increase mainly short 
astrocytic processes after short-term treatment around blood vessels. Therefore, I 
conducted an in-depth analysis of astrocytic processes, with regard to their specific 
numbers and lengths, under baseline and treatment conditions. In addition, because I 
hypothesized that GDF15 might be responsible of the outgrowth of new processes, I 
analyzed how exogenous GDF15 in different concentrations might affect astrocytic process 
in vitro. The following data were obtained in the framework of a Master thesis conducted 
together with Laura Mittmann. 
 
Fig. 44: GDF 15 protein 
expression in astrocytes derived 
from NAB and HAB treated with 
FLX for 48 h and 96 h 
No differences could be observed 
under basal conditions between 
NAB and HAB astrocytes, nor did 
FLX treatment change the protein 
expression of GDF15 significantly. 
Data are represented as mean 
+ SEM, One-way ANOVA with 
Dunnett´s multiple comparison 
post hoc test.  
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3.10.1. Number of processes in primary cortical astrocytes under baseline 
conditions  
First, I analyzed by means of IF-ICC, whether I could reproduce the findings that HAB 
astrocytes display deficits in their processes, as observed in ex vivo experiments [51]. 
Indeed, I could show that the number of astrocytic processes per cell was significantly 
reduced in HAB cells as compared to NAB cells under baseline conditions, confirming 
once again the previous results (Fig. 45: NAB C: n= 16,  6.313 ± 0.0560; HAB C: n= 12, 
4.083 ± 0.6211; Student´s t-test, t(26)= 2.808, p= 0.0093).  
 
3.10.2. Number of processes in primary cortical astrocytes after treatment with 
FLX and exogenous GDF15 
In order to investigate the hypothesis, if FLX treatment is able to increase the number of 
processes in astrocytes, and whether GDF15 might be a factor involved in this effect, I 
conducted further IF-ICC experiments using the cell culture model. Astrocytes of both 
strains were either treated with FLX (once 10 µM) or with different concentrations of 
exogenous GDF15 (1.0 ng/ml, 0.1 ng/ml or 0.01 ng/ml) in both experimental setups for 
48 h and 96 h. As depicted in Fig. 46 , I analyzed first the pharmacological effects of FLX. 
In both cell-types, FLX significantly increased the number of processes, already after 48 h 
(NAB 48 h: n= 14 , 11.43 ± 1.098, HAB 48 h: n= 12, 11.08 ± 1.500). This high increase in 
Fig. 45: Under baseline conditions 
HAB astrocytes have significantly less 
processes in vitro than NAB  
a) Representative microphotographs 
(Leica SP8, Z-stack series, 6-8 µm, 
step size 1.23 µm) of HAB and 
NAB astrocytes in vitro, using a 
double staining GFAP and S100β 
(both red).  
b) IF-ICC analysis of the number of 
processes revealed, a significant 
deficit HAB astrocytes (n= 12, 
4.083) compared to NAB (n= 16, 
6.313). Data are represented as 
mean + SEM, Student´s t-test, 
** p< 0.01 
b)  
a)  
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the number of processes per cell seemed to display a ceiling effect, substantiated by the 
finding that FLX treatment for a longer time (96 h) did not further increase the numbers 
neither in NAB nor in HAB (NAB 96 h: n= 11,  11.18 ± 1.426; HAB 96 h: n= 12, 
9.917 ± 1.228). Both one-way ANOVA with Dunnett´s multiple comparison post hoc test, 
NAB: F (2,38)= 9.227, p= 0.0005; HAB: F (82,33)= 9.901, p= 0.0004). I further investigated 
the effects of exogenous GDF15 on these cells, using three different concentrations (1.0, 
0.1 and 0.01 ng/ml) at two time points (48 h and 96 h).  
Treatment of the cell for 48 h revealed a significant increase in the number of processes per 
cell in NAB identical to the increase observed after FLX, but only with the highest 
concentration applied (1.0 ng/ml). (NAB 1.0: n= 12, 12.50 ± 1.936, NAB 0.1: n= 14, 
6.857 ± 0.9542, NAB 0.01: n= 11, 7.091 ± 1.171, one-way ANOVA with Dunnett´s 
multiple comparison post hoc test, NAB: F (3,49)= 5.910, p= 0.0016). HAB cells showed a 
higher sensitivity to exogenous GDF15, hence I observed the pronounced increase with 
1.0 ng/ml but also, tough slightly less, with 0.1 ng/ml (HAB 1.0: n= 11,  10.18 ± 1.052, 
HAB 0.1: n=11, 8.273 ± 0.8851, HAB 0.01: n= 11, 4.909 ± 1.013, one-way ANOVA with 
Dunnett´s multiple comparison post hoc test, NAB: F (3,43)= 10.21, p= 0.0001), indicative 
of a concentration-dependence in HAB cells. To investigate whether the treatment might 
also be time-dependent, I tested another time point (96 h). Here I observed in NAB cells a 
dependence on the concentration which seemed to include the time component, hence this 
effect was not present after 48 h treatment. The pronounced effect with 1.0 ng/ml was still 
present, as seen in FLX treatment, but in addition the intermediate concentration 0.1 ng/ml 
was able to increase the number of processes per cell to the same level (NAB 1.0: n= 12, 
10.75 ± 1.805, NAB 0.1: n= 11, 10.55 ± 1.194, NAB 0.01: n= 13, 8.154 ± 0.9047, one-way 
ANOVA with Dunnett´s multiple comparison post hoc test, NAB: F (3,48)= 3.772, 
p= 0.0165). HAB cells also responded in a dose- and time-dependent manner to exogenous 
GDF15, as we observed a significant increase in the number of processes per cell even 
with the intermediate concentration 0.1 ng/ml for 96 h (HAB 1.0: n= 14, 6.286 ± 0.8349, 
HAB 0.1: n= 10, 12.80 ± 1.769, HAB 0.01: n= 11, 5.636 ± 1.521, one-way ANOVA with 
Dunnett´s multiple comparison post hoc test, NAB: F (3,43)= 9.356, p< 0.0001). 
Surprisingly, I did not observe an increase in the number of processes with the highest 
concentration 1.0 ng/ml. A possible explanation for this result might be that GDF15 exerts 
toxic effects on astrocytes, when applied at potentially unphysiological concentrations for 
longer times.  
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3.10.3. Sprouting of processes in primary cortical astrocytes after treatment 
with FLX and exogenous GDF15 
Following the hypothesis that an appropriate length of astrocytic processes might be 
necessary to mediate effects of FLX, I investigated whether the increased number of 
processes may correlate with differences in the length of preexisting processes or caused 
the sprouting of new processes. Therefore, I measured the length of processes in both cell-
types after treatment with FLX and exogenous GDF 15. Fig. 47 a) depicts the differences 
in the number of processes at a specific length. NAB cells showed a very characteristic 
curve, with approximately three processes at a length between 0- 10 µm (very short 
processes), followed by a continuous decrease in the numbers as the length increased 
(approx. 2.5 processes at 10-20 µm (short processes) less than one process with higher 
length (intermediate length (20-30 µm, long 30-40 µm), whereas no very long (>60µm) 
processes were visible. On the contrary, HAB cells displayed significantly less processes at 
intermediate length, without changes in short or long processes under baseline conditions 
(NAB C: n= 16, HAB C: n= 12, 2-way ANOVA with Bonferroni´s multiple comparison 
post hoc test, F (15,390)= 35.26, p< 0.0001). In Fig. 47 b), I examined in depth the effects of 
FLX on the different lengths of processes. In NAB cells FLX treatment for 48 h and 96 h 
shifted the curve along the y-axis, which reflected an increase in the number of processes, 
without losing the characteristic shape of the curve. In detail, at both time points FLX 
increased the number of very short (0-10 µM) and short (10-20 µm) processes 
significantly, without changing intermediate or long processes, although in a few cells very 
long processes (>60µm) could be observed. Thus suggesting the generation of new 
Fig. 46: Pharmacological effects of FLX and exogenous GDF15 on the number of processes in 
astrocytes derived from HAB and NAB rats 
Pharmacolgical effects: FLX increased the number of processes per cell in both NAB and HAB 
astrocytes significalty after 48 h. This effect persisted with proglonged treatment, indicating a possible 
ceiling effect  
Exogenous GDF15: The highest concentraton of exogenous GDF15 (1.0 ng/ml for 48 h) increaed the 
number of processes in both cell types, identically to the effect observed with FLX. HAB cells seemed 
more sensitive to the treatment hence the intermediate concentration (0.1 ng/ml for 48 h) increased the 
number of processes significnatly. Prolonged treatment (96 h) revealed the same effect in NAB cell with 
a pronounced increase (1.0 ng/ml for 96h) and a dose- and time dependence, seen as an significant 
increase with intermediate concentrations (0.1 ng/ml). This dependenc is also observed in HAB cells (0.1 
ng/ml for 96 h), althought the highest concentrations (1.0 ng/ml for 96 h) seemed to exert toxic effects. 
Data are represented as mean + SEM, One-way ANOVA with Dunnett´s multiple comparison post hoc 
test * p< 0.05, ** p< 0.01, *** p< 0.001 
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processes (sprouting) after FLX treatment with possible prolongation of preexisting ones 
(2-way ANOVA with Dunnett´s multiple comparison post hoc test, F (15,570)= 105.8, 
p<0.0001) 
For a better comparison in the graph depicting HAB cells + FLX treatment, the NAB C 
curve is depicted in light gray color as well. However, statistical analysis was calculated to 
the respective control, in this case HAB C. FLX caused a pronounced increase in very 
short, short and intermediate-length processes, at both time points (48 h and 96 h). 
Interestingly, the shape of the curve in HAB cells after FLX treatment was almost identical 
to the very characteristic NAB curve. The data also suggest that in HAB cells a sprouting 
effect might have been elicited by FLX treatment. Additionally, some processes in the very 
long range (>60 µm), which could not be observed under basal conditions, were visible, 
possibly indicating a prolongation effect (2-way ANOVA with Dunnett´s multiple 
comparison post hoc test, F (15,495)= 52.96, p<0.0001) 
Furthermore, hence I saw that exogenous GDF15 increases the number of processes in 
both cell-types, in a dose- and time-dependent manner, I analyzed the length of the 
processes after GDF15 treatment. Fig. 47 c), depicts the data for both cell-types (NAB 
green colors, HAB blue colors) with different concentrations of GDF15 (1.0, 0.1, 0.01 
ng/ml) at both time points (48 h and 96 h). After 48 h treatment with exogenous GDF15, 
the number of very short (0-10 µm) and short (10-20 µm) increased significantly at the 
highest concentration (1.0 ng/ml) without losing the characteristic shape of the curve. 
Moreover, I observed some processes in the very long range that were not present under 
baseline conditions. The intermediate (0.1 ng/ml) and low (0.01 ng/ml) concentration did 
not increase the numbers at any length significantly (2-way ANOVA with Dunnett´s 
multiple comparison post hoc test, F (15,735)= 64.09, p<0.0001). In HAB cells GDF15 
treatment caused an astonishingly similar results. The high (1.0 ng/ml) and intermediate 
(0.1 ng/ml) concentration increased the number of very short, short and intermediate 
processes, significantly. No very long processes were present. The low concentration 
(0.01 ng/ml) did not seem to be effective (2-way ANOVA with Dunnett´s multiple 
comparison post hoc test, F (15, 465)= 58.78, p<0.0001). A prolongation of the treatment for 
96 h resulted in an increase in the number of very short processes in NAB cells with all 
three concentrations applied, whereas only with the intermediate and high concentration I 
observed a significant increase the number of short processes. These two concentrations 
also induced some processes in the very long range (2-way ANOVA with Dunnett´s 
multiple comparison post hoc test, F (15, 720)= 100.3, p<0.0001 In HAB cells, the highest 
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concentration failed to increase the number of very short processes at 96 h. On the contrary 
I even observed a significant decrease, whereas short, intermediate and long processes 
were significantly increased, suggsting a possible toxicity of GDF15 at least on the 
sprouting effect. The intermediate concentration was able to significantly increase very 
short, short and intermediate length processes, as well as prolonging some of the 
preexisting ones in the very long range (2-way ANOVA with Dunnett´s multiple 
comparison post hoc test, F (15,  495)= 43.77, p<0.0001).  
Overall these data showed that FLX and GDF15 can cause the sprouting of new processes, 
in our study defined as very short (0-10 µm) and short (10-20 µm) length and seemed to be 
able to prolong the preexisting processes, named here “very long” processes, in a dose and 
time-dependent manner. Furthermore, NAB cells showed a very characteristic shape of the 
curve indicating defined distribution of processes along different ranges, which still 
persisted after FLX and GDF15 treatment. Interestingly, the distribution of HAB 
processes, under baseline conditions, resulted in a distinct differently shaped curve, but 
treatment with FLX and GDF15 was able to shift this distribution into almost the identical 
direction as the NAB curve. 
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3.10.4. Knockdown of endogenous GDF15 in NAB cells 
After having established the effect of exogenous GDF15, we wanted to investigate whether 
GDF15 is necessary to induce FLX effects. Therefore, we transfected NAB cells with 
siRNA specifically designed to knockdown Gdf15 and subsequently treated them with 
FLX (Fig. 49).  
The analysis of the number of processes showed that siRNA-mediated knockdown of 
endogenous GDF15 is able to reduce the number of processes, although not significantly 
(NAB C: n= 12, 6.333 ± 0.882, NAB scr: n = 10, 5.800 ± 0.359; NAB siRNA2: n= 11, 
3.273 ± 1.833). However, 48 h FLX treatment restored the total number of processes in 
siRNA treated cells to similar amounts as not transfected and scr transfected cells (NAB 
FLX 48 h: n= 11,  10.82 ± 0.749, NAB scr+FLX: n= 11, 12.91 ± 1.148, NAB 
siRNA2+FLX: n= 5, 9.60 ± 1.833, Kruskal-Wallis test with Dunn´s multiple comparison 
post hoc test, p<0.0001).   
Fig. 47: Effects of FLX and exogenous GDF15 on the length of processes in HAB and NAB astrocytes, 
indicate sprouting of new processes  
a) Analysis of the length of processes in HAB and NAB under baseline conditions, reveled a 
significant deficit in HAB cells  
b) FLX treatment (48 h and 96 h) increased the number of processes at certain lengths in NAB cells 
(very short 0-10 µm, short 10-20 µm), as well as in HAB cells with a further increase at 
intermediate length (20-30 µm) processes  
c) Exogenous GDF15 increased the number of very short and short processes in NAB cells in does-
and time-dependent manner. Similar results were observed in HAB animals, with the addition of 
increases in intermediate and long processes.  
Data are represented as mean ± SEM for each length, very short (0-10 µm), short (10-20 µm), 
intermediate (20-30 µm), long (30-40 µm), very long (>60 µm). 2-way ANOVA with Dunnett´s 
multiple comparison post hoc test. *, # p< 0.05, **, ##,++ p< 0.01,***,###  p< 0.001  
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Hence, knockdown of endogenous GDF15 did not significantly inhibit the growth of 
processes in NAB astrocytes or inhibited the FLX-mediated effects, but still exogenous 
GDF15 elicited the same effects as observed after FLX treatment, we investigated the 
effects of GDF15 knockdown on then specific lengths of astrocytes.  
As seen in Fig. 49, knockdown of GDF15 decreased the number of very short processes in 
NAB cells below control levels. Thus, suggesting a role of GDF15 in stabilization of 
processes, as preexisting processes were lost when endogenous levels of GD15 were 
reduced. Subsequent treatment with FLX was able to increase the number of short 
processes, and the number of very short ones reached control levels (2-way ANOVA with 
Dunnett´s multiple comparison post hoc test, F (15,480)= 41.28, p< 0.0001). Thus it might be 
that GDF15 is necessary to induce the sprouting of new processes upon FLX treatment.  
 
 
 
 
 
 
 
 
 
Fig. 48: Knockdown of GDF15 via 
siRNA with subsequent FLX 
treatment does not inhibit AD-
mediated effects on the total number 
of processes in NAB cells.  
NAB astrocytes were transfected with 
siRNA directed against GDF15 or 
non-targeting scr siRNA, as well as 
untreated (NAB C). Subsequently cells 
were treated with for 48 h with FLX. 
Data are represented as mean + SEM, 
Kruskal-Wallis test with Dunn´s 
multiple comparison post hoc test, 
*p<0.05, **p<0.01 
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Fig. 49: Knockdown of endogenouse GDF15 in NAB astrocytes seem necessary for stabilisation of 
exisiting processed and FLX mediated sprouting  
siRNA mediated knockdown of exogenous GDF15 caused a loss of very short (0-10 µm) processes. This 
loss could not be rescued by subsequent FLX treatment. FLX did significantly increase the number of 
short (10-20 µm) processes. Data are represented as mean ± SEM for each single length. 
Microphotographs depict NAB astrocytes under different treatment conditions. Data were analyzed 
using 2-way ANOVA with Dunnett´s multiple comparison post hoc test, ***,### p< 0.001 
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 Discussion 4.
Depression was recently estimated to be the leading cause of disability worldwide [7]. 
Although since the 50s antidepressant therapy options are available, the exact underlying 
mechanisms of MDD and the action of ADs are still poorly understood. With the 
development of new generations of antidepressants, the focus of research changed, from 
examining solely the monoaminergic system, towards more advanced and specific 
alternative targets.  
However, the initial problems could still not be resolved. Antidepressants still require 
several weeks until the patients feel improvement of depressive symptoms and over 30 % 
of patients do not respond to the first treatment at all, thus requiring additional 
antidepressants. Thus, most clinical approaches are still based on trial and error, which 
represents a huge burden for patients, who have betaken themselves to seek medical help, 
although the stigmata for depression is still very present in our society. Therefore, the 
scientific effort should be directed to find novel, faster acting compounds and biomarkers 
that might predict the outcome of pharmacological treatments. A very promising approach 
to this type of “personalized medicine” developed with the emerging understanding of 
epigenetic mechanisms.  
With the postulation of the histone code hypothesis [143] the focus was drawn towards an 
understanding how, not only eventual genetic predispositions, but also daily life events can 
impact such a disorder. Epigenetic modifications have been broadly implicated in the 
pathophysiology of mood disorders. But this research field is still in its infant shoes and 
mainly based on global aberrancies or misbalances in neuronal cells. Although, very 
striking evidence exists about depression being not primarily a neuronal, but rather a glia 
cell disease. Foremost, aberrancies in astrocytes have been shown to cause depressive 
phenotypes and many currently available antidepressants act directly on astrocytic 
populations. However, almost nothing is known about epigenetic modifications in glia cell, 
specifically in astrocytes. With the present study I was trying to shed some light on the 
possible underlying mechanisms that may contribute to the development of MDD, with a 
major focus on cell-type specific alterations in the PFC of HAB animals, which represent a 
very promising animal model for “endogenous” depression.  
I investigated in our animal model which combination of different PTMs diverged from the 
“healthy” state and how antidepressant therapy impacted such modifications. Furthermore, 
I was able to identify a new candidate gene that was specifically regulated by PTMs, 
providing the first evidence that misregulation of this gene is linked to epigenetic 
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modifications in MDD. Moreover, using an unbiased microarray screening approach, 
another target of AD treatment was identified that is involved in regulating sprouting and 
maintenance of astrocytic processes, a mechanism that may be essential for AD responses. 
Astrocytic processes are known to be involved in MDD [51, 128] especially at the level of 
the blood-brain barrier. Improving brain plasticity by rescuing the reduced astrocytic 
processes might help to accelerate the uptake of antidepressants into the brain parenchyma, 
thus helping to establish a faster response to therapies and amelioration of symptoms.  
The major questions of this study were: 
1) How is the status quo in HAB animals compared to NAB animals regarding PTMs? 
2) Are these differences cell-type specific? 
3) How do ADs affect the misbalance? 
4) Which are the downstream effects of such an aberrant epigenetic modification? 
5) Can we target astrocytes at the level of processes in order to improve AD response 
6) Are these factors putative targets to improve depressive symptoms  
4.1. Posttranslational histonemodifications  
Coming from the knowledge about histone modifications impacting the brain in MDD, I 
investigated in HAB animals, whether PTMs depict also a target in this model for 
depression.  
Therefore, I investigated several PTMs in the PFC, which is one of the main regions 
affected in MDD [54, 62]. 
In the first approach, I analyzed H3K4me3, a PTM that is generally considered to be 
transcription activating (permissive mark) on a global level. Using IF-IHC, I analyzed the 
expression of H3K4me3 in the PFC of untreated HAB and NAB animals to establish a 
baseline between the two strains. This global analysis of H3K4me3 did not reveal any 
differences between the two strains. The missing global effects depicted a substantial 
deficit in the general epigenetic studies. Often only global differences are investigated, 
without taking into account that the expression of PTMs differs greatly not only among 
different brain regions or genes [68, 157, 220], but presumably also in different cell-types 
[151]. The PFC contains different cell-types, some of which might respond to ADs 
whereas others do not or even respond in opposite ways. These opposite effects may 
therefore counteract each other, ultimately leading to a nullification of the global effects. 
This sole investigation of global differences completely neglects existing changes in single 
cell-types, which might be even more important to understand the pathophysiology 
underlying MDD: 
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Thus, I decided to analyze the ex vivo brain slices in a cell-type specific manner. During 
this analysis two highly important results came up. First, I could show that HAB animals 
have significantly less astrocytes in the PFC, representing a further validation of HAB 
animals as a suitable model to study MDD, hence it was previously shown that reduced 
numbers of glia cells were found in the PFC of humans suffering from MDD [12, 31]. 
Secondly, I could reveal that the colocalization of H3K4me3 in HAB was significantly 
increased in astrocytes, but not in neurons, under baseline conditions. This indicated an 
astrocyte specific phenotype in HAB animals with regard to H3K4me3. This mark is 
generally thought to promote gene transcription, thus leading to the suggestion that HAB 
animals might display an aberrantly active expression of genes that could contribute to 
their behavioral phenotype. Further implicating that active gene transcription might not 
necessarily be beneficial in mood disorders, but rather induce a misregulation that could 
possibly lead to deleterious effects. With these data I provided evidence that, under 
baseline conditions, HAB animals do show epigenetic differences in comparison to 
“healthy” NAB animals and that such differences are specific to astrocytes of the PFC.  
After having established that H3K4me3 in HAB animals is distinctly different than in 
controls, I investigated whether the misregulated H3K4me3 is a target of antidepressants. 
Chronic treatment with paroxetine, a SSRI, of HAB rats showed antidepressant effects, as 
measure by the forced swim test (FST) [221]. Following up that HAB rats beneficially 
respond to SSRIs, I used in this study fluoxetine (FLX), another SSRI that was shown to 
beneficially affect depression in humans [222] and is among the most prescribed 
antidepressant on the market. In first instance, to evaluate whether H3K4me3 is a 
pharmacological target of FLX, NAB animals were injected FLX or SAL as controls. I 
chose this short-term treatment, because I was interested in the early molecular effects of 
FLX, which supposedly start after the first administration of a drug, long before behavioral 
improvement might take place.  
Indeed, I observed that FLX treatment in NAB rats increased the global expression of 
H3K4me3, showing that AD treatment upregulates H3K4me3 in the PFC already after this 
short-term treatment. This finding proved that H3K4me3 is targeted by FLX even under 
non-pathological conditions. In parallel, I investigated if a specific cell-type was affected 
by FLX injections and I could thereby reveal that, indeed, in NAB animals an upregulation 
of H3K4me3 occurred, again specifically in astrocytes, whereas neurons were not affected. 
Thus, emphasizing that specific cell-types might be more prone to respond differently to 
pharmacological treatment than others. Because astrocytes are part of the BBB, which is 
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the entrance for any drug into the brain, and the fact that HAB animals have less astrocytes 
in the PFC led to the suggestion that the delayed onset of AD efficacy might correlate with 
this misregulation.  
It is known that epigenetic modifications change according to the environment, especially 
upon stressors. Hence injection of substances is always accompanied by some kind of 
stress, I wanted to investigate whether the injection itself caused changes in H3K4me3. To 
rule this possibility out, I compared injected animal to naïve animals at the level of 
H3K4me3 and did not find significant differences, thus implicating that no injection effect 
is damping the findings.  
To see if HAB animals pharmacologically respond to FLX, I replicated this experiment in 
HAB animals injected with either SAL or FLX. The analysis of the global expression of 
H3K4me3 in the injected HAB animals did not show an overall difference in this mark. 
But the cell-type specific analysis revealed that, after the short-term treatment, H3K4me3 
in HAB astrocytes was not targeted by FLX, whereas in the colocalization with neurons I 
observed a strong tendency towards a decrease. On first instance, this finding was very 
surprising, because I observed that astrocytes and not neurons were the affected cell-type 
in HAB animals. However, this finding went quite well in line with the fact that ADs take 
some time to elicit positive effects. It might be that a prolongation of the treatment, which 
better corresponds to a beneficial behavioral outcome, might ultimately target astrocytes to 
restore their functionality. Furthermore, it is not surprising that the diseased cells did not 
immediately respond to a pharmacological intervention, but maybe first FLX targeted the 
non-affected cell-type. It might also be that a proper number of astrocytes in the PFC of 
HAB animals first needs to be re- established before AD treatment can elicit beneficial 
effects in these animals, thus requiring a prolongation of FLX treatment. To investigate if a 
prolonged treatment with FLX might be able to restore the imbalance of H3K4me3 in 
HAB astrocytes, I used our cell culture model of primary cortical astrocytes, isolated from 
HAB and NAB pups. First, I established whether the in vitro model was suitable to reflect 
the findings obtained from ex vivo experiments. HAB and NAB astrocytes were treated 
with FLX and compared to untreated cells. Western blot analysis confirmed the basal 
differences in H3K4me3 protein expression that I observed in the ex vivo experiments, 
with a pronounced upregulation in untreated HAB astrocytes compared to untreated NAB 
astrocytes. A prolonged treatment with FLX up to 120 h significantly decreased H3K4me3 
protein expression in HAB astrocytes, although this decrease was not yet visible after 48 h. 
These results further substantiated the suggestion that a short term treatment (48 h, or 2d ex 
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vivo) might not be sufficient to achieve beneficial effects in astrocytes yet, but a 
prolongation of the treatment might indeed target the diseased cells and they might have 
enough time to recover. To fully understand if a prolonged treatment with FLX might elicit 
the same effect in the PFC, it would be necessary to conduct a longitudinal study in HAB 
rats. To investigate if another AD, namely ESC, was also affecting H3K4me3 in HAB and 
NAB astrocytes, I treated the cells in the same manner as described with FLX. The 
baseline difference between untreated controls was persistent, confirming the strong 
molecular phenotype of our cell culture model. But ESC treatment did not target this 
methylation mark significantly, leading to the suggestion that the pharmacological effects 
may be specific to FLX. The differential effects of these two SSRIs, which supposedly 
should act in the same way, might be worth to be further investigated, in order to examine 
how specific ADs might target different epigenetic modifications also in light of finding 
putative markers for individual antidepressant responses.  
As suggested by the “histone code hypothesis” [143], typically gene expression is 
determined by a combination of different modifications. These modifications might act 
synergistically or opposing to establish specific gene expression patterns [5], which might 
represent novel target for pharmacological intervention. To investigate if in our animal 
model such a combinatorial code might be involved in the underlying pathogenesis, which 
additionally could be unique to HAB rats, I further investigated other PTMs.  
I analyzed H3K27ac, that is generally considered to be gene activating and has been 
implicated in MDD as well as being affected by ADs [223]. In our cell culture model, I 
identified that H3K27ac was downregulated under basal conditions, although this 
reduction was not significant. A possible explanation for this high variability in NAB 
astrocytes might be that because the cells are derived from outbred Wistar rats, they show a 
higher divergence than genetically driven HAB cells. This fact should be taken into 
account when interpreting such data, because, even if no significances occur, the biological 
effects should not be dismissed. After treating the cells with ADs, I observed a significant 
downregulation in NAB astrocytes after 120 h FLX treatment, speaking again for this mark 
also being a pharmacological target of ADs. In HAB astrocytes on the other hand, I 
observed an upregulation of H3K27ac after 120 h although it did not reach significance. 
The same biological effects were observed in HAB cells after ESC treatment, whereas in 
NAB animals the significant decrease of H3K27ac was not observed after 120 h ESC 
treatment, again speaking for different molecular pathways of these two drugs. This 
combination of the two PTMs might be explained by the fact that probably several genes 
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are impacted in different ways, emphasizing the necessity to analyze this combination at 
specific loci.  
I further analyzed the expression of the repressive H3K27me3. This mark is supposed to 
counteract H3K4me3 [224]. Under baseline conditions, H3K27me3 was significantly 
downregulated in HAB animals, substantiating the counteracting effects of the activating 
H3K4me3 and repressive H3K27me3. In NAB animals this mark was not affected by FLX 
or ESC treatment, although an increase could be suggested upon FLX treatment. In HAB 
astrocytes the low expression was even further decreased after FLX treatment for 120 h, 
suggesting another player in the novel combination between these PTMs that could be 
unique to our model. ESC treatment did to affect this mark neither in NAB nor in HAB 
cells. 
Having established the basal and pharmacological effects of H3K27me3 upon FLX 
treatment specifically in HAB astrocytes, I further analyzed the status quo in the PFC of 
NAB and HAB animals (ex vivo), as well as the pharmacological effects. Using brain slices 
derived from perfused animals represents a better possibility to analyze effects of ADs in a 
complex environment, than single cultures of astrocytes. Indeed, in the IF-IHC 
experiments I observed a significant downregulation of global H3K27me3 in the PFC of 
HAB animals of about 40 %.  
These results substantiated the hypothesis of an existing combinatorial histone code in 
HAB animals. Further, I analyzed the astrocyte-specific colocalization of H3K27me3 in 
NAB and HAB. Among the astrocytic population again only 40 % of the cells showed a 
colocalization with H3K27me3 in NAB and this expression showed a tendency to decrease 
in HAB animals (about 28 %). Interestingly, H3K27me3 was in general very low 
expressed in the PFC of control animals (NAB), in which the expression levels only 
reached about 36 %. This might implicate that the effect size could not be high enough to 
be detectable in a single culture, thus not disregarding an underlying biological effect. 
This combination of less repressive H327me3 together with the observed upregulation of 
the activating H3K4me3 provided evidence that astrocytes in the PFC of HAB animals, 
indeed, show a different combinatorial histone code than NAB animals under baseline 
conditions, further supporting the suggestion of aberrantly active gene transcription 
machinery involved in the behavioral phenotype. Here, I want to mention again that 
according to our cell culture model only a prolonged treatment might elicit significant 
molecular effects, emphasizing the necessity of a prolonged study in our animal model to 
be able to reveal possible treatment effects.  
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4.2. H3K4me3 regulation of ephrinA1  
As already indicated from other published data [117, 147, 225], investigation of global 
differences is a valid starting point to identify novel targets, but to identify specific 
functional differences, it might be rather more important to investigate changes in specific 
genes. In an unbiased microarray screening approach, conducted previously in our lab, we 
were able to identify several candidate genes that are differentially expressed in astrocytes 
and C6 glioma cells treated with FLX and DMI. Among them EphA2, which belongs to 
the Eph receptor tyrosine kinase family [218], came up to be a target of AD treatment. 
Hence we went on and analyzed in cooperation with Dr. Mira Jacovcevski at the Max 
Planck Institute of Psychiatry, Munich, if the ephrin/EphR system might be a possible new 
target of ADs in astrocytes. To investigate this possibility, we conducted a chromatin-
immunoprecipitation analysis (Ch-IP), to evaluate if our candidate gene might be regulated 
by H3K4me3. This approach confirmed that ephrinA1, a ligand of EphA2 and EphA4, was 
differentially regulated by the previously identified H3K4me3 in HAB astrocytes and 
prolonged treatment with FLX was able to decrease ephrinA1 to the baseline amounts 
observed in NAB. Consequently our data showed that ephrinA1 expression is specifically 
activated in HAB animals, probably leading to an imbalance in the ephrin/EphR system 
that might represent a molecular mechanism underlying the depression-like phenotype in 
HAB animals. These findings might open a novel approach in the field of understanding 
the pathophysiology of depression. Only one other study so far has implicated a 
misregulation in the ephrin/Eph system to MDD [199], but this study linked the 
ephrinB/EphB system to a misregulation on neuronal cells caused by stress-induced 
depressive symptoms.  
Further, I went on to characterize the expression patterns of ephrinA1 upon FLX treatment 
in astrocytes. The cells were treated with FLX and a western blot analysis confirmed the 
pronounced upregulation of ephrinA1 (4-fold increase) in HAB astrocytes under baseline 
conditions. Interestingly, the results of western blot experiments showed two very distinct 
bands for ephrinA1, one at 26 kDa and one at 15 kDa. According to the manufacturer, 
ephrinA1 protein should be visible at roughly 30 kDa, which would indicate the 26 kDa 
band to be the one to look at. But there is evidence that different isoforms of ephrinA1 
exist [218]. At present, I cannot rule out that these alternative spliced forms of ephrinA1 
might represent a cell-type specific difference. Currently, I am examining how H3K4me3 
and ephrinA1 are expressed in neurons and whether they might be modulated by AD 
treatment. Therefore, I decided to investigate both. Indeed, both isoforms were 
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differentially expressed in HAB animals, with a significant upregulation of the 15 kDa 
band and a strong tendency towards an upregulation of the 26 kDa band. Moreover, FLX 
treatment decreased the expression of both isoforms after 120 h treatment, although the 
effect did not reach significance, yet. In NAB astrocytes FLX caused an opposite effect, 
although also here no significance could be detected. A possible explanation why the 
effects after 120 h were not significant, might be that although we observed effects on the 
regulating PTM, the effects on gene specific expression, which involves the whole 
transcriptional and translational machinery, require longer times to be detectable. For 
future studies it might also be interesting to investigate if the two isoforms might play 
distinct roles. 
Together with the pronounced upregulation of ephrinA1 in HAB astrocytes regulated by 
H3K4me3, and the suggestion that FLX normalized these effects again, I hypothesized that 
blocking the overexpression of ephrinA1 by RNA interference might have beneficial 
effects on the surrounding neuronal environment. Therefore, I designed siRNA directed 
specifically against ephrinA1 and transfected HAB astrocytes. After transfection, I 
observed a decreased ephrinA1 protein expression in HAB astrocytes.  
With the establishment of this specific tool, I will be able further investigate, whether the 
knockdown of ephrinA1 is sufficient to reverse the morphological phenotype of HAB 
astrocytes and maybe even the depression-like behavior of HAB rats. 
But first to examine whether this high ephrinA1 expression could also be observed in the 
PFC of HAB animals, I conducted IF-IHC experiments in the PFC of both, HAB and 
NAB, analyzing the expression of ephrinA1 and EphA4. Under baseline conditions, we 
were able to detect a significantly higher global expression of ephrinA1 in the PFC of 
HAB rats, whereas the expression of EphA4 did not differ, suggesting a gene specific 
imbalance. The finding that in ephrinA1 is overexpressed in the PFC of HAB as well as in 
astrocytes (in vitro) regulated by H3K4me3 and may be responsive to AD treatment, led 
me to the hypothesis that this specific gene might be highly involved in molecular 
phenotype of the HAB animals and is very likely involved in the pathophysiology the 
depressive-like behavior. However, I further need to elucidate if the overexpression in the 
PFC of HAB animals is specific to astrocytes, as indicated by the cell culture experiments, 
and whether AD treatment can reverse this expression. Furthermore, to investigate if 
overexpression of ephrinA1 is also sufficient to induce a depressive-like phenotype, I 
should induce an overexpression of ephrinA1 in the PFC of NAB rats and test their 
resulting behavior in the FST.  
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4.3. EphrinA1 and its implication it the regulation of synapses  
The ephrin/EphR system is known to be involved in the regulation of synaptic 
compartments [203]. It is already known that a misregulation of the synaptic compartment 
is involved in MDD [123], and thus ephrinA1 may also play a distinct role in this 
regulation. In the present study, I was interested in investigating if synaptic contacts in 
HAB might differ from the normal phenotype. Therefore, I established a co-culture model 
to mimic a more “in vivo-like” situation.  
The model consisted in the cultivation of astrocytes, either derived from HAB or NAB 
pups, that were plated a few days before the freshly isolated neuronal cells (only NAB) 
were added onto the feeder layer. The idea behind this approach was to see whether the 
“diseased” HAB cells were able to induce an aberrant phenotype in “healthy” neuronal 
cells on synaptic level and if these deficiencies could be rescued by administering the 
soluble Eph-receptor that binds to exaggeratedly expressed ephrinA1, thereby saturating 
ephrinA1 and inhibiting the binding to the native receptors with consequent rescuing 
effects.  
Indeed, preliminary data on these co-cultures showed that neurons grown on HAB 
astrocytes seem to have less synapses as indicated by staining of pre- and postsynaptic 
terminals, as well as a reduction in the number of mature synapses. Interestingly, FLX 
treatment decreased the expression of synaptic markers in both co-cultures, further 
suggesting that ADs might cause plasticity changes into the direction of a de-
differentiation of the targeted cells, thereby eliciting a remodeling of synapses. From the 
preliminary experiments I further observed that administration of EphA4, indeed, 
dampened the effects of overexpressed ephrinA1. In fact, 48 h after application of soluble 
EphA4-Fc HAB co-cultures showed an increased expression of synaptic proteins, 
indicative of a possible rescue effect. Whereas, ephrinA1 applied to NAB co-cultures 
showed a reduction in synapses. However, further quantitative studies are needed in order 
to elucidate the specific effects on pre- and postsynaptic terminals.   
 
In a study by Nestor et al. [226] it was demonstrated that astrocytes in the rat hippocampus 
are able to respond to EphA receptor activation by increasing the length and number of 
fine processes. Furthermore, ephrins can regulate functional astrocyte-neuron 
communication by inhibiting Ca
2+
 oscillations in astrocytes, thereby leading to changes in 
glutamate release. This effect can be elicited by exogenous ephrinA-Fc application and by 
cleavage of the endogenous ephrinAs from their GPI anchors, indicating a cell-contact 
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independent mechanism. Furthermore, both, astrocytes and dendritic spines have been 
shown to express EphA receptors. Misregulation on both sides might cause morphological 
changes on the level of astrocytic processes and dendritic spines. Hence in the present 
study I saw a misbalance in the ligand (ephrinA1) but not in one of the receptors (EphA4), 
therefore it is likely that the exaggerated ligand expression is causing an inhibitory force on 
the normally expressed receptors, thus leading to retraction of spines and concomitantly to 
a reduced number in synapses. Alternatively, it might be that it also causes a repulsive 
force between the ephrinA1 expressing cells as it was already shown for example in 
gliomas [227]. Specifically, if cells which express the ligand come in close proximity to 
each other, they are able to sense the expression of the respective ligands and if the same 
ligand is expressed in the cell surface this elicits a repulsion force causing probably a 
transendocytosis of the complex into either cells, ultimately leading to cell rounding and 
retraction of processes. To clarify this aspect, it would be necessary to investigate the exact 
set of EphA receptors expressed by HABs in the PFC to determine whether other EphA 
receptors, like EphA2, might be misregulated. The high promiscuity of EphA receptors 
binding literally all ephrinA ligands requires a laborious experimental set up to investigate 
which specific combinations elicit these effects. Nonetheless, the fact that HAB astrocytes 
endogenously overexpress ephrinA1 in comparison to NAB astrocytes opens a new 
exciting possibility to identify novel mechanisms underlying MDD as an astrocytic 
pathology. 
4.4. Summary and outlook on PTMS and ephrinA1 
Interestingly, these data further suggested that the beneficial effects of blocking ephrinA1 
at the synaptic level might be faster acting that the regulation by ADs. Short-term AD 
treatment did not restore synapses. It rather seems like the ADs elicited general 
readjustment processes on synaptic levels as seen by decrease in synaptic compartments in 
NAB-NAB cultures after 48 h treatment, whereas EphA4-Fc seems to increase at least pre-
and postsynaptic protein expression already in this short time frame. It needs to be 
elucidated whether the 48 h EphA4 treatment is sufficient to induce an increase in the 
number of functional, mature synapses. Taken together my data indicate: 1) a unique 
combinatorial histone code in HAB animals with a pronounced upregulation of H3K4me3 
specifically in astrocytes and not in neurons, H3K27me3 (repressive) being downregulated 
in HAB astrocytes and H3K27ac (permissive) which was downregulated in HAB 
astrocytes as well; 
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2) upon FLX treatment H3K4me3 was downregulated almost to control levels, H3K27me3 
is downregulated as well, and H3K27ac was upregulated although not significantly, 
altogether indicating a novel mechanism of FLX treatment via PTMs. 
3) H3K4me3 at the promoter caused a pronounced overexpression of ephrinA1 in HAB 
astrocytes that can be counteracted by FLX treatment after 120 h but the downregulation 
did not reach significance, which might be dependent on the time that transcriptional 
machinery requires to be restored. Hence we see the significant effect in the PTM but the 
gene expression might require longer time to reveal the differences on protein level. We 
are currently examining the effects of FLX on ephrinA1 regulated by H3K4me3 at the 
promoter level via ChIP.  
4) knockdown of ephrinA1 was sufficient to reduce the protein expression in HAB 
astrocytes. Further analysis in needed to investigate if ephrinA1 is necessary for the FLX 
mediated effects. If this is the case, we will further investigate if siRNA mediated 
knockdown in HAB astrocytes might be able to rescue the deficiencies at the synaptic level 
and ultimately if virus mediated knockdown of ephrinA1 in the PFC might provide a 
mechanism to reverse the depressive-like phenotype in HAB animals, hence we see the 
pronounced upregulation in IF-IHC, corresponding to the changes observed in vitro.  
 
This study provides interesting new findings of deregulated PTMs in astrocytes, causing 
aberrant gene expression of a novel target, the Eph/ephrin system, in HAB animals that 
ultimately might contribute to the depressive-like phenotype. Preliminary data on synaptic 
levels also indicate a misregulation on synaptic plasticity at the astrocyte-neuron 
communication. EphrinA1 might account, at least in part, for the readjustment of synaptic 
contacts in HAB animals, letting me to speculate that a concomitant misregulation in 
synaptic transmission might further be involved in the depressive phenotype. For example, 
a decrease in the glutamate system may be correlated with our findings, causing too high 
concentrations of glutamate in the synaptic cleft that cannot be properly removed and 
therefore may exhibit deficits in cognitive functions, as seen by reduced long-term 
potentiation in the hippocampus of animal models for depression. Furthermore, I might 
speculate that the Eph/ephrin system could also play a role on the vascularization, as it is 
the case in many cancers, specifically at the level of the BBB, at which HAB animals 
display aberrant coverage of blood vessels by astrocytes under baseline conditions. But 
further studies are needed to investigate these implications of the Eph/ephrin system.  
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4.5. GDF15  
Among the 7 candidate genes in our microarray analysis, Gdf15, a member of the TGF-β 
superfamily came up to be highly upregulated after treatment in primary astrocytes and C6 
glioma cells. Therefore, I investigated how this factor might be involved in MDD. GDF15 
was previously identified as a biomarker for cardiovascular disease [184] and serum levels 
of GDF15 are a highly reliable predictor of disease progression. In the CNS GDF15 has 
been implicated to play an essential role in the maintenance of neurons and promotes 
survival of developing and lesioned neurons [187]. By identifying GDF15 as novel 
pharmacological target of antidepressants I was interested in investigating  the potential of 
this factor as a new putative marker for antidepressant response.  
So, I examined how GDF15 expression is modulated by FLX in primary cortical astrocytes 
and if HAB animals display a misregulation of this trophic factor, which might 
subsequently be restored by AD treatment. I especially focused on morphological 
alterations of astrocyte in the PFC of HAB animals as well as in our in vitro cell culture 
model to identify if GDF15 participates in the aberrant morphology of astrocytic processes 
specifically at the level of the BBB as previously shown [51].  
GDF15 is known to be expressed in the CNS, especially at the choroid plexus where it is 
released into the CSF, from which it can penetrate the brain parenchyma.  
 
By in situ hybridization, I could first verify the specificity and reliability of the generated 
in situ probe for Gdf15, and secondly observed that Gdf15 mRNA is also expressed around 
blood vessel in the PFC of NAB and HAB rats. This observation led to the suggestion that 
GDF15 might play a role at the glia-vasculature interface, which we recently have shown 
to be misregulated in HAB animals [51].  
By combining the ISH followed by IF-IHC in the PFC of HAB animals I identified that 2 h 
of FLX treatment was sufficient to significantly increase GDF15 expression around blood 
vessels in NAB rats, substantiating the hypothesis that it is a pharmacological target of 
FLX ex vivo. Furthermore, in the brain slices I observed the formation of Gdf15 positive 
protrusions between surrounding astrocytes and parenchymal cells of the blood vessels, 
implying a possible connection between FLX treatment and formation of astrocytic 
processes. Although, in HAB animals 2 d of AD treatment did not reveal differences in 
global Gdf15 expression around blood vessels of the PFC neither under basal conditions 
nor after FLX treatment.  
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Indicating that changes of Gdf15 might upon FLX treatment, as seen in the microarray, 
could be restricted to more specific sites. However, by quantifying GFAP
+
 processes 
around blood vessels, which represent processes derived from astrocytes, I confirmed the 
reduced number of blood vessel-associated astrocytic processes in HAB animals, which 
were be restored by FLX treatment, further suggesting that astrocytic processes around 
blood vessels, as part of the BBB, are impaired in HAB animals. 
Following these observations, I investigated whether increased GDF15 expression might 
occur on more specialized compartments like GFAP
+
 processes around blood vessels. 
Therefore, I quantified the relative number of GFAP
+
/Gdf15
+
 processes to total GFAP
+
 
processes, which also did not reveal major differences between HAB and NAB, but in 
HABs FLX seemed to slightly increase this proportion. Given the fact that HAB animals 
show a deficiency in astrocytic processes at the BBB, it is very likely that basal differences 
between NAB and HAB could be masked by this underlying deficiency. To avoid a 
possible masking effect of the reduced number of astrocytic processes, I performed a more 
in depth analysis. I quantified the density of GFAP
+
/Gdf15
+-
enriched astrocytic processes. 
Using this analysis I identified that in the HAB PFC not only the density of GFAP
+
/Gdf15
+
 
processes is reduced, but this reduction can be increased by FLX treatment with respect to 
both stains. These data indicated that in the PFC of HAB animals GDF15 expression is 
reduced at very specific sites such as astrocytic processes surrounding blood vessels, which 
might further indicate that GDF15 could play an important role in establishing and/or 
maintenance of the BBB. As well as that the deficient expression of GDF15 at astrocytic 
processes can be targeted by FLX treatment, thereby possibly mediating beneficial effects 
for the uptake of AD into the brain parenchyma. 
To investigate a potential functional role of GDF15 in astrocytes, I performed a 
preliminary western blot analysis using our cell culture model of primary astrocytes 
(HAB/NAB) under basal conditions and after treatment with FLX for 48 h and 96 h. As 
indicated by the global GDF15 expression in astrocytes from the PFC, I did not observe 
significant differences in protein expression of GDF15, although HAB astrocytes might 
tend to express less GDF15 under basal conditions and FLX might be able to increase the 
expression again. These findings might substantiate the hypothesis that a deficiency in 
astrocytic GDF15 expression might lead to an improper glia-vasculature interface in HAB 
animals, which could be restored by AD treatment.  
With respect to our recently published paper, in which we found that FLX seems to 
sufficient to increase structural aberrancies on shorter astrocytic processes, I decided to 
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investigate in a more sophisticated analysis how FLX might act on astrocytic processes of 
different lengths and whether GDF15 participates in these morphological changes. By 
means of IF-ICC I wanted to establish if our cell culture model reflectd the deficits in 
terms of reduced number of processes. Indeed, I observed that also in vitro HAB astrocytes 
have significantly less processes under baseline conditions, indicating the cell culture as a 
suitable model to investigate how GDF15 might be involved in the establishment of 
astrocytic processes and whether it is necessary to mediate effects of FLX on astrocytes. 
After treatment with FLX the number of processes per cell increased significantly, proving 
that FLX is sufficient to target outgrowth of astrocytic processes presumably by inducing a 
sprouting of new processes, an effect that could be observed in both cell-types. Moreover, 
these findings show that the deficiencies of astrocytic processes can be reversed by AD 
treatment. This increase in astrocytic processes could by a possible mechanism by which a 
proper glia-vasculature interface is reestablished, that is needed in order to mediate further 
AD effects, like changes in gene expression.  
The increase in the total number caused by FLX treatment remained stable after prolonged 
treatment, indicating a possible ´ceiling effect´ in astrocytes, meaning that a single cell can 
only establish a certain amount of processes. One could speculate that this ceiling effect 
might be involved in treatment resistance to ADs, either because the astrocytes of 
treatment resistant patients somehow lost their ability to form new processes, or they 
already reached the maximal capacity of possible processes without a beneficial effect on 
the pathophysiology of MDD. However, to investigate such an implication further studies 
would be needed examining the astrocytic morphology in treatment resistant animal 
models, or patients. 
Nevertheless, to investigate how GDF15 is involved in morphology of astrocytic processes 
I administered exogenous GDF15, hence GDF15 is a trophic factor that might be released 
from internal stores and is able to intact with distant cells. I applied three different 
concentrations at two time points in order to determine if the effects might be 
concentrations and/or time dependent. Indeed, after application of the highest 
concentration of GDF15, I observed an increase in the number of processes that reached 
the same amount as FLX, in both HAB and NAB astrocytes. NAB astrocytes did not 
respond to lower doses of GDF15, whereas HAB astrocytes are more sensitive to 
exogenous GDF15, hence they responded also to the intermediate dosage. These finding 
showed that GDF15 is able to elicit the same morphological changes in astrocytes as FLX, 
indicating GDF15 might be a new putative drug eliciting antidepressant effects. 
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Prolongation of the treatment with exogenous GDF15 resulted in a time and concentration 
dependence in NAB and HAB cells, but prolonged treatment with the highest 
concentration of GDF15 seemed to be toxic to HAB cells, further showing the higher 
sensitivity of HAB astrocyte to this trophic factor. Together these data strongly indicated 
that exogenous GDF15 is able to induce sprouting of astrocytic processes in a strikingly 
similar manner as FLX and this effect seems to be time- and concentration-dependent. A 
member of the TGF-β family, GDF10, has been implicated in axonal sprouting in the 
cortex after infarction and is able to activate a coordinated up- or down-regulation in 
specific pathways involved in axonal outgrowth [228]. Therefore, it can be speculated that 
GDF15 displays similar roles in astrocytes, although so far nothing is known about the 
effects of sprouting in astrocytes and GDF15.  
Driven by our previous findings that a certain length of astrocytic processes might be 
necessary to elicit beneficial effects at the BBB upon FLX treatment [51], I further 
investigated the specific effect of FLX and exogenous GDF15 on the length of astrocytic 
processes in vitro. Under baseline conditions I observed that NAB astrocytes displayed a 
very characteristic curve of different lengths of processes, whereas the distribution of 
processes at certain lengths in HAB astrocytes differed greatly from NAB especially at 
shorter lengths, providing evidence that HAB astrocytes not only have deficits in the total 
numbers of processes but also that these deficits are specific to certain subsets of 
processes. FLX treatment increased the length of processes in both cell-types, further 
implicating a sprouting effect.  
Interestingly, in HAB cells FLX caused an increase in the different lengths of processes, 
which resulted in almost identical shape of the curve as seen in NAB astrocytes. Moreover, 
I observed that especially after prolonged FLX treatment some processes occurred at the 
very long range, pointing towards an additional prolongation effect on preexisiting 
astrocytic processes, thereby supporting the hypothesis that prolonged FLX treatment 
might be able to restore the morphological alterations and might be implicated in further 
improving astrocytic connections around blood vessels, maybe even to reinstate a proper 
BBB.  
To establish if GDF15 might act specifically on a subset of astrocytic processes, I also 
analyzed the different concentrations of exogenous GDF15. NAB and HAB astrocyte both 
responded to the highest concentration of GDF15 with increase at the different lengths of 
processes, but HAB astrocytes were more sensitive, since they also responded to the 
intermediate concentration after short-term treatment. Additionally, I observed some 
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processes in the very long range in HAB astrocyte after GDF15 treatment, which were not 
detectable after FLX treatment. Given the higher sensitivity of HAB astrocytes to 
exogenous GDF15, it can be suggested that GDF15 might be a more potent factor acting 
on the prolongation of preexisiting processes than FLX, indicating that exogenous GDF15 
might be a faster acting pharmacological compound which could be tested for putative AD 
properties.  
Overall these data strongly indicated that FLX and exogenous GDF15 elicit the sprouting 
of new astrocytic processes as well as prolongation of preexisting ones, indicative for 
structural alterations that might be beneficial, especially at the glia-vasculature interface, 
and GDF15 is sufficient to induce similar effects as FLX. To establish whether there might 
be causal link between the effects of FLX and exogenous GDF15, I used siRNA designed 
to target specifically Gdf15 in order to investigate whether GDF15 is necessary to mediate 
the effects of FLX. Knockdown of Gdf15 is able to reduce the number of processes, 
although not significantly. However, subsequent FLX treatment of these cells restored the 
numbers of processes to baseline levels, showing that endogenous GDF15 is not necessary 
to mediate FLX effects on astrocytic processes. Nevertheless, I was interested to 
investigate also here whether GDF15 might be essential at specific subsets of processes. 
Therefore, I analyzed in detail the effects on siRNA-mediated knockdown of endogenous 
GDF15 on the sprouting and prolongation effects observed. In NAB cells knockdown of 
GDF15 decreases the numbers of very short processes even below the control levels 
indicating a role of endogenous GDF15 in sprouting of astrocytic processes, although also 
here subsequent treatment with FLX restored the numbers.  
Taken together the data indicate FLX is able to activate an intrinsic program that results in 
the sprouting of GDF15
+
 astrocytic processes and this effect is particularly significant 
around blood vessels. Indicating that there might be a connection between the effects of 
FLX and the formation of GDF15
+ 
 astrocytic processes in the PFC of HAB rats. These 
data indicate that GDF15 could be involved in restoring a proper glia-vasculature interface, 
especially at the level of the BBB. Administration of FLX increased the numbers 
significantly in both cell-types, an effect that remained stable also after prolonged 
treatment, hinting to a possible ´ceiling effect´, that might be worth to be further analyzed. 
In addition, although the endogenous protein levels do not significantly vary between HAB 
and NAB astrocyte in vitro, administration of exogenous GDF15 was sufficient to elicit the 
same increase of astrocytic processes in HAB and NAB cells in a dose- and time 
dependent manner, suggesting a beneficial role of GDF15 in HAB cells on restoring a 
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proper set of astrocytic processes. With the previously published data that FLX is able to 
restore the structural deficiencies of astrocytic processes but a short term treatment might 
not be sufficient to restore a proper glia-vasculature interface [51], we conducted a more in
depth analysis whether specific subset of processes might be specifically targeted and 
whether this effects might be mediated by GDF15. This analysis revealed that FLX 
enhanced sprouting of new processes as well as prolonged preexisting ones, an effect that 
could also be observed by application of exogenous GDF15, pointing towards a functional 
role of GDF15 in the morphology of astrocytes, possibly by interactions with other 
structural factors, like actin of GFAP. However, endogenous GDF15 is not necessary to 
mediate the effects of FLX. Although with respect to the different lengths of processes it 
might be that GDF15 is responsible for the stabilization of astrocytic processes, hence 
knockdown of causes a significant reduction in very short processes. Ongoing experiments 
on this subject point into the direction that endogenous GDF15 might not be necessary for 
the response of astrocytes to FLX but that the release of GDF15 might be impaired in HAB 
astrocytes, which may be restored upon FLX treatment. However, further studies on this 
subject are necessary to define the mechanism by which GDF15 (endogenous or 
exogenous) affect astrocytic processes. Therefore, I am going to conduct an ELISA assay 
to examine supernatants and cell lysates derived from FLX- and GDF15-treated cells as 
wells with serum samples of HAB and NAB rats to further clarify the possibility of GDF15 
as a potential diagnostic or treatment biomarker.  
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Suppl. 1: absolute numbers of cells do not 
differ between NAB and HAB  
a) Quantitative IF-IHC analysis for 
total cell number (DAPI) in the 
PFC of NAB (n= 6 animals,  135.5 
± 2.275) and HAB (n= 6 animals,  
141.4 ± 5.237) under baseline 
conditions 
The total cell number is depicted 
as mean +SEM. Student´s t-test, 
t(10)= 1.026, p= 0.3293, n.s. 
b) Total counts of astrocytes in the 
PFC NAB (n= 6,  20.98 ± 0.8083) 
and HAB. (n= 6,  17.49 ± 0.9501) 
Student´s t-test, t(10)= 0.2.796, p= 
0.0.0189 
c) Total counts of neurons in the PFC 
NAB (n= 6,  73.63 ± 6.336) and 
HAB (n= 5,  79.48 ± 3.388), 
Student´s t-test, t(9)= 0.7654, p= 
0.4636 
Supplementary  
Absolute number of cells in PFC of HAB and NAB 
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Suppl. 2: Analysis of possible effects on H3K4me3 cause by the injection itself 
Comparison of NAB and HAB rats under basal conditions and after injection with SAL, did not 
affect the expression of H3K4me3 in the PFC, neither in NAB, nor in HAB animals. NAB: n= 6,  
52.32 ± 3.409%; NAB SAL: n= 4,  40.07 ± 4.880%; HAB: n= 5,  51.21 ± 4.049%; HAB SAL: n=3,  
60.56 ± 5.480%.One-way ANOVA with Tukey post hoc test F(3, 14)= 3.107, p= 0.0607. All data are 
represented in [%] H3K4me3 normalized to DAPI and depicted as mean +SEM 
Effects of the injection itself on H3K4me3 
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Suppl. 3: Cell type specific analysis- injection effects  
Cell type specific comparison of NAB and HAB rats under basal conditions and after injection with 
SAL. The injection did not affect the expression of H3K4me3 in the PFC, neither in NAB, nor in 
HAB animals. NAB neurons: n= 6,  55.90 ± 3.204%; NAB SAL neurons: n= 4,  41.34 ± 5.003%; 
NAB astrocytes: n= 4,  47.21 ± 7.336%, NAB SAL astrocytes: n= 4,  38.81 ± 4.699%; One-way 
ANOVA with Tukey post hoc test F(3, 11)= 2.677, p= 0.0873 
HAB neurons: n= 5,  55.98 ± 6.300%; HAB SAL neurons: n=3,  54.72 ± 6.072%; HAB astrocytes: 
n=4,  48.67 ± 6.214%, HAB SAL astrocytes: 67.61 ± 7.183%; One-way ANOVA with Tukey´s post 
hoc test F(3, 11)= 1.280, p= 0.3293. All data are represented in [%] H3K4me3 normalized to DAPI 
and depicted as mean +SEM 
Effects of the injection itself on H3K4me3- cell-type specific  
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Suppl. 4: Proportional expression of H3K4me3 and H3K27me in NAB and HAB 
This figure shows the proportions of the activating mark H3K4me3 and H3K27me3 in HAB and 
NAB animals. Depicted here is DAPI, set as 100 % for both, NAB and HAB, and the proportional 
expression of H3K4me3 (in black; NAB: 52.32 %, HAB: 51.21 %) and H3K27me3 (in grey; NAB: 
36.05 %, HAB: 20.94 %).  
Proportional expression of H3K4me3 and H3K27me3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of abbreviations  - 133 - 
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WHO world health organization 
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DSM-Ⅴ Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition 
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NAc nucleus accumbens 
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AMY amygdala 
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5-HT 5- hydroxytryptamine = serotonin 
GABA γ-Aminobutyric acid 
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SSRI selective serotonin reuptake inhibitor 
FLX fluoxetine 
LC locus coereleus 
IMI imipramine 
NA noradrenalin 
NRI selective noradrenalin reuptake inhibitor 
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MAOI monoamine oxidase A inhibitor 
VEGF vascular endothelial growth factor 
IGF-2 insulin-like growth factor-2 
FGF-1 fibroblast growth factor-1 
GDNF glia-cell derived neurotrophic factor 
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SVZ subventricular zone 
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MAPK mitogen-activated protein kinase 
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Aqp-4 aquaporin-4 
PTM posttranslational histonemodification 
GR glucocorticoid receptor 
HDAC(i) histone-deacetylase (inhibitor) 
H3K4me3 histone 3- lysine 4- trimethylation 
H3K27me3 histone 3- lysine 27- trimethylation 
CNS central nervous system 
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GLAST-1 glutamate aspartate transporter -1 
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MMP(s) matrix metalloprotease(s) 
NGF nerve growth factor 
NT-3 neurotrophin-3 
TGF-β transforming growth factor- β 
IL-6 interleukin -6 
CUS chronic unpredictable stress 
ECS extracellular space 
RNAi RNA- interference 
CpG cytosine-guanine dyads 
DNMT DNA-methyltransferase 
MeCP methyl-CpG-binding proteins 
5-hmC 5-hydroxymethylcytosine 
TET ten-eleven-translocation 
K Lysine 
HAT histone-acetyltransferases 
NAD Nicotinamide adenine dinucleotide 
R Arginine 
H Histidine 
H3K9 histone 3- lysine 9 
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H3K36 histone 3- lysine 36 
H3K79 histone 3- lysine 79 
H4K29 histone 4- lysine 29 
HMT histone-methyltransferase 
SAM S-adenosyl-methionine 
HMD histone-demethylase 
KMT lysine methyltransferase 
MLL mixed lineage leukemia 
PRC2 polycomb repressive chromatin remodeling complex 2 
KMD lysine demethylase 
HG high grooming 
LG low grooming 
GRIK2 glutamate receptor, ionotropic kainate 2 
BEGAIN brain-enriched guanylate kinase-associated protein 
HAB high anxiety-related behavior 
LAB low anxiety-related behavior 
EPM elevated plus maze 
PND post-natal day 
FST forced swim test 
CRH corticotrophin-releasing hormone 
AVP arginine vasopressin 
ACTH adrenocorticotropic hormone 
DEX/CRH test dexamethasone-suppression/CRH challenge test 
GDF15 growth differentiation factor 15 
CSF cerebrospinal fluid 
shRNA short hairpin RNA 
NAB non-selectively bred 
Eph(R) erythropoietin-producing-heptaocellular carcinoma (receptor) 
RTK receptor tyrosine kinases 
ephrins Eph receptor-interacting-signals 
NAB non-selectively bred 
RT room temperature 
h hours 
E18 embryonic day 18 
ESC escitalopram 
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PBS phosphate buffered saline 
i.p. intraperitoneal 
HBSS Hank´s balanced salt solution 
SN supernatant 
min minutes 
DMEM Dulbecco´s modified eagle medium 
FCS fetal calf serum 
PDL poly-D-lysine 
DIV days in vitro 
DMSO dimethylsulfoxide 
d days 
P4 passage 4 
rpm rounds per minute 
IF immunofluorescence 
IF-IHC immunofluorescent-immunohistochemistry 
PFA paraformaldehyde 
O.N. over night 
NGS normal goat serum 
IF-ICC immunofluorescent-immunocytochemistry 
SEM standard error of means 
SDS sodium duodecyl-sulfate 
PVDF polyvinylidene fluoride 
BSA bovine serum albumine 
siRNA short interfering RNA 
ChIP chromatin-immunoprecipitation 
PBST PBS + tween 
H3K27ac histone 3-lysine 4-acetylation 
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